6-substituted-3-phenyl-isoindolin-1-ones as CBL-b inhibitors selective over c-cbl
6-substituted-3-phenyl-isoindolin-1-one compounds offer a selective inhibition of Cbl-B over C-Cbl, addressing the challenge of targeting Cbl-B in cancer immunotherapy and enhancing anti-tumor immunity while minimizing adverse effects.
Patent Information
- Application Number
- PCT/US2024/028664
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-09
- Filing Date
- 2024-05-09
- Publication Date
- 2024-11-14
AI Technical Summary
There is a need for compounds that inhibit Cbl-B while being selective over C-Cbl to effectively target Cbl-B in cancer immunotherapy, as C-Cbl inhibition can lead to undesirable effects such as expansion of hematopoietic stem cells and multipotent progenitors, and compounds with selectivity for Cbl-B over C-Cbl are required to avoid these dysregulations.
Development of 6-substituted-3-phenyl-isoindolin-1-one compounds and certain amide compounds that act as selective inhibitors of Cbl-B, which can be used in pharmaceutical compositions for treating cancer, optionally in combination with checkpoint inhibitors.
These compounds effectively inhibit Cbl-B with selectivity over C-Cbl, potentially enhancing anti-tumor immunity and reducing the risk of adverse effects associated with C-Cbl inhibition, thereby providing a promising approach for cancer immunotherapy.
Smart Images

Figure US2024028664_14112024_PF_FP_ABST
Abstract
Description
6-SUBSTITUTED-3-PHENYL-ISOINDOLIN-1-ONES AS CBL-B INHIBITORS SELECTIVE OVER C-CBLCROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 501,135 filed May 9, 2023, the content of which is incorporated herein by reference in its entirety.FIELD OF DISCLOSURE
[0002] The present disclosure relates to inhibitors of Cbl-B that are selective over C-Cbl, and more particularly relates to methods of making and using the same.BACKGROUND
[0003] Casitas B-lineage lymphoma-b (Cbl-b) is a member of the Cbl family of RING E3 ubiquitin ligases. A common function of Cbl family proteins is the negative regulation of receptor tyrosine kinase signaling. Since Cbl-b inhibition leads to immune activation, it has been expected that Cbl-b inhibitors could be broadly active in multiple oncology indications.
[0004] Cbl proteins comprise three principal domains: a conserved N-terminal tyrosine kinase binding (TKB) domain, a short linker region, and a RING finger (RF) domain. The TKB domain is, in turn, composed of three subdomains: a 4-helix bundle (4H), a calcium- binding domain with an EF-hand fold, and a variant Src homology region 2 (SH2) domain, all three of which are involved in phosphotyrosine binding. The TKB domain binds substrates, such as ZAP70, that contain phosphotyrosine motifs.
[0005] The conserved RF domain, which has intrinsic E3 ligase activity, can recruit E2 ubiquitin-conjugating enzymes, and mediate the transfer of ubiquitin to substrates.
[0006] Phosphorylation of Cbl-b at Y363 within the linker domain regulates its E3 ubiquitin ligase activity by removing the masking of the RF domain by the TKB domain.
[0007] In T-cells, Cbl-b is a key tolerogenic factor that directly regulates the cells’ activation. Specifically, Cbl-b is highly expressed in murine and human CD4+ and CD8+ T cells, where it functions as a potent negative regulator of T cell activation by controlling activation thresholds and the requirement for co-stimulation. Mechanistically Cbl-b acts by ubiquitinating multiple substrates downstream of the T cell receptor (TCR), including ZAP70, resulting in TCR internalization and termination of signaling. Loss of Cbl-b in T cells leads to prolonged TCR surface expression, and in combination with TCR stimulation results inincreased expression of activation markers, such as CD25, cytokine production and proliferation.
[0008] Mouse models have surprisingly demonstrated that the loss of Cbl-b leads to increased adaptive and innate anti-tumor immunity, mediated by enhanced T cell effector function as well as increased natural killer (NK) cell activity. Cbl-b deficient mice spontaneously reject a variety of cancer tumors, including spontaneous solid tumors and hematopoietic malignancies, in a CD8 T cell-dependent manner. Adoptive transfer of Cbl-b- / - CD8+ T cells is sufficient to reject tumors, demonstrating that Cbl-b has a non-redundant role in regulating T-cell-mediated anti-tumor activity.
[0009] Consequently, developing a small molecule approach to inhibit Cbl-b is a promising but challenging goal for cancer immunotherapy.
[0010] Nevertheless, c-Cbl, a closely related family member to Cbl-b, shares high sequence homology with Cbl-b at the N-terminus, including in the TKB and RING domains. c-Cbl negatively regulates signaling of a number of growth factor receptors, including Flt3 and c-Kit. Among other defects, c-Cbl deficient mice exhibit expansion of hematopoietic stem cells and multipotent progenitors in the bone marrow. In mice that are conditionally deficient in both c- Cbl and Cbl-b this defect is amplified, and the mice develop a rapidly -progressive and lethal myeloproliferative disease accompanied by splenomegaly by around 8 weeks of age. Given a broad spectrum of functions of c-Cbl in growth factor receptor regulation, and a strong amplification in the dysregulation of these pathways in the absence of both c-Cbl and Cbl-b, compounds with selectivity for Cbl-b over c-Cbl are likely to be highly desirable as cancer immunotherapy agents.
[0011] Accordingly, there is a need for compounds that both inhibit Cbl-b and exhibit selectivity over binding to c-Cbl.
[0012] The discussion of the background herein is included to explain the context of the technology. This is not to be taken as an admission that any of the material referred to was published, known, or part of the common general knowledge as at the priority date of any of the claims found appended hereto.SUMMARY
[0013] Disclosed are 6-substituted-3-phenyl-isoindolin-l-one compounds and certain amide for inhibiting the Cbl-B receptor that are also selective over the C-Cbl receptor, compositions containing these compounds, and methods for using the same.
[0014] In one asepct, provided is a compound of Formula (I) or (II), or any variation thereof, or a salt thereof (e.g., a pharmaceutically acceptable salt thereof), as detailed herein. Also provided is a pharmaceutical composition comprising a compound of Formula (I) or (II), or any variation thereof detailed herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
[0015] An enantiomer, diastereomer or a pharmaceutically acceptable salt or solvate of the structures of Formula (I) or (II) are also included.
[0016] The present disclosure includes a process for making compounds of formula (I) or (II), particularly according to any of the synthetic methods disclosed herein.
[0017] The present disclosure further includes a method of treatment comprising administering a compound of formula (I) or (II) optionally in combination with another agent, such as a checkpoint inhibitor, to a patient suffering from cancer.
[0018] The present disclosure further includes a use or uses of a compound of formula (I) or (II) optionally in combination with another agent, such as a checkpoint inhibitor, for the treatment of a type of cancer in an individual suffering therefrom.
[0019] The present disclosure further includes amide compounds of formula (II). It is to be assumed that such compounds are utilizable in the same way in which compounds of formula (I) are disclosed.BRIEF DESCRIPTION OF THE DRAWINGS
[0020] FIGs. 1 - 17 show, respectively, flow-charts of processes for synthesizing intermediates A - Q used in syntheses of compound of formula (I), as further described herein.
[0021] FIGs. 18 - 71 show, respectively, flow-charts of processes for synthesizing various exemplary compounds according to formula (I), as further described herein.
[0022] FIGs. 72 - 79 show, respectively, flow-charts of processes for synthesizing intermediates AA - AH used in syntheses of compound of formula (II), as further described herein.
[0023] FIGs. 80 - 89 show, respectively, flow-charts of processes for synthesizing various exemplary compounds according to formula (II), as further described herein.
[0024] FIGs. 90 - 101 show, respectively, flow-charts of processes for synthesizing intermediates R - Z and BA - BM used in syntheses of compound of formula (I), as further described herein.
[0025] FIGs. 102 - 152 show, respectively, flow-charts of processes for synthesizing various exemplary compounds according to formula (I), as further described herein.DETAILED DESCRIPTION
[0026] Disclosed herein, are compounds of Formula (I) or (II), or variations thereof, and pharmaceutical compositions thereof that are inhibitors or modulators of Cbl-B. As such, the compounds and compositions are useful in treating diseases and disorders mediated by Cbl-B.
[0027] The presently disclosed subject matter will now be described more fully hereinafter. However, many modifications and other embodiments of the presently disclosed subject matter set forth herein will come to mind to one skilled in the art to which the presently disclosed subject matter pertains having the benefit of the teachings presented in the foregoing descriptions. Therefore, it is to be understood that the presently disclosed subject matter is not to be limited to the specific embodiments disclosed and that modifications and other embodiments are intended to be included within the scope of the appended claims. In other words, the subject matter described herein covers all alternatives, modifications, and equivalents. In the event that one or more of the incorporated literature, patents, and similar materials differs from or contradicts this application, including but not limited to defined terms, term usage, described techniques, or the like, this application controls. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in this field. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety.Definitions
[0028] It is to be noted that the term “a” or “an” object may refer to one or more of that object. As such, the terms “a” (or “an”), “one or more,” and “at least one” can be used interchangeably herein.
[0029] All technical and scientific terms used herein have the same meaning as those understood respectively to those skilled in the art, unless otherwise specifically defined herein. Efforts have been made to ensure accuracy with respect to numbers used (e.g. amounts, temperature, etc.) but some experimental errors and deviations should be accounted for when reading this disclosure.
[0030] Throughout the specification and the claims, the words “comprise,” “comprises,” and “comprising” are used in a non-exclusive sense, except where the context requires otherwise. It is to be understood that embodiments described herein include “consisting of’ and / or “consisting essentially of’ embodiments refer to some aspect as being exclusively defined.
[0031] As used herein, the term “about,” when referring to a value is meant to encompass variations of, in some embodiments ± 50%, in some embodiments ± 20%, in someembodiments ± 10%, in some embodiments ± 5%, in some embodiments ± 1%, in some embodiments ± 0.5%, and in some embodiments ± 0.1% from the specified amount, as such variations are appropriate to perform the disclosed methods or employ the disclosed compositions.
[0032] Where a range of values is provided and unless the context clearly dictates otherwise, it is understood that each intervening value, to the tenth of the unit of the lower limit, between the upper and lower limit of the range, is also disclosed, and that any other stated or intervening value in that stated range, is encompassed within the invention. The upper and lower limits of these small ranges which may independently be included in the smaller rangers is also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.
[0033] “Geminal” refers to the relationship between two moieties that are attached to the same atom. For example, in the moiety -CH2-CRxRy-, Rxand Ryare geminal to one another, and Rxmay be referred to as a geminal R group to Ry.
[0034] “Vicinal” refers to the relationship between two moieties that are attached to adjacent atoms. For example, in the residue -CHRx-CHRy-, Rxand Ryare vicinal and Rxmay be referred to as a vicinal R group to Ry.
[0035] “Optionally substituted” unless otherwise specified means that a group may be unsubstituted, or it may be substituted by one or more (e.g., 1, 2, 3, 4 or 5) non-hydrogen atoms or monovalent groups, such that the substituents may be the same or different from one another. In one embodiment, an optionally substituted group has one substituent. In another embodiment, an optionally substituted group has two substituents. In another embodiment, an optionally substituted group has three substituents. In another embodiment, an optionally substituted group has four substituents. In some embodiments, an optionally substituted group has 1 to 2, 1 to 3, 1 to 4 or 1 to 5 substituents. In any embodiment in which a group is substituted by two or more substituents, any two such substituents may be situated germinal to one another, as in, e.g., 3,3-difluoro-cyclobutyl.
[0036] Structures of molecules herein are typically represented by 2D structure diagrams that embody a number of labeling and layout conventions well understood by synthetic and medicinal chemists. Hydrogen atoms that are bonded to carbon atoms are typically not displayed (principally to reduce clutter) and it is assumed that any depicted carbon has a valency of 4 and that any bonds not explicitly depicted are satisfied by bonds to the number of hydrogen atoms required to satisfy a valency of 4. Correspondingly when structures aredepicted in “Markush” form and substituents are presented as lists any “missing” valence is assumed to be completed by a hydrogen atom, in the absence of a specific direction to the contrary.
[0037] Heteroatom refers to any atom other than carbon or hydrogen. Typical heteroatoms found in small organic molecules are selected from: nitrogen, oxygen, fluorine, phosphorous, sulfur, chlorine, and bromine. It is understood by those of skill in the art that where the term heteroatom used to denote a member of a ring (e.g. , a heteroaromatic ring) then monovalent heteroatoms such as halogen are excluded.
[0038] “Alkyl” as used herein refers to a saturated linear (i.e., unbranched) or branched univalent hydrocarbon functional group derived by the removal of one hydrogen atom from one carbon atom of a parent alkane. An alkyl group having n carbon atoms, as a radical, has formulaCnH2n+1. Alkyl groups having a given number of carbon atoms can be designated as follows:Cn-alkyl to denote any alkyl radical having n carbon atoms, or Cn1-n2a-lkyl to denote any alkyl radical having from nl to n2 carbon atoms. Thus C1-10means any alkyl radical having from one to ten carbon atoms. Particular alkyl groups of interest herein are those having 1 to 20 carbon atoms (a “C1-20-alkyl”), those having 1 to 12 carbon atoms (a “C1-12- alkyl”), those having 1 to 6 carbon atoms (a “C1-6-alkyl”), having 2 to 6 carbon atoms (a “C2-6- alkyl”), or having 1 to 4 carbon atoms (a “C1-4-alkyl”). Examples of alkyl groups include, but are not limited to: methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl. It is to be understood that an alkyl group can bond to another group or moiety at any carbon atom in its structure: thus, for example, butan-l-yl (n-butyl) and butan-2-yl (sec-butyl) are contemplated by the definition herein.
[0039] “Alkenyl” as used herein refers to an unsaturated linear (i.e., unbranched) or branched univalent hydrocarbon functional group having at least one site of olefinic unsaturation, i.e., having at least one instance of a carbon-carbon double bond (represented by the formula C=C), and having the number of carbon atoms designated. An alkenyl group having n carbon atoms and a single double-bond, as a radical, has formula CnH2n-1and is derived by the removal of one hydrogen atom from one carbon atom of a parent alkene. Alkenyl groups having a given number of carbon atoms can be designated as follows: C-nalkenyl to denote any alkenyl radical having n carbon atoms, or Cn1-n2-alkenyl to denote any alkenyl radical having from nl to n2 carbon atoms. Thus, C2-10-alkenyl means an alkenyl group having from two to ten carbon atoms. An alkenyl group may contain constituent carbon atoms that are in “cis” or “trans” configurations, or “E” or “Z” configurations, with respect to a given double bond. Particular alkenyl groups are those having 2 to 20 carbon atoms (a “C2-20-alkenyl”), having 2 to 8 carbonatoms (a “C2-8-alkenyl”), having 2 to 6 carbon atoms (a “C2-6-alkenyl”), or having 2 to 4 carbon atoms (a “C2-4-alkenyl”). Preferred alkenyl groups have one double bond. Other alkenyl groups may have two double bonds (and may be referred to as dienyl). In alkenyl groups having more than one double bond, a pair of double bonds may be separated by one carbon - carbon single bond, in which case the arrangement is referred to as “conjugated”, or they may be separated by more than one carbon-carbon single bond. Examples of alkenyl group include, but are not limited to, groups such as ethenyl (or vinyl), prop-l-enyl, prop-2-enyl (or allyl), 2- methylprop-l-enyl, but-l-enyl, but-2-enyl, but-3-enyl, buta- 1,3 -dienyl, 2-methylbuta- 1,3- dienyl, homologs and isomers thereof, and the like.
[0040] “Alkynyl” as used herein refers to an unsaturated linear (i.e., unbranched) or branched univalent hydrocarbon having at least one site of acetylenic unsaturation, i.e., having at least one instance of a carbon-carbon triple bond (represented by the formula formula C=C) and having the number of carbon atoms designated. An alkynyl group having n carbon atoms and a single triple-bond, as a radical, has formula CnH2n-3, and is derived by the removal of one hydrogen atom from one carbon atom of a parent alkyne. Alkynyl groups having a given number of carbon atoms can be designated as follows: Cn-alkynyl to denote any alkynyl radical having n carbon atoms, orCni-n2-alkynyl to denote any alkynyl radical having from nl to n2 carbon atoms. Particular alkynyl groups are those having 2 to 20 carbon atoms (a “C2-20- alkynyl”), having 2 to 8 carbon atoms (a “C2-8-alkynyl”), having 2 to 6 carbon atoms (a “C2-6- alkynyl”), or having 2 to 4 carbon atoms (a “C2-4-alkynyl”). Examples of alkynyl groups include, but are not limited to, groups such as ethynyl (or acetylenyl), prop-l-ynyl, prop-2-ynyl (or propargyl), but-l-ynyl, but-2-ynyl, but-3-ynyl, homologs and isomers thereof, and the like.
[0041] “Alkylene” as used herein refers to a saturated linear (i.e., unbranched) or branched bivalent hydrocarbon group having the number of carbon atoms designated. An alkylene group having n carbon atoms, as a radical, has formula - CnH2n-. Particular alkylene groups are those having 1 to 6 carbon atoms (a “C1-6-alkylene”), 1 to 5 carbon atoms (a “C1-5-alkylene”), having 1 to 4 carbon atoms (a “C1-4-alkylene”), or 2 to 3 carbon atoms (a “C2-3-alkylene”). Examples of alkylene radicals include, but are not limited to, methylene (-CH2-), ethylene (- CH2-CH2-), propylene (-CH2-CH2-CH2-), butylene (-CH2-CH2-CH2-CH2-), sec-butylene (- CH(CH3)-CH2-CH2-) and the like.
[0042] Cyclic (ring-containing) moieties comprise atoms bonded together in a ring, and have one or more substituents other than hydrogen atoms bonded to one or more ring atoms. Each atom in the ring defines a vertex of a polygon.
[0043] Two ring atoms are adjacent to one another in that ring if they are bonded to one another in the ring. In rings having 4 or more ring atoms, adjacent atoms are bonded to one another but to no other atom in the same ring. In a three-membered ring, each atom is necessarily bonded to each other atom in the ring. Two adjacent ring atoms define one “edge” of the ring.
[0044] Two or more cyclic moieties may join to one another in one of several ways to form ring systems that comprise more than one ring.
[0045] Two rings are fused to one another if two ring atoms are adjacent to one another in both rings and are shared by both rings. Such rings are said to share an “edge”.
[0046] Spirocyclic ring systems comprise a pair of rings that share a single vertex. Such systems contain a ring junction at which the two rings share a single ring atom.
[0047] Bridged ring systems contain at least a pair of rings in which two or more non - adj acent ring atoms are shared by two or more rings. The two non-adj acent ring atoms in question are referred to as “bridgehead” atoms and the pair of bridgehead atoms are members of three different rings. Examples of carbocyclic radicals containing bridged bicyclic rings are norbomyl and adamantyl.
[0048] Chained ring systems contain two rings that are joined to one another but do not share any ring atom in common: one ring is a substituent of the other, and vice versa. Biphenyl is an example of a chained ring system.
[0049] Ring systems may contain pairs of rings that are fused or chained to one another, spiro-joined, or bridged, or in the case of three or more rings, joined in combinations of ways thereof.
[0050] “Carbocycle” as used herein refers to aromatic, saturated or unsaturated cyclic univalent hydrocarbon groups having the number of annular (i.e., ring) carbon atoms designated (i.e., , C3-10means three to ten annular carbon atoms). Carbocyclic groups have a single ring (“monocycles”) or more than one ring (“bicycles”, “tricycles”, or polycycles, more generally). Two or more carbocyclic rings may be joined to one another by fused, spiro, bridged, or chained connections as further described elsewhere herein.
[0051] It is intended herein that the term carbocycle encompasses radicals having one or more adjacent pairs of ring atoms between which are double bonds, and that, where more than one such double bond is present, the double bonds may or may not form a conjugated system within the ring. Thus carbocycles may be more specifically designated according to whether they are fully saturated (“cycloalkyl”), unsaturated at least in part (“cycloalkenyl”), or fully conjugated, (“aromatic” or “aryl”). Cycloalkyl groups are fully saturated radicals and arederived by the removal of one hydrogen atom from one carbon atom of a parent cycloalkane. Particular cycloalkyl groups are those having from 3 to 12 annular carbon atoms (C3-12- cycloalkyl). A preferred cycloalkyl is a monocyclic hydrocarbon having from 3 to 8 annular carbon atoms (a “C3-8-cycloalkyl”), or having 3 to 6 carbon atoms (a “C3-6-cycloalkyl”). Single ring cycloalkyl radicals have formula CnH2n-1. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.Cycloalkenyl groups have one or more double bonds between adjacent ring carbon atoms. Examples of cycloalkenyl groups include 1 -cyclohex- 1-enyl, and l-cyclohex-3-enyl.
[0052] “Aryl” as used herein refers to a carbocyclic group having a aromatic single ring (e.g., phenyl) or multiple aromatic rings fused to one another (e.g., naphthyl). Preferably, an aryl group comprises from 6 to 20 carbon atoms, more preferably between 6 to 12 carbon atoms. Particularly preferred aryl groups are those having from 6 to 14 annular carbon atoms (a “C6-14-aryl”). The term aromatic is used herein as it is typically used in organic chemistry, meaning, with a few understood exceptions, rings and ring systems in which the annular atoms contribute a total of (4n+2) pi electrons to a set of delocalized molecular orbitals, where n is a non-zero positive integer.
[0053] Typical aryl groups include, but are not limited to, groups derived from fused ring systems that comprise one or more aromatic rings, or conjugated ring systems, such as but not limited to aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, heptaphene, hexacene, hexaphene, as-indacene, s-indacene, indene, naphthalene (hexalene), octacene, octaphene, octalene, ovalene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, tetraphenylene, triphenylene, and trinaphthalene.
[0054] A “heterocyclic”, or “heterocyclyl”, group as used herein refers to a saturated or an unsaturated but non-aromatic, cyclic group having one or more rings that comprises at least one carbon atom and one or more heteroatoms. Typically such a group has from 1 to 14 ring carbon atoms and from 1 to 6 ring heteroatoms that can be same or different from each other. Such a group is typically derived by the removal of one hydrogen atom from one ring atom of a parent heterocycle. It is intended herein that the term heterocyclyl encompasses radicals having one or more double bonds between one or more respective adjacent pairs of ring atoms, and that where more than one such double bond is present, the double bonds do not form a conjugated system within the ring.
[0055] Particularly preferred heterocyclyl groups are: 3- to 14-membered rings having 1 to 13 annular carbon atoms and 1 to 6 annular heteroatoms independently selected from nitrogen,phosphorus, oxygen and sulfur; 3- to 12-membered rings having 1 to 11 annular carbon atoms and 1 to 6 annular heteroatoms independently selected from nitrogen, phosphorus, oxygen and sulfur; 3- to 10-membered rings having 1 to 9 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, phosphorus, oxygen and sulfur; 3- to 8- membered rings having 1 to 7 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, phosphorus, oxygen and sulfur; and 3- to 6-membered rings having 1 to 5 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, phosphorus, oxygen and sulfur. In one variation, heterocyclyl include monocyclic 3-, 4-, 5-, 6- or 7-membered rings having from 1 to 2, 1 to 3, 1 to 4, 1 to 5 or 1 to 6 annular carbon atoms and 1 to 2, 1 to 3 or 1 to 4 annular heteroatoms independently selected from from nitrogen, phosphorus, oxygen and sulfur. In another variation, heterocyclyl includes polycyclic non-aromatic rings having from 1 to 12 annular carbon atoms and 1 to 6 annular heteroatoms independently selected from nitrogen, phosphorus, oxygen and sulfur. Exemplary heterocyclic rings include: oxirane, aziridine, azetidine, pyrrolidine, piperazine, piperidine, oxetane, tetrahydrofuran, and morpholine.
[0056] A heterocyclic ring may make fused, spiro, or bridged, connections or make any combination of such connections to one or more other rings.
[0057] “Heteroaryl” or “heteroaromatic”, as used herein, refers to an aromatic cyclic group having from 1 to 14 ring carbon atoms and at least one ring heteroatom, including but not limited to heteroatoms such as nitrogen, phosphorus, oxygen and sulfur. The term refers to a monovalent heteroaromatic radical derived by the removal of one hydrogen atom from a single ring atom of a parent heteroaromatic ring system. A heteroaryl group may have a single ring (e.g., pyridyl, furyl) or multiple fused rings (e.g., indolizinyl, benzothienyl). Particular heteroaryl groups are 5- to 14-membered rings having 1 to 12 annular (i.e., ring) carbon atoms and 1 to 6 annular (i.e., ring) heteroatoms independently selected from nitrogen, phosphorus, oxygen and sulfur; 5- to 10-membered rings having 1 to 8 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, phosphorus, oxygen and sulfur; and 5-, 6- or 7-membered rings having 1 to 5 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur In one variation, heteroaryl include monocyclic aromatic 5-, 6- or 7-membered rings having from 1 to 6 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur. In another variation, heteroaryl includes polycyclic aromatic rings having from 1 to 12 annular carbon atoms and 1 to 6 annular heteroatoms independently selected from nitrogen, phosphorus, oxygen and sulfur.
[0058] Typical heteroaryl groups include, but are not limited to, groups derived from acridine, arsindole, carbazole, P-carboline, chromane, chromene, cinnoline, furan, imidazole, indazole, indole, indoline, indolizine, isobenzofuran, isochromene, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, perimidine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizine, quinazoline, quinoline, quinolizine, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazole, xanthene, and the like. Preferred heteroaryl groups are thiophene, pyrrole, benzothiophene, benzofuran, indole, pyridine, quinoline, imidazole, oxazole and pyrazine, and those derived therefrom.
[0059] Rings of different categories may be connected to one another, such as by fused, spiro, or bridged, connections, or by combinations thereof. Such a ring system can be referred to as a “mixed” ring system.
[0060] For example, at least one ring of a multiple ring system can be aromatic on its own, though one or more of the remaining fused rings may be not aromatic. Examples of fused ring systems that contain at least one aromatic ring and at least one partially saturated ring include fluorene, indane, and biphenylene.
[0061] A mixed ring system having more than one ring where at least one ring is aromatic and at least one ring is non-aromatic may be connected to another structure by bonding to either an aromatic ring atom or a non-aromatic ring atom.
[0062] A heteroaryl group having more than one ring where at least one ring is non-aromatic may be connected to another structure at either an aromatic ring position or at a non-aromatic ring position.
[0063] Similarly, carbocyclic and heterocyclic groups may join to one another in one of several ways to form ring systems that comprise more than one ring.
[0064] “Halo” or Halogen” refers to fluoro, chloro, bromo, and / or iodo. An alkyl group in which one or more hydrogen atoms is replaced with a halogen is referred to as a “haloalkyl”, for example, “C1-6-haloalkyl.” Where a moiety is substituted with more than one halogen, it may be referred to by using a prefix corresponding to the number of halogen moieties attached, e.g., dihaloaryl, trihaloaryl, refer to aryl groups substituted with two (“di”) or three (“tri”) halo groups respectively. It is to be understood that, where more than one halo groups are present they are not necessarily the same as one another. Thus 4-chloro-3 -fluorophenyl is within the scope of dihaloaryl. An alkyl group in which every hydrogen atom is replaced with a halogen atom is referred to as a “perhaloalkyl.” The term haloalkyl thus includes perhaloalkyl unlessfrom context perhaloalkyl is specifically excluded. A preferred perhaloalkyl group is trifluoromethyl (-CF3). Similarly, “perhaloalkoxy” refers to an alkoxy group in which a halogen takes the place of each H in the hydrocarbon making up the alkyl moiety of the alkoxy group. An example of a perhaloalkoxy group is trifluoromethoxy (-OCF3).
[0065] “Carbonyl” refers to the group C=O.
[0066] “Carbenyl”, when used as a ring substituent, refers to the moiety =C, i.e., a carbon atom double-bonded to a carbon atom in a ring. It means that a single carbon atom replaces two hydrogen (or other monovalent) atoms that are bonded to a ring carbon atom and is therefore bonded to the ring carbon atom via a double bond. In general, a carbenyl may be represented as RcRdC=, where RcRc are independently either hydrogen or alkyl.
[0067] “Thiocarbonyl” refers to the group C=S.
[0068] “Oxo” refers to the moiety =0, i.e., an oxygen atom double-bonded to a second atom other than oxygen. When used as a ring substituent it means that a ring atom such as a carbon atom is bonded via a double bond to an oxygen atom other than a ring atom.
[0069] “Prodrug” refers to a pharmacologically inactive derivative of a drug molecule that requires a transformation within the body, usually a metabolic transformation, to release the active drug.
[0070] “Promoiety” refers to a form of protecting group that, when used to mask a functional group within a drug molecule converts the drug into a prodrug. Typically, the promoiety will be attached to the drug via bond(s) that are cleaved by enzymatic or non-enzymatic means in vivo. Ideally, the promoiety is rapidly cleared from the body upon cleavage from the prodrug.
[0071] “Protecting group” refers to a grouping of atoms that when attached to a reactive group in a molecule masks, reduces or prevents that reactivity. Examples of protecting groups can be found in Green et al., "Protective Groups in Organic Chemistry", (Wiley, 2nd ed. 1991) and Harrison et al., "Compendium of Synthetic Organic Methods", Vols. 1-8 (John Wiley and Sons, 1971-1996). Representative amino protecting groups include, but are not limited to, formyl, acetyl, trifluoroacetyl, benzyl, benzyloxycarbonyl"("CBZ"), tert-butoxycarbonyl ("Boc"), trimethylsilyl ("TMS"), 2-trimethylsilyl-ethanesulfonyl ("SES"), trityl and substituted trityl groups, allyloxycarbonyl, 9-fluorenylmethyloxycarbonyl ("FMOC"), nitro- veratryloxycarbonyl ("NVOC") and the like. Representative hydroxy protecting groups include, but are not limited to, those where the hydroxy group is either acylated or alkylated such as benzyl, and trityl ethers as well as alkyl ethers, tetrahydropyranyl ethers, trialkylsilyl ethers and allyl ethers.
[0072] Compounds of Formula (I), described herein, or a salt or solvate thereof, may exist in stereoisomeric forms (e.g., such a compound contains one or more asymmetric carbon atoms). The individual stereoisomers (such as purified enantiomers and diastereomers) and mixtures of these or enantiomerically / diastereomerically enriched mixtures are included within the scope of the subject matter disclosed herein. The stereochemistry, as shown in the examples, is arbitrarily assigned.
[0073] It is further understood that a compound or salt of Formula (I) may exist in tautomeric forms other than that shown in the formula and these are also included within the scope of the subject matter disclosed herein.
[0074] The subject matter disclosed herein also includes isotopically-labelled forms of the compounds described herein, i.e., compounds that have the Formulae shown herein but for the fact that one or more constituent atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number of that atom that is usually found in nature and / or at an abundance not normally found in nature. Examples of isotopes that can be incorporated into compounds described herein and pharmaceutically acceptable salts thereof, at levels that differ from the natural distribution of such isotopes, include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulphur, fluorine, iodine, and chlorine, such as2H (denoted D),3H,11C,13C,14C,15N,17O,180,31P,32P,35S,18F,36C1,1231,125I, and131I. In most instances any hydrogen atom in a molecule disclosed herein may be substituted by a deuterium atom. A given isotopically substituted molecule may then contain a deuterium atom at more than one position. In particular, a methyl group in a molecule may be perdeuterated, denoted CD3. In the case of deuterated molecules, a molecule preferably has an isotopic enrichment factor of at least 3500 (~52.5% deuterium incorporation) at a given position, where an isotopic enrichment factor of 6633 represents 99.5% incorporation.
[0075] The subject matter disclosed herein further includes prodrugs, metabolites, and pharmaceutically acceptable salts of compounds of Formula (I). Metabolites of the compounds of Formula (I) include compounds produced by a process comprising contacting a compound of Formula (I) with a mammal for a period of time sufficient to yield a metabolic product thereof.
[0076] In some embodiments, the salts of the compounds of the invention are pharmaceutically acceptable salts. “Pharmaceutically acceptable salts” are those salts that retain at least some of the biological activity of the free (non-salt) compound and that can be administered as drugs or pharmaceuticals to a subject. Such salts, for example, include: (1) acid addition salts; (2) salts formed when an acidic proton is replaced by a metal ion; or (3) anacdic proton coordinates with an organic base. Pharmaceutically acceptable salts can be prepared in situ in the manufacturing process, or by separately reacting a purified compound of the invention in its free acid or base form with a suitable organic or inorganic base or acid respectively, and isolating the salt thus formed during subsequent purification.
[0077] If the compound of Formula (I) is a base, the desired pharmaceutically acceptable salt may be prepared as an acid addition salt by any suitable method available in the art, for example, treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, methanesulfonic acid, phosphoric acid and others of like property, or with an organic acid, such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, propionic acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an alpha hydroxy acid, such as citric acid or tartaric acid, an amino acid, such as aspartic acid or glutamic acid, an aromatic acid, such as benzoic acid or cinnamic acid, a sulfonic acid, such as p-toluenesulfonic acid or ethanesulfonic acid, and others of like property.
[0078] If the compound of Formula (I) is an acid, one or more acidic protons present may be replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion.The desired pharmaceutically acceptable salt may then be prepared by any suitable method, for example, treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), an alkali metal hydroxide or alkaline earth metal hydroxide, or the like. Examples of suitable salts include, but are not limited to, organic salts derived from amino acids, such as glycine and arginine, ammonia, and cyclic amines, such as piperidine, morpholine and piperazine, alcoholamines such as ethanolamine, diethanolamine, and triethanolamine, and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum and lithium. Acceptable inorganic bases include aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide, and the like.
[0079] The compounds herein may also be present as solvates, such as crystallized with a corresponding quantity of a solvent molecule, in a ratio that may or may not be stoichiometric.
[0080] A compound of Formula (I) can also be in the form of a “prodrug,” which includes compounds with moieties that can be metabolized in vivo. Generally, prodrugs are metabolized in vivo by esterases or by other mechanisms to form active drugs inside the patient’s body. Examples of prodrugs and their uses are well known in the art (see, e.g., Berge et al. (1977) “Pharmaceutical Salts”, J. Pharm. Sei., 66:1-19). The prodrugs can be prepared in situ during the final isolation and purification of the compounds, or by separately reacting thepurified compound in its free acid form or hydroxyl with a suitable esterifying agent.Hydroxyl groups can be converted into esters via treatment with a carboxylic acid. Examples of prodrug moieties include substituted and unsubstituted, branch or unbranched lower alkyl ester moieties, (e.g., propionoic acid esters), lower alkenyl esters, di-lower alkyl-amino lower- alkyl esters (e.g., dimethylaminoethyl ester), acylamino lower alkyl esters (e.g., acetyloxymethyl ester), acyloxy lower alkyl esters (e.g., pivaloyloxymethyl ester), aryl esters (phenyl ester), aryl-lower alkyl esters (e.g., benzyl ester), substituted (e.g., with methyl, halo, or methoxy substituents) aryl and aryl-lower alkyl esters, amides, lower-alkyl amides, di-lower alkyl amides, and hydroxy amides. Prodrugs which are converted to active forms through other mechanisms in vivo are also included. In aspects, the compounds of the invention are prodrugs of any of the Formula herein.
[0081] It is also to be understood that the subject matter disclosed herein includes combinations and subsets of the particular categories (e.g., salt forms, tautomers, stereoisomeric forms) described herein.
[0082] The terms “treat” and “treatment” refer to therapeutic treatment, wherein an object is to slow down, diminish, or attenuate, an undesired physiological change or disorder, such as the development or spread of arthritis or cancer. For purposes of this disclosure, beneficial or desired clinical results include, but are not limited to: alleviation of one or more symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. “Treatment” can also mean prolonging survival as compared to a patient’s expected survival if not receiving treatment. Those in need of treatment include those with the condition or disorder, and further include those who are only experiencing an early stage of the disorder or disease, in which one or more typical symptoms may yet to manifest.
[0083] The phrase “therapeutically effective amount” means an amount of a compound of the present invention (or a salt thereof), that produces a desired therapeutic outcome, such as: (i) treating the particular disease, condition, or disorder, (ii) attenuating, ameliorating, or eliminating one or more symptoms of the particular disease, condition, or disorder, or (iii) preventing or delaying the onset of one or more symptoms of the particular disease, condition, or disorder described herein. In the case of a cancer, the therapeutically effective amount of the drug may reduce the severity or duration of, stabilize the severity of, or eliminate one or more symptoms of the cancer. It may do this by reducing the number of cancer cells; reducing a tumor size or checking its rate of growth; inhibiting (i.e. , slow to some extent and preferablystop) cancer cell infiltration into peripheral organs; inhibit (i.e., slow to some extent and preferably stop) tumor metastasis; inhibit, to some extent, tumor growth; and / or relieve to some extent one or more of the symptoms associated with the cancer. To the extent the drug may prevent growth and / or kill existing cancer cells, it may be cytostatic and / or cytotoxic. For cancer therapy, efficacy can be measured, for example, by assessing the time to disease progression (TTP) and / or determining the response rate (RR). In other therapeutic areas, to be termed a therapeutic use, beneficial or desired results include, e.g., decreasing one or more symptoms resulting from the disease (biochemical, histologic and / or behavioral), including its complications and intermediate pathological phenotypes presenting during development of the disease, increasing the quality of life of those suffering from the disease, decreasing the dose of other medications required to treat the disease, enhancing effect of another medication, delaying the progression of the disease, and / or prolonging survival of patients.
[0084] The term “cancer” refers to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth and an invasive nature, wherein the cancerous cells are capable of local invasion and / or metastasis to noncontiguous sites. As used herein, “cancer cells,” “cancerous cells,” or “tumor cells” refer to the cells that are characterized by this unregulated cell growth and invasive property. A “tumor” comprises more than one cancerous cells. Cancers can further be divided into liquid or solid types. The term “cancer” as used herein generally encompasses all types of cancers, subject to specific context. Examples of cancers include, but are not limited to, carcinoma, melanoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies. More particular examples of such cancers include squamous cell cancer (e.g., epithelial squamous cell cancer), lung cancer including small- cell lung cancer, non-small cell lung cancer (“NSCLC”), adenocarcinoma of the lung and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, esophageal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, Ewing’ s sarcoma, medulloblastomer, as well as head and neck cancer.
[0085] A “chemotherapeutic agent” is a chemical compound or biologic useful in the treatment of cancer. A chemotherapeutic agent can be an immunotherapeutic agent. As used herein, an “immunotherapeutic agent” is a compound that enhances the immune system to helpfight cancer, specifically or non-specifically. Immunotherapeutics include monoclonal antibodies and non-specific immunotherapies that boost the immune system,
[0086] As used herein, a “combination therapy” is a therapy that includes two or more different compounds, administered simultaneously or contemporaneously. Typically, each of the two or more different compounds has a different mechanism of action. Thus, in one aspect, a combination therapy comprising a compound detailed herein and another compound is provided. In some variations, the combination therapy optionally includes one or more pharmaceutically acceptable carriers or excipients, non-pharmaceutically active compounds, and / or inert substances. Combination therapies can comprise two more compounds in a single delivery vehicle such as a tablet, or can comprise doses in separate formulations, such as different tablets, or a tablet and an injectable solution.
[0087] As used herein, the term “effective amount” means such an amount of a compound of the invention that, in combination with its parameters of efficacy and toxicity, should be effective in a given administered form. As is understood in the art, an effective amount may be in one or more doses, i.e., a single dose or multiple doses may be required to achieve the desired treatment endpoint. An effective amount may be considered in the context of administering one or more therapeutic agents, and a single agent may be considered to be given in an effective amount if, in conjunction with one or more other agents, a desirable or beneficial results may be or is achieved. Suitable doses of any of the co-administered compounds may optionally be lowered due to the combined action (e.g., additive or synergistic effects) of the compounds. In various embodiments, an effective amount of the composition or therapy may (i) reduce the number of cancer cells; )(ii) reduce tumor size; (iii) inhibit, retard, slow to some extent, and preferably stop cancer cell infiltration into peripheral organs; (iv) inhibit (e.g., slow to some extent and preferably stop) tumor metastasis; (v) inhibit tumor growth; (vi) prevent or delay occurrence and / or recurrence of a tumor; and / or (vii) relieve to some extent one or more of the symptoms associated with the cancer. In various embodiments, the amount is sufficient to ameliorate, palliate, lessen, and / or delay one or more of symptoms of cancer.
[0088] A “prophylactically effective amount” refers to an amount of a compound, or pharmaceutically acceptable salt thereof, sufficient to prevent or reduce the severity of one or more future symptoms of a disease or disorder when administered to a subject who is susceptible and / or who may develop the disease or disorder. For prophylactic use, beneficial or desired results include, e.g., results such as eliminating or reducing the risk, lessening the severity of future disease, or delaying the onset of the disease (e.g., delaying biochemical,histologic and / or behavioral symptoms of the disease, its complications, and intermediate pathological phenotype presenting during future development of the disease).
[0089] It is understood that an effective amount of a compound as disclosed herein, or pharmaceutically acceptable salt thereof, including a prophylactically effective amount, may be given to a subject in the adjuvant setting, which refers to a clinical setting in which a subject has had a history of the disease or disorder, and generally (but not necessarily) has been responsive to therapy, which includes, but is not limited to, surgery (e.g., surgical resection), radiotherapy, and chemotherapy. However, because of their or their family’s history of the disease or disorder, these subjects are considered at risk of developing it. Treatment or administration in the “adjuvant setting” refers to a subsequent mode of treatment.
[0090] As used herein, “unit dosage form” refers to physically discrete units, suitable as unit dosages, each unit containing a predetermined quantity of active ingredient calculated to produce a desired therapeutic effect, in association with the required pharmaceutical carrier or excipient. Unit dosage forms may contain a single compound or a combination therapy.
[0091] As used herein, the term “controlled release” refers to a formulation or fraction thereof containing an active pharmaceutical ingredient in which release of the pharmaceutical is not immediate. Thus, with a “controlled release” formulation, administration to a subject does not result in immediate release of the drug into the subject’s circulation. The term encompasses depot formulations designed to gradually release the drug compound over an extended period of time. Controlled release formulations can include a wide variety of drug delivery systems, generally involving mixing the drug compound with carriers, polymers or other compounds having the desired release characteristics (e.g., pH-dependent or non-pH- dependent solubility, different degrees of water solubility, and the like), and formulating the mixture according to the desired route of delivery, (e.g., coated capsules, implantable reservoirs, injectable solutions containing biodegradable capsules, and the like).
[0092] As used herein, by “pharmaceutically acceptable” or “pharmacologically acceptable” is meant a material that is not biologically or otherwise undesirable, e.g., the material may be incorporated into a pharmaceutical composition administered to a patient without causing any significant undesirable biological effects or interacting in a deleterious manner with any of the other components of the composition in which it is contained. Pharmaceutically acceptable carriers or excipients have preferably met the required standards of toxicological and manufacturing testing and / or are included on the Inactive Ingredient Guide prepared and updated by the U.S. Food and Drug Administration.
[0093] The term “excipient” as used herein means an inert or inactive substance that may be used in the production of a drug or pharmaceutical, such as a tablet containing a compound of the invention as an active ingredient. Various substances may be embraced by the term excipient, including without limitation any substance used as a binder, disintegrant, coating, compression / encapsulation aid, cream or lotion, lubricant, solutions for parenteral administration, materials for chewable tablets, sweetener or flavoring, suspending / gelling agent, or wet granulation agent. Binders include, e.g., carbomers, povidone, or xanthan gum. Coatings include, e.g., cellulose acetate phthalate, ethylcellulose, gellan gum, maltodextrin, enteric coatings. Compression / encapsulation aids include, e.g., calcium carbonate, dextrose, fructose de (de means “directly compressible”), honey de, lactose (anhydrate or monohydrate; optionally in combination with aspartame, cellulose, or microcrystalline cellulose), starch de, sucrose. Disintegrants include, e.g., croscarmellose sodium, gellan gum, sodium starch glycolate. Creams or lotions include, e.g., maltodextrin, carrageenans. Lubricants include, e.g., magnesium stearate, stearic acid, sodium stearyl fumarate. Materials for chewable tablets include, e.g. dextrose, fructose de, lactose (monohydrate, optionally in combination with aspartame or cellulose). Suspending / gelling agents include, e.g., carrageenan, sodium starch glycolate, xanthan gum. Sweeteners include, e.g., aspartame, dextrose, fructose de, sorbitol, sucrose de, etc.; and wet granulation agents include, e.g., calcium carbonate, maltodextrin, microcrystalline cellulose, etc. In some cases, the terms “excipient” and “carrier” are used interchangeably.
[0094] The term “subject” or “patient” refers humans, whether adult juvenile or infant, but may also encompass other higher animals such as mammals, in which case the term may include, but is not limited to, primates, cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice.
[0095] The terms “abnormal cell growth,” “unregulated cell growth,” and “hyperproliferative disorder” are used interchangeably in this application. “Abnormal cell growth”, as used herein, unless otherwise indicated, refers to cell growth that is independent of normal regulatory mechanisms (e.g., loss of contact inhibition).Compounds
[0096] The compounds disclosed herein are compounds of Formula (I) ot (II), or salts (e.g., pharmaceutically acceptable salts), solvates (e.g,, hydrates), prodrugs, metabolites, or derivatives thereof These compounds are useful inhibitors of Cbl-B, and are slective over C-cbl.
[0097] In one aspect, provided is a compound of Formula (I):or a salt (e.g., a pharmaceutically acceptable salt), solvate (e.g., hydrate), prodrug, metabolites or derivative thereof, wherein:Q is a 5 -membered heteroaryl group, optionally substituted by one or more alkyl, cycloalkyl, or haloalkyl groups;Y1and Y2 are independently CH, CF, or N; R1is dialkylamino, cyano, halo, haloalkyl, alkoxy, haloalkoxy, sulfonyl, alkyl, or cycloalkyl,J is C(R3)(R4), wherein: R3, R4are independently selected from: H, halogen, CN, OH, amino, and LoaR2a, wherein Loa is O, NRo, CHRo, C(=O), or a bond, wherein Ro is H or alkyl, and R2a is selected from alkyl, alkenyl, alkynyl, alkylcarboxy, cyanoalkyl, aminoalkyl, hydroxy alkyl, haloalkyl, and a 3 - 14 membered ring moiety, wherein at least one of R3and R4is not H; or R3and R4together with the carbon atom to which they are both bonded form a 3 - 14 membered ring moiety, wherein: if either of R3or R4is alkyl, haloalkyl, or hydroxyalkyl, R3or R4is optionally substituted by a 3 - 14 membered ring moiety; and wherein, if either of R3or R4is a 3 - 14 membered ring moiety, or R3and R4together are a 3 - 14 membered ring moiety, the ring moiety is selected from: a monocyclic ring, a fused bicyclic ring system, a bridged bicyclic ring system, and a spirocyclic ring system, and wherein the ring moiety: is saturated; is carbocyclic, heterocyclic, or heteroaryl; and is optionally substituted by one or more groups independently selected from halogen, CN, amino, oxo, alkenyl, carbenyl, alkynyl, OH, or L0bR2b, wherein L0bis CH2, C(=O), NH, O, S, S(=O), S(=O)2, or a bond, and R2bis alkyl, cycloalkyl, heterocyclyl, alkenyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, cyanoalkyl, and aminoalkyl;R5is selected from: H, halo, or L1-R10, wherein L1is -N(Rii)-, -C(=O)N(R11)-, O, S, carbonyl, or a bond, and wherein R10and R11are independently H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, and when either of R10and R11are not H, R10or R11is optionally substituted by one or more groups selected from: halo, CN, amino, oxo, OH, alkoxy, alkyl, perhaloalkyl, haloalkyl, heterocyclyl, aryl, and heteroaryl, or R10and R11together form a cycloalkyl or heterocyclyl ring, a spirocyclic ring, a fused bicyclic ring, or a bridged bicyclic ring, wherein the ring formed by R10and R11together is optionally substituted by one or more groups selected from halo, CN, amino, oxo, carbenyl, OH, alkoxy, alkyl, perhaloalkyl, or haloalkyl;Z is - L2NR7R8wherein:L2is -C(H)R6a- or-C(H)R6aC(H)R6b-;R6aand R6bare each independently selected from H, alkyl, hydroxyl, halo, cycloalkyl, heterocyclyl, haloalkyl, alkoxy, and hydroxyalkyl, wherein if either of R6aor R6bis allcyl it is optionally substituted by cycloalkyl, and if either of R6aor R6bis cycloalkyl it is optionally substituted by halo, cyano, sulfonyl, hydroxyl, alkoxy, aminocarbonyl, hetercyclyl, heteroaryl, alkyl or cycloalkyl; and R7andR8are independentLly3R9, wherein:L3= -(C(H) R10)n-, or a bond, wherein n = 1 or 2; R10is selected from H and alkyl; R9is selected from H, alkyl, haloalkyl, perhaloalkyl, hydroxyalkyl, aminoalkyl, cycloalkyl, hydroxyalkyl, alkoxyalkyl, alkyl alkanoate, heterocyclyl, spirocyclyl ring system, fused ring system, bicyclyl ring system, a 5 or 6 member heteroaromatic ring, or a 3 - 10 member fused heteroaromatic ring system, and a bridged bicyclyl ring; and wherein, if any of R7or R8is cycloalkyl, heterocyclyl, spirocyclyl, a fused bicyclyl, a bridged bicyclic ring, a 5 or 6 member heteroaromatic ring, or a 3 - 10 member fused heteroaromatic ring system, said ring or ring system is optionally substituted with one or more groups selected from: sulfonyl, halo, hydroxyl, alkoxy, alkyl, cycloalkyl, alkoxyalkyl, carbenyl, alkenyl, hydroxyalkyl, cyano, carboxyalkyl, or haloalkyl.
[0098] In some preferred embodiments of the compound of formula (I), or a salt (e.g., a pharmaceutically acceptable salt) thereof, Q is a 1,3,4-triazole (e.g., l,3,4-triazol-2-yl) optionally substituted by one or more alkyl, cycloalkyl, or haloalkyl groups; Y1is CH, CF, or N; Y2 is CH; J is C(R3)(R4); R1is halo or haloalkyl (e.g., trifluoromethyl); R5is H or or L1-R10; Z is -L2NR7R8wherein L2is -C(H)R6a-; and R3, R4, R6a, R7, R8, L1and R10are as defined for formula (I) or variations detailed herein. In some of these embodiments, R6ais H or alkyl (e.g.,methyl). In some of these embodiments, J is C(R3)(R4) where R3and R4together with the carbon atom to which they are both bonded to form a 3 - 14 membered ring moiety. In one variation, the 3 - 14 membered ring moiety is a cycloalkyl (e.g., cyclobutyl) optionally substituted by one or more groups independently selected from halogen, CN, amino, oxo, alkenyl, OH, and LobR2b, wherein L0bis CH2, C(=O), NH, O, S, S(=O), S(=O)2, or a bond, and R2bis alkyl, cycloalkyl, heterocyclyl, alkenyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, cyanoalkyl, and aminoalkyl. In one variation, L0bis CH2or O, and R2bis alkyl or haloalkyl. In some of these embodimentRs,8is H or alkyl and R7is L3R9whereinL3is CH2and R9is cycloalkyl (e.g., cyclobutyl) optionally substituted by one or more groups independently selected from halogen, CN, amino, oxo, OH, alkyl and haloalkyl.
[0099] In some embodiments, provided is a compound of Formula (I):or a salt (e.g., a pharmaceutically acceptable salt), solvate (e.g., hydrate), prodrug, metabolites or derivative thereof, wherein:Q is a 5 -membered heteroaryl group, optionally substituted by one or more alkyl, cycloalkyl, or haloalkyl groups;Y1and Y2 are independently CH, CF, orN; R1is dialkylamino, cyano, halo, haloalkyl, alkoxy, haloalkoxy, alkyl, or cycloalkyl,J is C(R3)(R4), wherein: R3, R4are independently selected from: H, halogen, CN, OH, amino, and LoaR2a, wherein L0ais O, NRo, CHRo, C(=O), or a bond, wherein Ro is H or alkyl, and R2ais selected from alkyl, alkenyl, alkynyl, alkylcarboxy, cyanoalkyl, aminoalkyl, hydroxy alkyl, haloalkyl, and a 3 - 14 membered ring moiety, wherein at least one of R3and R4is not H; or R3and R4together with the carbon atom to which they are both bonded form a 3 - 14 membered ring moiety, wherein: if either of R3or R4is alkyl, haloalkyl, or hydroxyalkyl, R3or R4is optionally substituted by a 3 - 14 membered ring moiety; and wherein, if either of R3or R4is a 3 - 14 membered ring moiety, or R3and R4together are a 3 - 14 membered ring moiety, the ring moiety is selected from:a monocyclic ring, a fused bicyclic ring system, a bridged bicyclic ring system, and a spirocyclic ring system, and wherein the ring moiety: is saturated; is carbocyclic, heterocyclic, or heteroaryl; and is optionally substituted by one or more groups independently selected from halogen, CN, amino, oxo, alkenyl, carbenyl, OH, or L0bR2b, wherein L0bis CH2, C(=O), NH, O, S, S(=O), S(=O)2, or a bond, and R2bis allcyl, cycloalkyl, heterocyclyl, alkenyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, cyanoalkyl, and aminoalkyl; R5is selected from: H, halo, or L1-R10, wherein L1is -N(R11)-, -C(=O)N( R11)-, O, S, carbonyl, or a bond, and wherein R10and R11are independently H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, and when either of R10and R11are not H, R10or R11is optionally substituted by one or more groups selected from: halo, CN, amino, oxo, OH, alkoxy, alkyl, perhaloalkyl, haloalkyl, heterocyclyl, aryl, and heteroaryl, or R10and R11together form a cycloalkyl or heterocyclyl ring, a spirocyclic ring, a fused bicyclic ring, or a bridged bicyclic ring, wherein the ring formed by R10and R11together is optionally substituted by one or more groups selected from halo, CN, amino, oxo, carbenyl, OH, alkoxy, alkyl, perhaloalkyl, or haloalkyl;Z is -L2NR7R8wherein:L2is -C(H)R6a- or -C(H)R6aC(H)R6b-;Rba and R6bare each independently selected from H, alkyl, hydroxyl, halo, cycloalkyl, haloalkyl, alkoxy, and hydroxyalkyl, wherein if either of R6aor R6bis alkyl it is optionally substituted by cycloalkyl, and if either of R6aor R6bis cycloalkyl it is optionally substituted by halo, alkyl or cycloalkyl; and R7andR8are independentLly3R9, wherein: L3= — (C(H) R10)n— , or a bond, wherein n = 1 or 2; R10is selected from H and alkyl; R9is selected from H, alkyl, haloalkyl, perhaloalkyl, hydroxyalkyl, aminoalkyl, cycloalkyl, hydroxyalkyl, alkoxyalkyl, alkyl alkanoate, heterocyclyl, spirocyclyl ring system, fused ring system, bicyclyl ring system, a 5 or 6 member heteroaromatic ring, or a 3 - 10 member fused heteroaromatic ring system, and a bridged bicyclyl ring; and wherein, if any of R7orR8is cycloalkyl, heterocyclyl, spirocyclyl, a fused bicyclyl, a bridged bicyclic ring, a 5 or 6 member heteroaromatic ring, or a 3 - 10 member fused heteroaromatic ring system, said ring or ring system is optionally substituted with one or moregroups selected from: sulfonyl, halo, hydroxyl, alkoxy, alkyl, cycloalkyl, alkoxyalkyl, carbenyl, alkenyl, hydroxyalkyl, cyano, carboxyalkyl, or haloalkyl.
[0100] In some embodiments, the compound of formula (I) is of the formula (I-A):or a salt (e.g., a pharmaceutically acceptable salt), solvate (e.g., hydrate), prodrug, metabolites or derivative thereof, wherein Yi, Ri, R3, R4, R5, R6a, R7andR8are as defined herein for formula (I) or any applicable variations detailed herein.
[0101] In some embodiments of the compound of formula (I-A), or a salt (e.g., a pharmaceutically acceptable salt) thereof, wherein:Y1is CH, CF, or N (e.g., CH or N); R1is halo (e.g., chloro) or haloalkyl (e.g., trifluoromethyl); R3and R4together with the carbon atom to which they are both bonded to form a 3-14 membered ring moiety (e.g., 3-14 membered cycloalkyl or 3-14 membered heterocyclyl), optionally substituted by one or more groups independently selected from halogen, CN, amino, oxo, alkenyl, OH, and L0bRab, wherein L0bis CH2, C(=O), NH, O, S, S(=O), S(=O)2, or a bond, and R2bis alkyl, cycloalkyl, heterocyclyl, alkenyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, cyanoalkyl, and aminoalkyl; R5is H or L1-R10, wherein L1is -N(R11)-, -C(=O)N(R11)-, O, S, carbonyl, or a bond, and wherein R10and R11are independently H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, and when either of R10and R11are not H, R10or R11is optionally substituted by one or more groups selected from: halo, CN, amino, oxo, OH, alkoxy, alkyl, perhaloalkyl, haloalkyl, heterocyclyl, aryl, and heteroaryl;R6ais H or alkyl (e.g., methyl); R7isL3R9wherein L3is CH2and R9is alkyl or cycloalkyl (e.g., cyclobutyl), each is optionally substituted by one or more groups independently selected from halogen, CN, amino, oxo, OH, alkyl and haloalkyl; and R8is H or alkyl.
[0102] In some embodiments of the compound of formula (I-A), or a salt (e.g., a pharmaceutically acceptable salt) thereof, wherein:Y1is CH, CF, or N (e.g., CH or N); R1is halo (e.g., chloro) or haloalkyl (e.g., trifluoromethyl); R3is a 3-14 membered ring moiety (e.g., 3-14 membered cycloalkyl or 3-14 membered heterocyclyl), optionally substituted by one or more groups independently selected from halogen, CN, amino, oxo, alkenyl, OH, and L0bR2b, wherein L0bis CH2, C(=O), NH, O, S S(=O), S(=O)2, or a bond, and R2bis alkyl, cycloalkyl, heterocyclyl, alkenyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, cyanoalkyl, and aminoalkyl; R4is H; R5is H or L1-R10, wherein L1is -N(R11)-, -C(=O)N(R11)-, O, S, carbonyl, or a bond, and wherein R10and R11are independently H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, and when either of R10and R11are not H, R10or R11is optionally substituted by one or more groups selected from: halo, CN, amino, oxo, OH, alkoxy, alkyl, perhaloalkyl, haloalkyl, heterocyclyl, aryl, and heteroaryl;R6ais H or alkyl (e.g., methyl); R7isL3R9whereinL3is CH2and R9is cycloalkyl (e.g., cyclobutyl) optionally substituted by one or more groups independently selected from halogen, CN, amino, oxo, OH, alkyl and haloalkyl; and R8is H or alkyl.
[0103] Also consistent with the methods and desriptions herein are certain amide compounds, in particular picolinamide compounds havinln another aspect, provided is a compound of the formula (II)or a salt (e.g., a pharmaceutically acceptable salt), solvate (e.g., hydrate), prodrug, metabolites or derivative thereof, wherein:Y1is CH, CF, or N; R5is selected from: H, halo, or L1-R10, wherein L1is -N(R11)-, -C(=O)N(Rii)-, O, S, carbonyl, or a bond, and wherein R10and R11are independently H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, and when either of R10and R11are not H, R10or R11is optionally substituted by one or more groups selected from: halo, CN, amino, oxo, OH, alkoxy, alkyl, perhaloalkyl, haloalkyl, heterocyclyl, aryl, and heteroaryl, or R10and R11together form a cycloalkyl or heterocyclyl ring, a spirocyclic ring, a fused bicyclic ring, or a bridged bicyclic ring, wherein the ring formed by R10and Rii together is optionally substituted by one or more groups selected from halo, CN, amino, oxo, carbenyl, OH, alkoxy, alkyl, perhaloalkyl, or haloalkyl;J is C( R3)(R4), wherein: R3, R4are independently selected from: H, halogen, CN, OH, amino, and LoaR2a, wherein Loa is O, NRo, CHRo, C(=O), or a bond, wherein Ro is H or alkyl, and R2a is selected from alkyl, alkenyl, alkynyl, alkylcarboxy, cyanoalkyl, aminoalkyl, hydroxy alkyl, haloalkyl, and a 3 - 14 membered ring moiety, wherein at least one of R3and R4is not H; or R3and R4together with the carbon atom to which they are both bonded form a 3 - 14 membered ring moiety, wherein: if either of R3or R4is allcyl, haloalkyl, or hydroxyalkyl, R3or R4is optionally substituted by a 3 - 14 membered ring moiety; and wherein, if either of R3or R4is a 3 - 14 membered ring moiety, or R3and R4together are a 3 - 14 membered ring moiety, the ring moiety is selected from: a monocyclic ring, a fused bicyclic ring system, a bridged bicyclic ring system, and a spirocyclic ring system, and wherein the ring moiety is saturated, carbocyclic, heterocyclic, or heteroaryl, and is optionally substituted by one or more groups independently selected from halogen, CN, amino, oxo, alkenyl, carbenyl, OH, or L0bR2b, wherein L0bis CH2, C(=O), NH, O, S, S(=O), S(=O)2, or a bond, and R2bis alkyl, cycloalkyl, heterocyclyl, alkenyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, cyanoalkyl, and aminoalkyl;Q is a 5-membered heteroaryl, optionally substituted by one or more alkyl, cycloalkyl, or haloalkyl groups;Xi and X2 are independently H, halo, haloalkyl, dialkylamino, cyano, alkoxy, haloalkoxy, alkyl, or cycloalkyl, wherein at least one of Xi and X2 is not H; one of Zi and Z2 is H and the other is -L2aNR7R8,L2ais -C(H)R6a- or -C(H)R6aC(H)R6b-;R6aand R6bare each independently selected from H, alkyl, hydroxyl, halo, cycloalkyl, haloalkyl, alkoxy, and hydroxyalkyl, wherein if either of R6aor R6bis alkyl it is optionally substituted by cycloalkyl, and if either of R6aor R6bis cycloalkyl it is optionally substituted by halo, alkyl or cycloalkyl; and R7andR8are independentLly3R9, wherein: L3= — (C(H) R10)n— , or a bond, wherein n = 1 or 2; R10is selected from H and alkyl;R9is selected from H, alkyl, haloalkyl, perhaloalkyl, hydroxyalkyl, aminoalkyl, cycloalkyl, hydroxyalkyl, alkoxyalkyl, alkyl alkanoate, heterocyclyl, spirocyclyl ring system, fused ring system, bicyclyl ring system, a 5 or 6 member heteroaromatic ring, or a 3 - 10 member fused heteroaromatic ring system, and a bridged bicyclyl ring; and wherein, if any of R7orR8is cycloalkyl, heterocyclyl, spirocyclyl, a fused bicyclyl, a bridged bicyclic ring, a 5 or 6 member heteroaromatic ring, or a 3 - 10 member fused heteroaromatic ring system, said ring or ring system is optionally substituted with one or more groups selected from: sulfonyl, halo, hydroxyl, alkoxy, alkyl, cycloalkyl, alkoxyalkyl, carbenyl, alkenyl, hydroxyalkyl, cyano, carboxyalkyl, or haloalkyl.
[0104] In one aspect, the present disclosure provides for compounds of formula (I):
[0105] In the following description of substituents and variable positions in formula (I), it would be understood that subsets, including any individual member, of the list of possible substituents at any position can be chosen freely when describing preferred classes of compounds.
[0106] In formula (I), Q is a 5-membered heteroaryl group, optionally substituted by one or more alkyl, cycloalkyl, or haloalkyl groups.
[0107] In formula (I), Y1and Y2 are independently CH, CF, or N.
[0108] In formula (I), R1is dialkylamino, cyano, halo, haloalkyl, alkoxy, haloalkoxy, alkyl, or cycloalkyl.
[0109] In formula (I), J is C(Ra)(R4), wherein: R3, R4are independently selected from: H, halogen, CN, OH, amino, and LoaR2a, wherein Loa is O, NRo, CHRo, C(=O), or a bond, wherein R0is H or alkyl, and R2a is selected from alkyl, alkenyl, alkynyl, alkylcarboxy, cyanoalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, and a 3 - 14 membered ring moiety, wherein at least one of R3and R4is not H; or
[0110] R3and R4together with the carbon atom to which they are both bonded form a 3 - 14 membered ring moiety, wherein:if either of R3or R4is alkyl, haloalkyl, or hydroxyalkyl, R3or R4is optionally substituted by a 3 - 14 membered ring moiety; and wherein, if either of R3or R4is a 3 - 14 membered ring moiety, or R3and R4together are a 3 - 14 membered ring moiety, the ring moiety is selected from: a monocyclic ring, a fused bicyclic ring system, a bridged bicyclic ring system, and a spirocyclic ring system, and wherein the ring moiety: is saturated; is carbocyclic, heterocyclic, or heteroaryl; and is optionally substituted by one or more groups independently selected from halogen, CN, amino, oxo, alkenyl, carbenyl, OH, or L0bRsb, wherein L0bis CH2, C(=O), NH, O, S, S(=O), S(=O)2, or a bond, and R2bis alkyl, cycloalkyl, heterocyclyl, alkenyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, cyanoalkyl, and aminoalkyl.
[0111] R5is selected from: H, halo, or L1-R10, wherein L1is -N(Rii)-, -C(=O)N(R11)-, O, S, carbonyl, or a bond, and wherein R10and R11are independently H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, and when either of R10and R11are not H, R10or R11is optionally substituted by one or more groups selected from: halo, CN, amino, oxo, OH, alkoxy, alkyl, perhaloalkyl, haloalkyl, heterocyclyl, aryl, and heteroaryl, or R10and R11 together form a cycloalkyl or heterocyclyl ring, a spirocyclic ring, a fused bicyclic ring, or a bridged bicyclic ring, wherein the ring formed by R10and R11together is optionally substituted by one or more groups selected from halo, CN, amino, oxo, carbenyl, OH, alkoxy, alkyl, perhaloalkyl, or haloalkyl;
[0112] Z is -L2NR7R8wherein:L2is -C(H)R6a- or -C(H)R6aC(H)R6b-;R6aand R6bare each independently selected from H, alkyl, hydroxyl, halo, cycloalkyl, haloalkyl, alkoxy, and hydroxyalkyl, wherein if either of R6aor R6bis alkyl it is optionally substituted by cycloalkyl, and if either of R6aor R6bis cycloalkyl it is optionally substituted by halo, alkyl or cycloalkyl; and R7andR8are independentlLy3R9, wherein: L3= — (C(H) R10)n_, or a bond, wherein n = 1 or 2; R10is selected from H and alkyl;R9is selected from H, alkyl, haloalkyl, perhaloalkyl, hydroxyalkyl, aminoalkyl, cycloalkyl, hydroxyalkyl, alkoxyalkyl, alkyl alkanoate, heterocyclyl, spirocyclyl ring system, fused ring system, bicyclyl ring system, a 5 or 6 member heteroaromatic ring, or a 3 — 10 member fused heteroaromatic ring system, and a bridged bicyclyl ring; and wherein, if any of R7or R8is cycloalkyl, heterocyclyl, spirocyclyl, a fused bicyclyl, a bridged bicyclic ring, a 5 or 6 member heteroaromatic ring, or a 3 - 10 member fused heteroaromatic ring system, said ring or ring system is optionally substituted with one or more groups selected from: sulfonyl, halo, hydroxyl, alkoxy, alkyl, cycloalkyl, alkoxyalkyl, carbenyl, alkenyl, hydroxyalkyl, cyano, carboxyalkyl, or haloalkyl.
[0113] Enantiomers, diastereomers or pharmaceutically acceptable salts or solvates of the structures of Formula (I) are also included.
[0114] The disclosure comprises compounds of formula (I), wherein Q is 4-methyl-3- cyclobutyl-4H- 1 ,2,4-triazole.
[0115] The disclosure comprises compounds of formula (I), wherein Y1= Y2 = CH.
[0116] The disclosure comprises compounds of formula (I), wherein R1= H, CHF2, CF3, cyclopropyl, F, Cl, CH3, OCH3, OCF3, OCHF2, -CN, or -N(CH3)2.
[0117] The disclosure comprises compounds of formula (I), wherein R1= CF3.
[0118] The disclosure comprises compounds of formula (I), wherein R1= Cl.
[0119] The disclosure comprises compounds of formula (I), wherein R3is H or F, and R4is selected from 3-oxetanyl, cyclobutyl, alkyl, and alkoxyalkyl, and wherein R4is optionally substituted by one or more groups selected from: halo, cyano, hydroxyl, and cyanoalkyl.
[0120] The disclosure comprises compounds of formula (I), wherein R3is H and R4is selected from 3-oxetanyl, 3-fhioro-cyclobytyl, and 3 -cyanomethylcyclobutyl.
[0121] The disclosure comprises compounds of formula (I), wherein R3is H, and R4is selected from: methyl, ethyl, isopropyl, methoxymethyl, and cyanoethyl, and wherein R4is optionally substituted by halo, or hydroxyl.
[0122] The disclosure comprises compounds of formula (I), wherein R3and R4together with the carbon atom to which they are both bonded form a 3 - 8 membered ring moiety selected from: cyclobutyl, oxetanyl, and spiro[3.3]hept-2-yl, wherein the ring moiety is optionally substituted by one or more groups independently selected from: halo, alkenyl, cyano, haloalkyl, alkoxy, and haloalkoxy.
[0123] The disclosure comprises compounds of formula (I), wherein R3and R4together with the carbon atom to which they are both bonded form a cyclobutyl ring, and the cyclobutyl ring is substituted by a group selected from: fluoro, chloro, cyano, vinyl, methoxy, difluoromethoxy, trifluoromethoxy, difluoromethyl, trifluoromethyl, and 1,1, -difluoroethyl.
[0124] The disclosure comprises compounds of formula (I), wherein R3and R4together with the carbon atom to which they are both bonded form a cyclobutyl ring.
[0125] The disclosure comprises compounds of formula (I), wherein R3and R4together with the carbon atom to which they are both bonded form a spirocyclic ring moiety having 5 - 8 ring atoms.
[0126] The disclosure comprises compounds of formula (I), wherein R3and R4together with the carbon atom to which they are both bonded form a ring moiety twice substituted by fluoro.
[0127] The disclosure comprises compounds of formula (I), where one of R3and R4is C1-6alkyl and the other is H.
[0128] The disclosure comprises compounds of formula (I) wherein R5is H.
[0129] The disclosure comprises compounds of formula (I), wherein L2is -C(H)R6aC(H)R6b-, and R6ais hydroxyl, methyl, or H, and R6bis H.
[0130] The disclosure comprises compounds of formula (I), wherein: R7is cyclobutyl, optionally substituted by one or two instances of fluoro, or methyl; andR8is H.
[0131] The disclosure comprises compounds of formula (I), wherein R7is1 -methylcyclobutyl, andR8is H.
[0132] The disclosure comprises compounds of formula (I), wherein Z is -C(H)R6aNR7R8, and wherein: R6ais H, methyl, or cyclopropyl-methy; R7is cyclobutyl, which is optionally substituted with one or more methyl or fluoro groups; andR8is H.
[0133] The disclosure comprises compounds of formula (I), wherein Z is -C(H)R6aNR7R8, and wherein: R6ais H, or methyl; R7isL3R9, whereinL3is CH2, and R9is cyclobutyl or cyclopropyl, and wherein R9is optionally substituted with methyl or fluoro; andR8is H.
[0134] The disclosure comprises compounds of formula (I), wherein Z is -C(H)R6aNR7R8, and wherein: R6ais H, or methyl; R7isL3R9, whereinL3is a bond, and R9is alkyl; andR8is H.
[0135] The disclosure comprises compounds of formula (I), wherein Z is -C(H)R6NR7R8, and wherein: R6 is H or methyl; R7is cyclobutyl, optionally substituted with methyl or fluoro; andR8is H.
[0136] The disclosure comprises compounds of formula (I), wherein Z is -C(H)R6aNR7R8, and wherein: R6ais H, or methyl; R7isL3R9, whereinL3is a bond, and R9is Ci-ealkyl; and R8is H.
[0137] The disclosure comprises compounds of formula (I), wherein Z is -C(H)R6aN R7R8, and wherein: R6ais H, or methyl; R7is L3R9, whereinL3is CH(CH3), and R9is cyclobutyl; and R8is H.
[0138] R6presentative lactam (isoindolin-l-one) compounds according to formula (I) are shown in Table 1. It is understood that individual enatiomers and diastereomers are included in the table below by Compound No. and Copound Name, and their corresponding structures can be readily determined therefrom. In some instances, the enantiomers or diastereomers are identified by their respective perperties, for example, retention times on a chiral HPLC or its biological activities, and the absolute stereo configurations of the chiral centers are arbitrarily assigned. It is further to be understood that inclusion of a single particular stereoisomer (such as enantiomer or diastereomer) of a particular molecule does not preclude its partner enantiomer, or another stereoisomer thereof, from being encompassed by the current disclosure.Table 1L3
[0139] In some embodiments, provided is a compound selected from Compound Nos.1-345 in Table 1, or a salt (e.g., a pharmaceutically acceptable salt) thereof. In some embodiments, provided is a compound selected from Compound Nos.1-128 in Table I, or a salt (e.g., a pharmaceutically acceptable salt) thereof. In some embodiments, provided is a compound selected from Compound Nos.129-345 in Table 1, or a salt (e.g., a pharmaceutically acceptablesalt) thereof. In some embodiments, provided is a compound selected from Compound Nos. 6, 13, 19, 55, 63 and 113 in Table 1, or a salt (e.g., a pharmaceutically acceptable salt) thereof. In some embodiments, provided is a compound selected from Compound Nos. 129, 137, 153, 155, 157, 167, 180, 182, 202, 224, 245, 247, 281 and 289 in Table 1, or a salt (e.g., a pharmaceutically acceptable salt) thereof.
[0140] Also consistent with the methods and desriptions herein are certain amide compounds, in particular picolinamide compounds having formula (II).
[0141] In the following description of substituents and variable positions in formula (II), it would be understood that subsets, including any individual member, of the list of possible substituents at any position can be chosen freely when describing preferred classes of compounds.
[0142] In formula (II), J is C( R3)(R4), wherein: R3, R4are independently selected from: H, halogen, CN, OH, amino, and Loa R2a, wherein Loa is O, NRo, CHRo, C(=O), or a bond, wherein Ro is H or alkyl, and R2ais selected from alkyl, alkenyl, alkynyl, alkylcarboxy, cyanoalkyl, aminoalkyl, hydroxy alkyl, haloalkyl, and a 3 - 14 membered ring moiety, wherein at least one of R3and R4is not H; or R3and R4together with the carbon atom to which they are both bonded form a 3 - 14 membered ring moiety, wherein: if either of R3or R4is alkyl, haloalkyl, or hydroxyalkyl, R3or R4is optionally substituted by a 3 - 14 membered ring moiety; and wherein, if either of R3or R4is a 3 - 14 membered ring moiety, or R3and R4together are a 3 - 14 membered ring moiety, the ring moiety is selected from: a monocyclic ring, a fused bicyclic ring system, a bridged bicyclic ring system, and a spirocyclic ring system, and wherein the ring moiety: is saturated; is carbocyclic, heterocyclic, or heteroaryl; and is optionally substituted by one or more groups independently selected from halogen, CN, amino, oxo, alkenyl, carbenyl, OH, or L0bR2b, wherein L0bis CH2,C(=O), NH, O, S, S(=O), S(=O)2, or a bond, and R2bis alkyl, cycloalkyl,heterocyclyl, alkenyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, cyanoalkyl, and aminoalkyl.
[0143] Q is a 5-membered heteroaryl, optionally substituted by one or more alkyl, cycloalkyl, or haloalkyl groups;
[0144] Y1is CH, CF, orN;
[0145] In some embodiments of R5is selected from: H, halo, or Li- R10, wherein L1is - N(R11)-, -C(=O)N(R1i)-, O, S, carbonyl, or a bond, and wherein R10and R11are independently H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, and when either of R10and R11are not H, R10or R11is optionally substituted by one or more groups selected from: halo, CN, amino, oxo, OH, alkoxy, alkyl, perhaloalkyl, haloalkyl, heterocyclyl, aryl, and heteroaryl, or R10and R11together form a cycloalkyl or heterocyclyl ring, a spirocyclic ring, a fused bicyclic ring, or a bridged bicyclic ring, wherein the ring formed by R10and R11together is optionally substituted by one or more groups selected from halo, CN, amino, oxo, carbenyl, OH, alkoxy, alkyl, perhaloalkyl, or haloalkyl;
[0146] Xi and X2 are independently H, halo, haloalkyl, dialkylamino, cyano, alkoxy, haloalkoxy, alkyl, or cycloalkyl, wherein at least one of Xi and X2 is not H;
[0147] One of Zi and Z2 is H and the other is -L2aNR7R8,L2a is -C(H)R6a- or -C(H)R6aC(H)R6b-;R6aand R6bare each independently selected from H, alkyl, hydroxyl, halo, cycloalkyl, haloalkyl, alkoxy, and hydroxyalkyl, wherein if either of R6aor R6bis alkyl it is optionally substituted by cycloalkyl, and if either of R6aor R6bis cycloalkyl it is optionally substituted by halo, alkyl or cycloalkyl; and R7and R8are independently L3R9, wherein: L3= -(C(H) R10)n- or a bond, wherein n = 1 or 2; R10is selected from H and alkyl; R9is selected from H, alkyl, haloalkyl, perhaloalkyl, hydroxyalkyl, aminoalkyl, cycloalkyl, hydroxyalkyl, alkoxyalkyl, alkyl alkanoate, heterocyclyl, spirocyclyl ring system, fused ring system, bicyclyl ring system, a 5 or 6 member heteroaromatic ring, or a 3 - 10 member fused heteroaromatic ring system, and a bridged bicyclyl ring; and wherein, if any of R7or R8is cycloalkyl, heterocyclyl, spirocyclyl, a fused bicyclyl, a bridged bicyclic ring, a 5 or 6 member heteroaromatic ring, or a 3 - 10 member fused heteroaromatic ring system, said ring or ring system isoptionally substituted with one or more groups selected from: sulfonyl, halo, hydroxyl, alkoxy, alkyl, cycloalkyl, alkoxyalkyl, carbenyl, alkenyl, hydroxyalkyl, cyano, carboxyalkyl, or haloalkyl.
[0148] An enantiomer, diastereomer or a pharmaceutically acceptable salt or solvate of the structures of Formula (II) are also included.
[0149] The disclosure comprises compounds of formula (II), wherein Q is 4-methyl-3- cyclobutyl-4H- 1 ,2,4-triazole .
[0150] The disclosure comprises compounds of formula (II), wherein Y1= CH.
[0151] The disclosure comprises compounds of formula (II), wherein X2 = H, and Xi = CHF2, CF3, cyclopropyl, F, Cl, CH3, OCH3, OCF3, OCHF2, -CN, or -N(CH3)2.
[0152] The disclosure comprises compounds of formula (II), wherein X2 = H and Xi = CF3.
[0153] The disclosure comprises compounds of formula (II), wherein X2 = H and Xi = cyclopropyl.
[0154] The disclosure comprises compounds of formula (II), wherein R3is H or F, and R4is selected from 3-oxetanyl, cyclobutyl, alkyl, and alkoxyalkyl, and wherein R4is optionally substituted by one or more groups selected from: halo, cyano, hydroxyl, and cyanoalkyl.
[0155] The disclosure comprises compounds of formula (II), wherein R3is H and R4is selected from 3-oxetanyl, 3-fluoro-cyclobytyl, and 3 -cyanomethylcyclobutyl.
[0156] The disclosure comprises compounds of formula (II), wherein R3is H, and R4is selected from: methyl, ethyl, isopropyl, methoxymethyl, and cyanoethyl, and wherein R4is optionally substituted by halo, or hydroxyl.
[0157] The disclosure comprises compounds of formula (II), wherein R3and R4together with the carbon atom to which they are both bonded form a 3 - 8 membered ring moiety selected from: cyclobutyl, oxetanyl, and spiro[3.3]hept-2-yl, wherein the ring moiety is optionally substituted by one or more groups independently selected from: halo, alkenyl, cyano, haloalkyl, alkoxy, and haloalkoxy.
[0158] The disclosure comprises compounds of formula (II), wherein R3and R4together with the carbon atom to which they are both bonded form a cyclobutyl ring, and the cyclobutyl ring is substituted by a group selected from: fluoro, chloro, cyano, vinyl, methoxy, difluoromethoxy, trifluoromethoxy, difluoromethyl, trifluoromethyl, and 1,1, -difluoroethyl.
[0159] The disclosure comprises compounds of formula (II), wherein R3and R4together with the carbon atom to which they are both bonded form a cyclobutyl ring.
[0160] The disclosure comprises compounds of formula (II), wherein R3and R4together with the carbon atom to which they are both bonded form a cyclobutyl ring substituted by a group selected from: methoxy, difluoromethoxy, and chloro.
[0161] The disclosure comprises compounds of formula (II), wherein R3and R4together with the carbon atom to which they are both bonded form a spirocyclic ring moiety having 5 - 8 ring atoms.
[0162] The disclosure comprises compounds of formula (II), wherein R3and R4together with the carbon atom to which they are both bonded form a ring moiety twice substituted by fluoro.
[0163] The disclosure comprises compounds of formula (II), where one of R3and R4is C1-6alkyl and the other is H.
[0164] The disclosure comprises compounds of formula (II) wherein R5is H.
[0165] The disclosure comprises compounds of formula (II), wherein L2is -C(H)R6aC(H)R6b-, and R6ais hydroxyl, methyl, or H, and R6bis H.
[0166] The disclosure comprises compounds of formula (II), wherein: Z2 = H; Zi = -L2aNR7R8; R7is cyclobutyl, optionally substituted by one or two instances of fluoro, or methyl; and R8is H.
[0167] The disclosure comprises compounds of formula (II), wherein R7is1 -methylcyclobutyl, and R i8s H.
[0168] The disclosure comprises compounds of formula (II), wherein Z2 = H and Zi is -C(H)R6aNR7R8, and wherein:R6ais H, methyl, or cyclopropyl-methy; R7is cyclobutyl, which is optionally substituted with one or more methyl or fluoro groups; and R8is H.
[0169] The disclosure comprises compounds of formula (I), wherein Z2 = H and Zi is - C(H)R6aNR7R8, and wherein:R6ais H, or methyl; R7is L3R9, wherein L i3s CH2, and R9is cyclobutyl or cyclopropyl, and wherein R9is optionally substituted with methyl or fluoro; and R8is H.
[0170] The disclosure comprises compounds of formula (I), wherein Z2 = H and Zi is -C(H)R6aNR7R8, and wherein:R6a is H, or methyl;R7is L3R9, wherein L3is a bond, and R9is alkyl; and R8is H.
[0171] The disclosure comprises compounds of formula (I), wherein Z2 = H and Zi is - C(H)R6NR7R8, and wherein:R6 is H or methyl; R7is cyclobutyl, optionally substituted with methyl or fluoro; and R8is H.
[0172] The disclosure comprises compounds of formula (I), wherein Z2 = H and Zi is - C(H)R6aNR7R8, and wherein:R6a is H, or methyl; R7is L3R9, wherein L3is a bond, and R9is Cl-6alkyl; and R8is H.
[0173] The disclosure comprises compounds of formula (I), wherein Z2 = H and Zi is - C(H)R6aNR7R8, and wherein:R6ais H, or methyl; R7is L3R9, wherein L i3s CH(CH3), and R9is cyclobutyl; and R8is H.
[0174] The present disclosure includes a process for making compounds of formula (II), particularly according to any of the synthetic methods disclosed herein.
[0175] Structure (II-A) is a preferred embodiment of formula (II), wherein, specifically, Ri and R2 are selected from H, C1-ealkyl, cycloalkyl, haloalkyl, halo, alkoxy, and haloalkoxy.
[0176] R6presentative amide compounds according to formula (II) are shown in Table Al. It is understood that individual enantiomers and diastereomers are included in Table Al, as applicable. It is further to be understood that inclusion of a single particular stereoisomer (such as enantiomer or diastereomer) of a particular molecule does not preclude its partner enantiomer, or another stereoisomer thereof, from being encompassed by the current disclosure.
[0177] The disclosure further comprises a method of treating a cancer, comprising administering to a subject in need thereof, a compound of formula (II), or a pharmaceutically acceptable salt or solvate thereof.Table Al
[0178] In some embodiments, provided is a compound selected from Compound Nos. Al- A14 in Table Al, or a salt (e.g., a pharmaceutically acceptable salt) thereof. In some embodiments, provided is a compound selected from Compound Nos. A1-A10 in Table Al, or a salt (e.g., a pharmaceutically acceptable salt) thereof. In some embodiments, provided is acompound selected from Compound Nos. Al 1-A14 in Table Al, or a salt (e.g., a pharmaceutically acceptable salt) thereof.General Synthetic Method
[0179] Compounds of Formula (I) can be prepared by precedures in the Examples and generally by General Scheme I, where R groups are as described in Formula (I), or precursors thereof.General Scheme I(la) (lb) (I)
[0180] A compound of formula (I), wherein Yi, Y2, Ri, R5, J, Q and Z are as defined herein for formula (I) and any applicable variations detailed herein, can be synthesized by coupling of a halide (e.g., bromide) compound of formula (la) with a lactam of formula (lb) in the presence of copper (I) iodide, (LS\2;S)-A A2-dimethylcyclohexane-I ,2-diamine (DMCyDA), a base (such as potassium carbonate) in an alcoholic solvent (such as tert-amyl alcohol) under heated conditions, for example at 100 °C under nitrogen for 2h. After cooled, the reaction mixture was diluted with ethyl acetate (25 mL).
[0181] In one example, a certain embodiment of formula (I), having the formula (I- A) may be synthesized according to General Scheme II, wherein Yi, Ri, R3, R4, R5, R6a, R7and areR8as defined herein for formula (I) and any applicable variations detailed herein.General Scheme II
[0182] The target compounds of formula (I-A) are sythesized from carboxylic acid starting material Al . Amide coupling with thio-urea A2 leads to intermediate A3, which undergoes cyclization to form triazole A4. R6moval of thiol is accomplished when A4 is treated with sodium nitrite in the presence of nitric acid to give triazole intermediate A5. Deprotonation with a base followed by mono- or di-alkylation gives intermediate A6. In the presence of copper (I) iodide, A6 is coupled to lactam A7 to produce the final target compounds.
[0183] Amide compounds of formula (II) may be synthesized according to the following exemplary synthetic procedures and generally by General Scheme III, where R groups are as described in Formula (II), or precursors thereof.
[0184] A compound of formula (II), wherein Xi, X2, Yi, Zi, Z2, R5, J and Q are as defined herein for formula (II) and any applicable variations detailed herein, can be synthesized by coupling of an amine of formula (Ila) with a carboxylic acid of formula (lib) in the presence of peptide coupling agents under suitable conditions, for example, HATU and DIEA, in DMF at 25°C.Pharmaceutical Compositions and Formulations
[0185] The presently disclosed compounds, such as those of formula (I) or (II), can be formulated into pharmaceutical compositions along with a pharmaceutically acceptable carrier or excipient. R6ferences in this section to compounds of formula (I) are as applicable to compounds of formula (II).
[0186] Compounds of Formula (I), can be formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition. According to this aspect, there is provided a pharmaceutical composition comprising a compound of Formula (I) in association with a pharmaceutically acceptable excipient, diluent or carrier.
[0187] A typical formulation is prepared by mixing a compound of Formula (I), and a carrier, diluent or excipient. Suitable carriers, diluents and excipients are well known to those skilled in the art and include materials such as carbohydrates, waxes, water soluble and / or swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water and the like. The particular carrier, diluent or excipient used will depend upon the means and purpose for which the compound of Formula (I), is being applied. Solvents are generally selected based on solvents recognized by persons skilled in the art as safe (GRAS) to be administered to a mammal. In general, safe solvents are non-toxic aqueous solvents such as water and other non-toxic solvents that are soluble or miscible in water. Suitable aqueous solvents include water, ethanol, propylene glycol, polyethylene glycols (e.g., PEG 400, PEG 300), etc. and mixtures thereof. The formulations may also include one or more buffers, stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents and other known additives to provide an elegant presentation of the drug (i.e., a compound of Formula (I), or pharmaceutical composition thereof) or aid in the manufacturing of the pharmaceutical product (i.e., medicament).
[0188] The formulations may be prepared using conventional dissolution and mixing procedures. For example, the bulk drug substance (i.e., compound of Formula (I), or stabilized form of the Compound of Formula (I), (e.g., complex with a cyclodextrin derivative or other known complexation agent) is di ssolved in a suitable solvent in the presence of one or more of the excipients described above. The compound of Formula (I) is typically formulated into pharmaceutical dosage forms to provide an easily controllabl e dosage of the drug and to enable patient compliance with the prescribed regimen.
[0189] The pharmaceutical composition (or formulation) for application may be packaged in a variety of ways depending upon the method used for administering the drug. Generally, an article for distribution includes a container having deposited therein the pharmaceutical formulation in an appropriate form. Suitable containers are well known to those skilled in the art and include materials such as bottles (plastic and glass), sachets, ampoules, plastic bags, metal cylinders, and the like. The container may also include a tamper-proof assemblage to prevent indiscreet access to the contents of the package. In addition, the container has deposited thereon a label that describes the contents of the container. The label may also include appropriate warnings.
[0190] Pharmaceutical formulations may be prepared for various routes and types of administration. For example, a compound of Formula (I) having the desired degree of purity may optionally be mixed with pharmaceutically acceptable diluents, carriers, excipients or stabilizers (R6mington’s Pharmaceutical Sciences (1980) 16thedition, Osol, A. Ed.), in the form of a lyophilized formulation, milled powder, or an aqueous solution. Formulation may be conducted by mixing at ambient temperature at the appropriate pH, and at the desired degree of purity, with physiologically acceptable excipients or carriers, i.e., excipients or carriers that are non-toxic to recipients at the dosages and concentrations employed. The pH of the formulation depends mainly on the particular use and the concentration of compound, but may range from about 3 to about 8. Formulation in an acetate buffer at pH 5 is a suitable embodiment.
[0191] The compounds of Formula (I) can be sterile. In particular, formulations to be used for in vivo administration should be sterile. Such sterilization is readily accomplished by filtration through sterile filtration membranes.
[0192] The compound of Formula (I) ordinarily can be stored as a solid composition, a lyophilized formulation or as an aqueous solution.
[0193] The pharmaceutical compositions comprising a compound of Formula (I) can be formulated, dosed and administered in a fashion, i.e., amounts, concentrations, schedules, course, vehicles and route of administration, consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners. The “therapeutically effective amount” of the compound to be administered will be governed by such considerations, and is the minimum amount necessary to prevent, ameliorate, or treat thecoagulation factor mediated disorder. In some embodiments, the amount is below the amount that is toxic to the host or renders the host more susceptible to bleeding.
[0194] Acceptable diluents, carriers, excipients and stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g., Zn-protein complexes); and / or non-ionic surfactants such as TWEEN™, PLURONICS™ or polyethylene glycol (PEG). The active pharmaceutical ingredients may also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in R6mington’s Pharmaceutical Sciences 16thedition, Osol, A. Ed. (1980).
[0195] Sustained-release preparations of Formula (I) compounds may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing a compound of formula (I), which matrices are in the form of shaped articles, e.g., films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinyl alcohol)), polylactides (US Pat. No. 3,773,919), copolymers of L-glutamic acid and gamma- ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT™ (injectable microspheres composed of lactic acid- glycolic acid copolymer and leuprolide acetate) and poly-D-(-)-3-hydroxybutyric acid.
[0196] The formulations include those suitable for the administration routes detailed herein. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Techniques and formulations generallyare found in Remington ’s Pharmaceutical Sciences (Mack Publishing Co., Easton, PA). Such methods include the step of bringing into association the active ingredient with the excipient or carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid excipients or carriers or finely divided solid excipients or carriers or both, and then, if necessary, shaping the product.
[0197] Formulations of a compound of Formula (I) suitable for oral administration may be prepared as discrete units such as pills, capsules, cachets or tablets each containing a predetermined amount of a compound of Formula (I).
[0198] Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered active ingredient moistened with an inert liquid diluent. The tablets may optionally be coated or scored and optionally are formulated so as to provide slow or controlled release of the active ingredient therefrom.
[0199] Tablets, troches, lozenges, aqueous or oil suspensions, dispersible powders or granules, emulsions, hard or soft capsules, e.g., gelatin capsules, syrups or elixirs may be prepared for oral use. Formulations of compounds of Formula (I) intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents including sweetening agents, flavoring agents, coloring agents and preserving agents, in order to provide a palatable preparation. Tablets containing the active ingredient in admixture with non-toxic pharmaceutically acceptable excipient which are suitable for manufacture of tablets are acceptable. These excipients may be, for example, inert diluents, such as calcium or sodium carbonate, lactose, calcium or sodium phosphate; granulating and disintegrating agents, such as maize starch, or alginic acid; binding agents, such as starch, gelatin or acacia; and lubricating agents, such as magnesium stearate, stearic acid or talc. Tablets may be uncoated or may be coated by known techniques including microencapsulation to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax may be employed.
[0200] For treatment of the eye or other external tissues, e.g., mouth and skin, the formulations are preferably applied as a topical ointment or cream containing the active ingredient(s) in an amount of, for example, 0.075 to 20% w / w. When formulated in anointment, the active ingredients may be employed with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredients may be formulated in a cream with an oil- in-water cream base.
[0201] If desired, the aqueous phase of the cream base may include a polyhydric alcohol, i.e., an alcohol having two or more hydroxyl groups such as propylene glycol, butane 1 ,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol (including PEG 400), and mixtures thereof. The topical formulations may desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethyl sulfoxide and related analogs.
[0202] The oily phase of the emulsions may be constituted from known ingredients in a known manner. While the phase may comprise solely an emulsifier, it may also comprise a mixture of at least one emulsifier and a fat or oil, or both a fat and an oil. A hydrophilic emulsifier included together with a lipophilic emulsifier may act as a stabilizer. Together, the emulsifier(s) with or without stabilizer(s) make up the so-called emulsifying wax, and the wax together with the oil and fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations. Emulsifiers and emulsion stabilizers suitable for use in the formulation include Tween® 60, Span® 80, cetostearyl alcohol, benzyl alcohol, myristyl alcohol, glyceryl mono-stearate and sodium lauryl sulfate.
[0203] Aqueous suspensions of Formula (I) compounds contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients include a suspending agent, such as sodium carboxymethylcellulose, croscarmellose, povidone, methylcellulose, hydroxypropyl methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as a naturally occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethyleneoxycetanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride (e.g., polyoxyethylene sorbitan monooleate). The aqueous suspension may also contain one or more preservatives such as ethyl or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as sucrose or saccharin.
[0204] The pharmaceutical compositions of compounds of Formula (I), may be in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersingor wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such 1,3-butanediol. The sterile injectable preparation may also be prepared as a lyophilized powder. Among the acceptable vehicles and solvents that may be employed are water, Ringer’s solution and isotonic sodium chloride solution. In addition, sterile fixed oils may conventionally be employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid may likewise be used in the preparation of injectables.
[0205] The amount of active ingredient that may be combined with the excipient or carrier material to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a time-release formulation intended for oral administration to humans may contain approximately 1 to 1000 mg of active material compounded with an appropriate and convenient amount of excipient or carrier material which may vary from about 5 to about 95% of the total compositions (weightweight). The pharmaceutical composition can be prepared to provide easily measurable amounts for administration. For example, an aqueous solution intended for intravenous infusion may contain from about 3 to 500 pg of the active ingredient per milliliter of solution in order that infusion of a suitable volume at a rate of about 30 mL / hr can occur.
[0206] Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
[0207] Formulations suitable for topical administration to the eye also include eye drops wherein the active ingredient is dissolved or suspended in a suitable excipient or carrier, especially an aqueous solvent for the active ingredient. The active ingredient is preferably present in such formulations in a concentration of about 0.5 to 20% w / w, for example about 0.5 to 10% w / w, for example about 1.5% w / w.
[0208] Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
[0209] Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.
[0210] Formulations suitable for intrapulmonary or nasal administration have a particle size for example in the range of 0.1 to 500 microns (including particle sizes in a range between 0.1 and 500 microns in increments microns such as 0.5, 1, 30 microns, 35 microns, etc.), which is administered by rapid inhalation through the nasal passage or by inhalation through the mouth so as to reach the alveolar sacs. Suitable formulations include aqueous or oily solutions of the active ingredient. Formulations suitable for aerosol or dry powder administration may be prepared according to conventional methods and may be delivered with other therapeutic agents such as compounds heretofore used in the treatment or prophylaxis of disorders as described below.
[0211] Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such excipients or carriers as are known in the art to be appropriate.
[0212] The formulations may be packaged in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid excipient or carrier, for example water, for injection immediately prior to use. Extemporaneous injection solutions and suspensions are prepared from sterile powders, granules and tablets of the kind previously described. Preferred unit dosage formulations are those containing a daily dose or unit daily sub-dose, as herein above recited, or an appropriate fraction thereof, of the active ingredient.
[0213] The subject matter further provides veterinary compositions comprising at least one active ingredient as above defined together with a veterinary excipient or carrier therefore. Veterinary excipients or carriers are materials useful for the purpose of administering the composition and may be solid, liquid or gaseous materials which are otherwise inert or acceptable in the veterinary art and are compatible with the active ingredient. These veterinary compositions may be administered parenterally, orally or by any other desired route.
[0214] In particular embodiments the pharmaceutical composition comprising the presently disclosed compounds further comprise a chemotherapeutic agent. In some of these embodiments, the chemotherapeutic agent is an immunotherapeutic agent.
[0215] Methods of Use
[0216] The presently disclosed compounds find use in inhibiting the activity of Cbl-B. The compounds additionally do so with an inhibitory effect that is greater than that for C-cbl,R6ferences in this section to compounds of formula (I) are as applicable to compounds of formula (II).
[0217] The presently disclosed compounds find use in inhibiting the activity of Cbl-B. The compounds additionally do so with an inhibitory effect that is greater than that for C-cbl.R6ferences in this section to compounds of formula (I) are as applicable to compounds of formula (II).
[0218] In one embodiment, the subject matter disclosed herein is directed to a method of inhibiting Cbl-B, the method comprising contacting one or more cells containing active Cbl-B proteins with an effective amount of a compound of formula (I), or a pharmaceutical composition described herein. By “contacting” is meant, bringing the compound within close enough proximity to an isolated Cbl-B enzyme or a cell expressing Cbl-B (e.g., T cell, B cell, dendritic cell) such that the compound is able to bind to and inhibit the activity of Cbl-B. The compound can be contacted with Cbl-B in vitro or in vivo via administration of the compound to a subject.
[0219] In an embodiment, the subject matter disclosed herein is directed to a method for enhancing an immune response in a subject in need thereof, wherein the method comprises administering to said subject an effective amount of a compound of Formula (I), or variations thereof such as Formula (I)), or a pharmaceutical composition described herein. In certain aspects of this embodiment, the T cells in the subject have at least one of enhanced priming, enhanced activation, enhanced migration, enhanced proliferation, enhanced survival, and enhanced cytolytic activity relative to prior to the administration of the compound or pharmaceutical composition. In certain aspects of this embodiment, the T cell activation is characterized by an elevated frequency of y-IFN+ CDS T cells, an elevated frequency of y- IFN+ CD4 T cells, or enhanced levels of IL-2 or granzyme B production by T cells, relative to prior to administration of the compound or phar aceutical composition. In certain aspects of this embodiment, the number of T cells is elevated relative to prior to administration of the compound or pharmaceutical composition. In certain aspects of this embodiment, the T cell is an antigen-specific CDS T cell. In certain aspects of this embodiment, the T cell is an antigenspecific CD4 T cell. In certain aspects of this embodiment, the antigen presenting cells in the subject have enhanced maturation and activation relative prior to the administration ofthe compound or pharmaceutical composition. In certain aspects of this embodiment, the antigen presenting cells are dendritic cells. In certain aspects of this embodiment, the maturation of the antigen presenting cells is characterized by increased frequency of CD83+ dendritic cells. In certain aspects of this embodiment, the activation of the antigen presenting cells is characterized by elevated expression of CD80 and CD86 on dendritic cells. In some aspects, compounds of Formula (I), or variations thereof, or a pharmaceutical composition thereof provides general priming of the immune response (i.e., vaccines) to tumors or viruses for boosting / generating anti-viral / tumor immunity.
[0220] In another embodiment, the subject matter disclosed herein is directed to a method for treating a cancer, the method comprising administering to a subject in need thereof an effective amount of a compound of formula (I), or a pharmaceutical composition thereof as further described herein. It is understood that the compound functions by inhibiting Cbl-B in a manner that leads to activated T cells that are able to kill cancer cells, regardless of their origin in the body. In certain aspects of this embodiment, the cancer comprises at least one cancer selected from the group consisting of colorectal cancer, melanoma, non-small cell lung cancer, ovarian cancer, breast cancer, pancreatic cancer, a hematological malignancy, and a renal cell carcinoma. In certain aspects of this embodiment, the cancer has elevated levels of T-cell infiltration. In certain aspects of this embodiment, the cancer cells in the subject selectively have elevated expression of MHC class I antigen expression relative to prior to the administration of the compound or composition.
[0221] In the methods described herein, the method can further comprise administering a therapeutic, or chemotherapeutic agent to said subject. For example, such an agent may be an inhibitor of PD-L1 / PD-1. In certain aspects of this embodiment, the therapeutic or chemotherapeutic agent is administered to the subject simultaneously with the compound or the composition. In certain aspects of this embodiment, the therapeutic or chemotherapeutic agent is administered to the subject prior to administration of the compound or the composition. In certain aspects of this embodiment, the therapeutic or chemotherapeutic agent is administered to the subject after administration of the compound or said composition.
[0222] As used herein, "enhancing an immune response" refers to an improvement in any immunogenic response to an antigen. Non-limiting examples of improvements in an immunogenic response to an antigen include enhanced maturation or migration of dendritic cells, enhanced activation of T cells (e.g., CD4 T cells, CDS T cells), enhanced T cell (e.g., CD4 T cell, CDS T cell) proliferation, enhanced B cell proliferation, increased survival of T cells and / or B cells, improved antigen presentation by antigen presenting cells (e.g., dendriticcells), improved antigen clearance, increase in production of cytokines by T cells (e.g., interleukin-2), increased resistance to prostaglandin E2-induced immune suppression, and enhanced priming and / or cytolytic activity of CDS T cells.
[0223] In some embodiments, the CDS T cells in the subject have enhanced priming, activation, proliferation and / or cytolytic activity relative to prior to the administration of the compound of Formula (I), or variations thereof such as Formula (IA), (IB) and (IC), or a pharmaceutically acceptable salt, prodrug, metabolite, or derivative thereof. In some embodiments, the CDS T cell priming is characterized by elevated CD44 expression and / or enhanced cytolytic activity in CDS T cells. In some embodiments, the CDS T cell activation is characterized by an elevated frequency of y-IFN+ CDS T cells. In some embodiments, the CDS T cell is an antigen-specific T-cell.
[0224] In some embodiments, the CD4 T cells in the subject have enhanced priming, activation, proliferation and / or cytolytic activity relative to prior to the administration of the compound of Formula (I), or variations thereof such as Formula (IA), (IB) and (IC), or a pharmaceutically acceptable salt, prodrug, metabolite, or derivative thereof. In some embodiments, the CD4 T cell priming is characterized by elevated CD44 expression and / or enhanced cytolytic activity in CD4 T cells. In some embodiments, the CD4 T cell activation is characterized by an elevated frequency of y-IFN+ CD4 T cells. In some embodiments, the CD4 T cell is an antigen-specific T-cell.
[0225] Accordingly, the presently disclosed compounds of Formula (I), or pharmaceutically acceptable salts, prodrugs, metabolites, or derivatives thereof are useful in treating T cell dysfunctional disorders. A "T cell dysfunctional disorder" is a disorder or condition of T cells characterized by decreased responsiveness to antigenic stimulation.
[0226] Thus, the presently disclosed compounds can be used in treating conditions where enhanced immunogenicity is desired, such as increasing tumor immunogenicity for the treatment of cancer.
[0227] "Immunogenicity" refers to the ability of a particular substance to provoke an immune response. Tumors are immunogenic and enhancing tumor immunogenicity aids in the clearance of the tumor cells by the immune response. Viruses may also be immunogenic and enhancing / activating immunogenicity may aid in clearance of viral particles by the immune response.
[0228] "Tumor immunity" refers to the process in which tumors evade immune recognition and clearance. Thus, as a therapeutic concept, tumor immunity is "treated" when such evasionis atenuated, and the tumors are recognized and atacked by the immune system. Examples of tumor recognition include tumor binding, tumor shrinkage and tumor clearance.
[0229] In some embodiments, the compound is administered to the subject at a dose of between about 0.001 pg / kg and about 1000 mg / kg, including but not limited to about 0.001 pg / kg, about 0.01 pg / kg, about 0.05 pg / kg, about 0.1 pg / kg, about 0.5 pg / kg, about 1 pg / kg, about 10 pg / kg, about 25 pg / kg, about 50 pg / kg, about 100 pg / kg, about 250 pg / kg, about 500 pg / kg, about 1 mg / kg, about 5 mg / kg, about 10 mg / kg, about 25 mg / kg, about 50 mg / kg, about 100 mg / kg, and about 200 mg / kg.Kits
[0230] Further provided are kits for carrying out the methods detailed herein, which kits comprise one or more compounds described herein or a phamaceutical composition comprising a compound described herein. The kits may employ any of the compounds disclosed herein. In one variation, the kit employs a compound described herein or a pharmaceutically acceptable salt thereof. The kits may be used for any one or more of the uses described herein, and, accordingly, may contain instructions for use in the treatment of a disorder such as cancer. In some embodiments, the kit contains instructions for use in the treatment of a cancer.
[0231] Kits generally comprise suitable packaging. The kits may comprise one or more containers comprising any compound described herein. Each component (if there is more than one component) can be packaged in separate containers or some components can be combined in one container where cross-reactivity and shelflife permit. One or more components of a kit may be sterile and / or may be contained within sterile packaging.
[0232] The kits may be in unit dosage forms, bulk packages (e.g., multi-dose packages) or sub-unit doses. For example, kits may be provided that contain sufficient dosages of a compound as disclosed herein (e.g., a therapeutically effective amount) and / or a second pharmaceutically active compound useful for a disorder (e.g., cancer) to provide effective treatment of an individual for an extended period, such as any of a week, 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 4 months, 5 months, 7 months, 8 months, 9 months, or more. Kits may also include multiple unit doses of the compounds and instructions for use and may be packaged in quantities sufficient for storage and use in pharmacies (e.g., hospital pharmacies and compounding pharmacies).
[0233] The kits may optionally include a set of instructions, generally writen instructions, although electronic storage media (e.g., magnetic diskete or optical disk) containing instructions are also acceptable, relating to the use of component(s) of the methods of thepresent invention. The instructions included with the kit generally include information as to the components and their administration to a subject.
[0234] The following examples are offered by way of illustration and not by way of limitation.EXAMPLESSynthetic Examples
[0235] Compounds of the invention, for example, compounds of formula (I) or (II) described herein, or variations thereof detailed herein, may be synthesized according to the following exemplary synthetic procedures. Unless otherwise indicated, absolute configuration was arbitrarily assigned to each enantiomer or diastereomer where a pair of (or more than two) such stereoisomeric compounds was synthesized or isolated. In an instance in which only one member of a stereoisomerically related pair was identified, the absolute stereochemistry of such a final product was assigned arbitrarily.Example 1: Intermediate A
[0236] Intermediate A [4-chloro-6-((isobutylamino)methyl)isoindolin-l-one] may be synthesized according to scheme 1 (FIG. 1).Step 1 (Intermediate 2: methyl 5-bromo-3-chloro-2-methylbenzoate)
[0237] To a solution of methyl 3-amino-5-bromo-2-methylbenzoate (100 g, 409.69 mmol) and CuCl2(110.17 g, 819.39 mmol) in acetonitrile (2 L) was added tert-butyl nitrite (84.50 g, 819.39 mmol) at room temperature, then the reaction mixture was heated to 60 °C and stirred for 16 hours. The reaction was diluted with water (500 mL) and extracted with ethyl acetate (2 x 2 L), the organic phase was washed with brine (500 mL) then dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography on silica gel (0-5% ethyl acetate in petroleum ether) to afford methyl 5-bromo-3-chloro-2-methyl-benzoate (96.1 g, 89% yield) as a yellow solid.1H NMR (400 MHz, CDCb) δ 7.85 (d, J= 2.4 Hz, 1H), 7.67 (d, J= 2.0 Hz, 1H), 3.91 (s, 3H), 2.55 (s, 3H).Step 2 (Intermediate 3: methyl 5-bromo-2-(bromomethyl)-3-chlorobenzoate)
[0238] To a solution of methyl 5-bromo-3-chloro-2-methyl-benzoate (96.1 g, 364.68 mmol) and BPO (26.50 g, 109.41 mmol) in carbon tetrachloride (1.2 L) was added NBS (97.36 g, 547.03 mmol). The solution was stirred at 80 °C for 16 h. The reaction mixture was concentrated under reduce pressure, the residue was purified by chromatography on silica gel (0-5% ethyl acetate in petroleum ether) to afford methyl 5-bromo-2-(bromomethyl)-3-chlorobenzoate (101 g, 81% yield) as a yellow solid.1H NMR (400 MHz, CDCl3) 3 8.00 (d, J = 2.4 Hz, 1H), 7.75 (d, J= 2.0 Hz, 1H), 5.05 (s, 2H), 3.97 (s, 3H).Intermediate 4: 6-bromo-4-chloroisoindolin-l-one
[0239] To a solution of methyl 5-bromo-2-(bromomethyl)-3-chlorobenzoate (101 g, 294.96 mmol, 1 eq) in dichloromethane (500 mL) was added ammonia (4 M in methanol, 500 mL). Then the mixture was stirred at 25 °C for 16h then concentrated. The residue was triturated with ethyl acetate, then filtered to give crude 6-bromo-4-chloroisoindolin-l-one (76 g) as a white solid.1H NMR (400 MHz, methanol-d4) δ 7.86 (d, J= 1.6 Hz, 1H), 7.83 (d, J= 1.6 Hz, 1H), 4.42 (s, 2H).Intermediate 5: 4-chloro-6-vinylisoindolin-l-one
[0240] To a solution of 6-bromo-4-chloroisoindolin-l-one (2 g, 8.17 mmol) in 1,4-dioxane (50 mL) and water (1 mL) was added potassium trifluoro(vinyl)borate (2.2 g, 16.33 mmol), Pd(dppf)Cl2 (597.5 mg, 0.82 mmol) and potassium carbonate (3.36 g, 24.34 mmol) at 80°C under N2 atmosphere for 3h. Then quenched by water (20 mL), extracted with ethyl acetate (3 x 20 mL), the organic phase was washed with brine (20 ml), dried over sodium sulfate, filtrated and concentrated under vacuum. The residue was purified by chromatography on silica gel (0 - 50% ethyl acetate in petroleum) to afford 4-chloro-6-vinylisoindolin-l-one (800 mg, 51% yield) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 8.82 (s, 1H), 7.82 (s, 1H), 7.74 (s, 1H), 6.88 - 6.80 (m, 1H), 6.04 (d, J= 18.0 Hz, 1H), 5.39 (d, J= 11.2 Hz, 1H), 4.37 (s, 2H). LCMS [M+H]+=193.9.Intermediate 6: 7-chloro-3-oxoisoindoline-5-carbaldehyde.
[0241] To a solution of 4-chloro-6-vinylisoindolin-l-one (800.0 mg, 4.13 mmol) in tetrahydrofuran (10 mL) and water (2 mL) was added potassium osmate (0.14 g, 0.41 mmol) and sodium periodate (3.53 g, 16.53 mmol), the mixture was stirred at 25 °C for 8 h then quenched by water (3 mL), extracted with ethyl acetate (3 ^ 10 mL), the organic phase was washed with brine (20 ml), dried over sodium sulfate, filtrated and concentrated under vacuum. The residue was purified by chromatography on silica gel (0 - 50% ethyl acetate in petroleum) to afford 7-chloro-3-oxoisoindoline-5-carbaldehyde (150 mg, 19% yield) as a yellow solid. 'll NMR (400 MHz, DMSO-d6) δ 10.10 (s, 1H), 8.16 (s, 2H), 4.50 (s, 2H), 4.18 (s, 1H). LCMS [M+H]+= 196.3.Production of Intermediate A:
[0242] To a solution of 7-chloro-3 -oxoisoindoline-5 -carbaldehy de (1 g, 5.11 mmol) in methanol (7 mL) was added 2-methylpropan-l -amine (1.02 mL, 10.22 mmol), the vial was sealed and stirred for Imin at 100 °C by microwave, cooled to room temperature, NaBH3CN(979.29 mg, 15.34 mmol) was added and the mixture was stirred for another 45 min at 80 °C by microwave. Quenched by water (5 mL), extracted with dichloromethane (3 X 10 mL), the organic phase was washed with brine (4 ml), dried over sodium sulfate, filtered and the filtrate was concentrated under vacuum. The residue was purified by chromatography on silica gel (0 - 10% methanol in dichloromethane) to afford 4-chloro-6-((isobutylamino)methyl)isoindolin- 1-one (900 mg, 70% yield)1.H NMR (400 MHz, DMSO-d6) δ 8.79 (s, 1H), 7.63 (s, 2H), 4.36 (s, 2H), 3.88 (s, 2H), 2.37 (d, J= 6.4 Hz, 2H), 1.74 - 1.68 (m, 1H), 0.92 - 0.85 (m, 6H). LCMS [M+H]+= 253.2. .Example 2: Intermediate B
[0243] Intermediate B [4-chloro-6-(((cyclobutyhnethyl)-amino)methyl)isoindolin- 1 -one] may be synthesized according to Scheme 2, FIG. 2.
[0244] To a solution of 7-chloro-3-oxoisoindoline-5-carbaldehyde (1.5 g, 7.7 mmol) in methanol (10 mL) was added cyclobutylmethanamine (783.6 mg, 9.2 mmol). The reaction was stirred at 100 °C for 3 min under microwave. After cooling to room temperature, sodium cyano trihydroborate (963 mg, 15.3 mmol) was added. The vial was sealed again and microwaved under 80 °C for 45 min. The reaction solution was diluted with water (20 mL), extracted with dichloromethane (3 x 50 mL). The organic layers were combined and washed with brine (50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (0-6% methanol in dichloromethane) to afford 4-chloro-6- (((cyclobutylmethyl)amino)methyl)isoindolin-l-one (1.2 g, 59% yield) as yellow oil.1H NMR (400 MHz, methanol-d4) δ 7.72 (s, 1H), 7.68 (d, J = 1.2 Hz, 1H), 4.45 (s, 2H), 3.92 (s, 2H),2.68 (d, J= 7.6 Hz, 2H), 2.56 - 2.54 (m, 1H), 2.12 - 2.09 (m, 2H), 1.91 - 1.77 (m, 2H), 1.72 -1.69 (m, 2H).Example 3: Intermediate C
[0245] Intermediate C [6-(l-((l-methylcyclobutyl)amino)propan-2-yl)-4- (trifluoromethyl)isoindolin-l-one] can be synthesized according to Scheme 3, FIG. 3.Intermediate 2: N-(2-bromoallyl)-l-methylcyclobutan-l-amine
[0246] To a solution of 2,3-dibromoprop-l-ene (2.0 g, 10.01 mmol), 1-methylcyclobutan-l- amine hydrochloride (1.58 g, 13.01 mmol) in tetrahydrofuran (30 mL) was added potassium carbonate (2.77 g, 20.01 mmol), the mixture was stirred at 60 °C for 12 h then diluted with ethyl acetate (100 mL) and washed with water (3 x 30 mL). The organic was dried over sodiumsulfate and concentrated, the residue was purified by chromatography on silica (0-20 % ethyl acetate in petroleum ether) to afford N-(2 -bromoallyl)- 1-methylcyclobutan-l -amine (1.5 g, 73% yield) as a yellow oil1.H NMR (400 MHz, CDCl3) δ 5.85 (s, 1H), 5.51 (s, 1H), 3.40 (s, 2H), 2.02 - 1.91 (m, 2H), 1.89 - 1.81 (m, 2H), 1.78 - 1.68 (m, 2H), 1.28 (s, 3H).Intermediate 3: tert-butyl (2-bromoallyl)(l-methylcyclobutyl)carbamate
[0247] To a solution of N-(2-bromoallyl)- 1-methylcyclobutan-l -amine (1.5 g, 7.35 mmol) in tetrahydrofuran (20 mL) was added di-tert-butyl dicarbonate (3.2 g, 14.7 mmol), trimethylamine (1.48 g, 14.68 mmol) and A(JV-dimethylpyridin-4-amine (89.8 mg, 0.73 mmol), the reaction mixture was stirred at 70 °C for 12 h then diluted with ethyl acetate (100 mL), washed with water (3 x 30 mL). The organic was dried over sodium sulfate, filtered and concentrated, the residue was purified by chromatography on silica (0-5% ethyl acetate in petroleum ether) to afford tert-butyl (2-bromoallyl)(l-methylcyclobutyl)carbamate (2.0 g, 89% yield) as a yellow oil.1H NMR (400 MHz, CDCl3) δ 5.81 (d, J= 1.6 Hz, 1H), 5.57 (d, J= 1.6 Hz, 1H), 3.81 (s, 2H), 2.37 - 2.22 (m, 2H), 2.00 - 1.87 (m, 2H), 1.73 - 1.65 (m, 2H), 1.47 (s, 9H), 1.39 (s, 3H).Intermediate 4: tert-butyl (l-methylcyclobutyl)(2-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)allyI)carbamate
[0248] To a solution of tert-butyl (2-bromoallyl)(l-methylcyclobutyl)carbamate (500.0 mg, 1.64 mmol) in toluene (10 mL) was added 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(l,3,2- dioxaborolane) (500.8 mg, 1.97 mmol), triphenylphosphane (43.1 mg, 0.16 mmol), potassium phenolate (434.5 mg, 3.29 mmol), bis(triphenylphosphine)palladium(II)dichloride (115.3 mg, 0.16 mmol), the resulting mixture was stirred at 65 °C for 16 h. The organic layer was concentrated under vacuum to give tert-butyl (l-methylcyclobutyl)(2-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2-yl)allyl)carbamate (577 mg, 99% yield) as black oil which was used directly without further purification. LCMS [M+H]+= 352.1.Intermediate 5: tert-butyl (l-methylcyclobutyl)(2-(3-oxo-7-(trifluoromethyI)isoindolin- 5-yl)allyl)carbamate
[0249] To a solution of 6-bromo-4-(trifhioromethyl)isoindolin- 1 -one (300.0 mg, 1.07 mmol, prepared using the procedures of Intermediate 4 as shown in Scheme 1), potassium phosphate (0.27 mL, 3.21 mmol), dicyclohexyl(2',4',6'-triisopropyl-[1, 1'-biphenyl]-2-yl)phosphane (50.0 mg, 0.10 mmol), tert-butyl (l-methylcyclobutyl)(2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)allyl)carbamate (500.0 mg, 1.42 mmol) in ethanol (15 mL) and water (2 mL) was dropwise added diacetoxypalladium (50.0 mg, 0.22 mmol). The resulting mixture was stirred at 70 °C for 16 h then diluted with water (50 mL), extracted with ethyl acetate (3 x 50 mL), the organiclayer was combined then dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by chromatography on silica (0-5% methanol in dichloromethane) to afford tert-butyl (1 -methylcyclobutyl)(2-(3-oxo-7-(trifhioromethyl)isoindolin-5- yl)allyl)carbamate (300 mg, 86% yield) as a yellow solid. LCMS [M+H]+= 324.9.Intermediate 6: tert-butyl (l-methylcyclobutyl)(2-(3-oxo-7-(trifluoromethyl)isoindolin- 5-yI)propyI)carbamate
[0250] To a solution tert-butyl (l-methylcyclobutyl)(2-(3-oxo-7-(trifluoromethyl)isoindolin- 5-yl)allyl)carbamate (300.0 mg, 0.71 mmol) in methanol (20 mL) was added palladium on carbon (225.0 mg), the mixture was stirred at 20 °C under H2atmosphere (15 psi) for 12 h.The reaction was filtered and concentrated to give tert-butyl (l-methylcyclobutyl)(2-(3-oxo-7- (trifluoromethyl)isoindolin-5-yl)propyl)carbamate (300 mg, 99% yield) as a colorless oil.LCMS [M+H]+= 326.8.Production of Intermediate C:.
[0251] To a solution tert-butyl (l-methylcyclobutyl)(2-(3-oxo-7-(trifluoromethyl)isoindolin- 5-yl)propyl)carbamate (300.0 mg, 0.70 mmol) in dichloromethane (5 mL) was added 2,2,2- trifluoroacetaldehyde (0.75 mL, 9.74 mmol), the mixture was stirred at 20 °C under for 2 h then adjusted to pH = 8 with saturated sodium bicarbonate aqueous. The mixture was extracted with ethyl acetate (3 x 30 mL), combined the organic layers and concentrated. The residue was purified by silica gel chromatography (mobile phase 0-5% methanol in dichloromethane) to afford 6-(l-((l-methylcyclobutyl)amino)propan-2-yl)-4-(trifluoromethyl)- isoindolin-l-one (150 mg, 50% yield) as yellow solid. LCMS [M+H]+= 327.4.Example 4: Intermediate D
[0252] Intermediate D [4-cyclopropyl-6-(((l -methylcyclobutyl) amino)methyl)isoindolin-l- one] can be synthesized according to the scheme shown in FIG. 4 (Scheme 4), where PMB = para-methyoxybenzyl.Intermediate 2: methyl 5-bromo-3-iodo-2-methylbenzoate
[0253] 2 To a mixture of methyl 3-amino-5-bromo-2 -methylbenzoate (5.0 g, 20.48 mmol), tert-butyl nitrite (4.87 mL, 40.97 mmol) and copper (I) iodide (5.85 g, 30.73 mmol) in acetonitrile (100 mL) was added potassium iodide (6.8 g, 40.97 mmol), the reaction mixture was stirred at 80 °C for 6 h. The reaction was diluted with water (50 mL) and extracted with ethyl acetate (3 x 50 mL), combined the organic phase and washed with brine (2 x 50 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography on silica (solvent gradient: 0-15 % ethyl acetate in petroleum ether) to affordmethyl 5-bromo-3-iodo-2-methylbenzoate (6.0 g, 83% yield) as brown solid.1H NMR (400 MHz, CDC13) δ 8.12 (d, J= 2.0 Hz, 1H), 7.89 (d, J= 2.0 Hz, 1H), 3.91 (s, 3H), 2.62 (s, 3H).Intermediate 3: methyl 5-bromo-3-iodo-2-methylbenzoate
[0254] To a solution of methyl 5-bromo-3-iodo-2-methylbenzoate (6.0 g, 16.9 mmol) and benzoylperoxide (6.14 g, 25.35 mmol) in Carbon tetrachloride (70 mL) was added l-bromo-2,5-pyrrolidinedione (0.9 g, 5.07 mmol). The solution was stirred at 80 °cfor 12 h. The reaction mixture was cooled to 25 °C and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (10% ethyl acetate in petroleum ether) to afford methyl 5-bromo-3-iodo-2 -methylbenzoate (6.3 g, 86% yield) as light yellow solid1.H NMR (400 MHz, methanol-A) δ 8.29 (d, J= 2.0 Hz, 1H), 8.03 (d, J= 2.4 Hz, 1H), 5.08 (s, 2H), 3.94 (s, 3H).Intermediate 4: 6-bromo-4-iodo-2-(4-methoxybenzyl) isoindolin-l-one
[0255] A mixture of methyl 5-bromo-3-iodo-2-methylbenzoate (15 g, 34.57 mmol), triethylamine (9.64 mL, 69.15 mmol) and (4-methoxyphenyl) methanamine (5.42 mL, 41.49 mmol) in methanol (100 mL) was stirred at 70 °C for 5 h. The mixture was concentrated and the residue was diluted with water (50 mL) and extracted with ethyl acetate (3 x 100 mL). The organics were washed with brine (2 x 50 mL), dried over sodium sulfate, filtered and concentrated. The residue was triturated with MTBE (100 mL), the solid was filtered to give6-bromo-4-iodo-2-(4-methoxybenzyl)isoindolin-l-one (15.5 g, 98% yield) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 8.19 (d, J= 1.6 Hz, 1H), 7.87 (d, J= 1.6 Hz, 1H), 7.24 (d, J = 8.4 Hz, 2H), 6.91 (d, J= 8.8 Hz, 2H), 4.66 (s, 2H), 4.10 (s, 2H), 3.73 (s, 3H).Intermediate 5: 6-bromo-4-cyclopropyl-2-(4-methoxybenzyl) isoindolin-l-one
[0256] A mixture of 6-bromo-4-iodo-2-(4-methoxybenzyl)isoindolin-l-one (2.0 g, 4.37 mmol), Pd(dppf)Cl2 (319.46 mg, 0.44 mmol, CAS: 95464-05-4), cesium carbonate (4.27 g, 13.1 mmol) and cyclopropyl boronic acid (337.53 mg, 3.93 mmol) in 1,4-dioxane (20 mL) and water (2 mL) was stirred for 16 h at 100 °C under N2. The reaction was diluted with water (20 mL) and extracted with ethyl acetate (3 x 20 mL). The organics were washed with brine (2 x 20 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography on silica gel (0 - 30% ethyl acetate in petroleum ether) to afford 6-bromo-4- cyclopropyl-2-(4-methoxybenzyl) isoindolin-l-one (800 mg, 49% yield) as a white solid1.H NMR (400 MHz, CDCl3) δ 7.81 (d, J= 1.2 Hz, 1H), 7.24 (s, 2H), 7.13 (d, J= 1.6 Hz, 1H), 6.89 (d, J= 8.8 Hz, 2H), 4.75 (s, 2H), 4.25 (s, 2H), 3.81 (s, 3H), 1.77 - 1.68 (m, 1H), 1.02 - 0.98 (m, 2H), 0.76 - 0.73 (m, 2H).Intermediate 6: 4-cyclopropyl-2-(4-methoxybenzyl)-6-vinylisoindoIin-l-one
[0257] To a solution of 6-bromo-4-cyclopropyl-2-(4-methoxybenzyl)isoindolin-l-one (400.0 mg, 1.07 mmol), sodium carbonate (341.66 mg, 3.22 mmol) and 4,4,5,5-tetramethyl-2-vinyl- 1,3,2-dioxaborolane (165 mg, 1.07 mmol) in 1,4-dioxane (5 mL) and water (0.5 mL) was added Pd(dppf)Cl2 (78.62 mg, 0.11 mmol) was stirred for 16 h at 100 °C. The reaction was diluted with dichloromethane (50 mL), washed with brine (2 x 10 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by preparative TLC (solvent gradient: 30% ethyl acetate in petroleum ether) to afford 4-cyclopropyl-2-(4-methoxybenzyl)- 6-vinylisoindolin-l-one (280 mg, 82% yield) as a white solid. LCMS [M+H]+= 320.2.Intermediate 7 : 7-cyclopropyl-2-(4-methoxybenzyl)-3-oxoisoindoline-5-carbaldehyde
[0258] To a solution of 4-cyclopropyl-2-(4-methoxybenzyl)-6-vinylisoindolin-l-one (380.0 mg, 1.19 mmol) in tetrahydrofuran (9 mL) and water (3 mL) was added sodium periodate (1.02 g, 4.76 mmol) and potassium osmate (VI) dihydrate (43.84 mg, 0.12 mmol), then the reaction solution was stirred for 16 h at 25 °C. The mixture was diluted with water (30 mL), then extracted with ethyl acetate (3 x 20 m), combined the organic then washed with brine (2 x 20 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography on silica gel (0 - 30% ethyl acetate in petroleum ether) to afford 7- cyclopropyl-2-(4-methoxybenzyl)-3-oxoisoindoline-5-carbaldehyde (260 mg, 68% yield) as a light yellow oil.1H NMR (400 MHz, CDCl3) δ 10.04 (s, 1H), 8.14 (s, 1H), 7.57 (s, 1H), 7.30 - 7.25 (m, 2H), 6.90 - 6.86 (m, 2H), 4.78 (s, 2H), 4.37 (s, 2H), 3.80 (s, 3H), 1.84 - 1.74 (m, 1H), 1.07 - 1.01 (m, 2H), 0.84 - 0.79 (m, 2H). LCMS [M+H]+= 322.1.Intermediate 8: 4-cyclopropyl-2-(4-methoxybenzyl)-6-(((l-methylcyclobutyl) amino) methyl) isoindolin-l-one
[0259] The mixture of 7-cyclopropyl-2-(4-methoxybenzyl)-3-oxoisoindoline-5-carbaldehyde (260.0 mg, 0.81 mmol), triethylamine (0.28 mL, 2.02 mmol) and 1 -methylcyclobutan- 1 -amine hydrochloride (295.16 mg, 2.43 mmol) in methanol (2 mL) was stirred for 1 min at 100 °C at microwave, then sodium cyanoborohydride (152.52 mg, 2.43 mmol) was added, the mixture was stirred for another 45 min at 80 °C at microwave. The reaction was concentrated then purified by chromatography on silica gel (0 - 60% ethyl acetate in petroleum ether) to afford 4- cyclopropyl-2-(4-methoxybenzyl)-6-(((l -methylcyclobutyl) amino) methyl) isoindolin-l-one (300 mg, 95% yield) as a white solid. LCMS [M+H]+= 391.2.Production of Intermediate D: 4-cycIopropyl-6-(((l-methylcycIobutyl) amino)methyl)isoindolin-l -one
[0260] To a solution of 4-cyclopropyl-2-(4-methoxybenzyl)-6-(((l- methylcyclobutyl)amino)methyl)isoindolin-l-one (300.0 mg, 0.77 mmol) in acetonitrile (9 mL) and water (3 mL) was added diammonium cerium(IV) nitrate (2.1 g, 3.84 mmol), the reaction mixture was stirred for 16 h at 25 °C then adjusted pH = 8 with saturated sodium bicarbonate aqueous, extracted with ethyl acetate (3 x 50 mL). The organics were washed with brine (2 x 20 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography on silica gel (0 -10 % methanol in dichloromethane) to afford 4- cyclopropyl-6-(((l -methylcyclobutyl) amino) methyl) isoindolin-l-one (80 mg, 39% yield) as a light yellow solid. LCMS [M+H]+= 271.3.Example 5: Intermediate E
[0261] Intermediate E [6-(((cyclopropylmethyl)amino)methyl)-4-(trifluoromethyl)isoindolin- 1-one] can be synthesized according to Scheme 5 (FIG. 5).Intermediate 2: 4-(trifluoromethyI)-6-vinyIisoindoIion-1-one I
[0262] To a solution of 6-bromo-4-(trifluoromethyl)isoindolin-l-one (5.0 g, 17.85 mmol, prepared using the procedures of Intermediate 4 as shown in Scheme 1) in 1,4-dioxane (100 mL) and water (10 mL) was added potassium trifluoro(vinyl)borate (4.7 g, 35.71 mmol), Pd(dppf)Cl2 (1.31 g, 1.78 mmol) and potassium carbonate (2.5 g, 17.85 mmol) at 80°C under N2 atmosphere for 3h. The reaction mixture was diluted water (20 mL), extracted with ethyl acetate (3 * 20 mL), the organic phase was washed with brine (20 ml), dried over sodium sulfate, filtrated and concentrated under vacuum. The residue was purified by chromatography on silica gel (0 - 50% ethyl acetate in petroleum ether) to afford 4-(trifluoromethyl)-6- vinylisoindolin-l-one (2.3 g, 57% yield) as white solid1.H NMR (400 MHz, methanol-d4) δ 8.09 (s, 1H), 7.96 (s, 1H), 6.98 - 6.88 (m, 1H), 6.02 (d, J= 17.6 Hz, 1H), 5.48 (d, J= 11.2 Hz, 1H), 4.62 (s, 2H). LCMS [M+H]+= 269.1. § Intermediate 3: 3-oxo-7-(trifluoromethyl)isoindoline-5-carbaIdehyde
[0263] To a solution of 4-(trifluoromethyl)-6-vinylisoindolin-l-one(800.0 mg, 3.52 mmol) in tetrahydrofuran (9 mL) and water (3 mL) was added potassium osmate(VI) dehydrate (129.75 mg, 0.35 mmol) and sodium periodate (3.01 g, 14.09 mmol) the mixture was stirred at 25 °C for 16 h, then quenched by water (3 mL), extracted with ethyl acetate (3 x 10 mL), the organic phase was washed with brine (20 ml), dried over sodium sulfate, filtrated and concentrated under vacuum. The residue was purified by chromatography on silica gel (0 -10 % methanolin dichloromethane) to afford 3-oxo-7-(trifluoromethyl)isoindoline-5-carbaldehyde (670 mg, 83% yield) as a yellow oil.1H NMR (400 MHz, CDCl3) δ 10.18 (s, 1H), 8.55 (s, 1H), 8.39 (s, 1H), 6.74 (s, 1H), 4.74 (s, 2H). LCMS [M+H]+= 458.Production of Intermediate E:
[0264] To a solution of 3-oxo-7-(trifluoromethyl)isoindoline-5-carbaldehyde (500.0 mg, 2.18 mmol) in methanol (10 mL) was added cyclopropylmethanamine (0.23 mL, 2.62 mmol), the vial was sealed and stirred for 1 min at 100°C by micro wave then sodium cyanotrihydridoborate (278.63 mg, 4.36 mmol) was added, the mixture was stirred for another 45 min at 80°C by microwave then quenched by water (5 mL), extracted with dichloromethane (3 x 10 mL), the organic phase was washed with brine (4 mL), dried over sodium sulfate, filtrated and concentrated under vacuum. The residue was purified by chromatography on silica gel (0-55% ethyl acetate in petroleum ether) to afford 6- (((cyclopropylmethyl)amino)methyl)-4-(trifluoromethyl)isoindolin-l-one (240 mg, 39% yield) as a yellow solid.NMR (400 MHz, CDCl3) δ 8.01 (s, 1H), 7.86 (s, 1H), 6.68 (s, 1H), 4.87 (s, 2H), 3.97 (s, 2H), 2.50 (d, J= 6.8 Hz, 2H), 1.10 - 0.80 (m, 1H), 0.51 - 0.49 (m, 2H), 0.13 - 0.08 (m, 2H). LCMS [M+H]+= 286.1.Example 6: Intermediate F
[0265] Intermediate F [4-methyl-6-((( 1 -methylcyclobutyl)amino)methyl)isoindolin- 1 -one] can be synthesized according to the approach of Scheme 6 (FIG. 6).Intermediate 2: 6-bromo-2-(4-methoxybenzyI)-4-methylisoindolin-l-one
[0266] To a solution of 6-bromo-4-iodo-2-(4-methoxybenzyl)isoindolin- 1 -one (3.9 g, 8.6 mmol), cesium carbonate (8.4 g, 25.8 mmol) and 2,4,6-trimethyl-l,3,5,2,4,6-trioxatriborinane (0.36 mL, 2.58 mmol) in 1,4-dioxane (15 mL) and water (1.5 mL) was added Pd(dppf)Cl2 (629.33 mg, 0.86 mmol), the mixture was stirred at 100 °C for 16 hours under N2. The reaction was diluted with water (20 mL), extracted with ethyl acetate (3 x 50 mL), combined the organic phase and washed with brine (2 x 50 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography on silica gel (0-21% ethyl acetate in petroleum ether) to afford 6-bromo-2-(4-methoxybenzyl)-4-methylisoindolin- 1 -one (780 mg, 26% yield) as yellow oil.Intermediate 3: 2-(4-methoxybenzyl)-4-methyl-6-vinylisoindolin-l-one
[0267] To a mixture of 6-bromo-2-(4-methoxybenzyl)-4-methylisoindolin-l-one (780.0 mg, 2.25 mmol) in 1,4-dioxane (8 mL) and water (0.80 mL) was added Pd(dppf)Cl2 (164.84 mg, 0.23 mmol), potassium vinyl fluoroborate (392.31 mg, 2.93 mmol) and sodium carbonate (0.93g, 6.76 mmol), the reaction solution was stirred at 90 °C for 16 hours under N2 protection. The reaction solution was concentrated under vacuum, the residue was purified by chromatography on silica gel (0-16% ethyl acetate in petroleum ether) to afford 2-(4-methoxybenzyl)-4-methyl- 6-vinylisoindolin-l-one (497 mg, 75% yield) as a yellow oil.1H NMR (400 MHz, CDCl3) δ 7.78 (s, 1H), 7.34 (s, 1H), 7.26 - 7.24 (m, 2H), 6.88 (d, J= 8.8 Hz, 2H), 6.81 - 6.72 (m, 1H), 5.84 (d, J= 18.0 Hz, 1H), 5.31 (d, J= 10.8 Hz, 1H), 4.76 (s, 2H), 4.15 (s, 2H), 3.80 (s, 3H), 2.28 (s, 3H).Intermediate 4: 2-(4-methoxybenzyl)-7-methyl-3-oxoisoindoIine-5-carbaldehyde
[0268] A solution of 2-(4-methoxybenzyl)-4-methyl-6-vinylisoindolin-l-one (730.0 mg, 2.49 mmol), potassium osmate(VI)dihydrate (91.68 mg, 0.25 mmol) and sodium periodate (2.66 mg, 12.44 mmol) in tetrahydrofuran (7 mL) and water (1.4 mL) was stirred at 25 °Cfor 16 hours. The mixture was quenched by the dropwise addition of saturated sodium sulfite aqueous (20 mL), extracted with ethyl acetate (3 x 30 mL). The organic phase was washed with brine (30 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography on silica gel (0-20% ethyl acetate in petroleum ether) to afford 2- (4-methoxybenzyl)-7-methyl-3-oxoisoindoline-5-carbaldehyde (514 mg, 70% yield) as a yellow oil.1H NMR (400 MHz, CDCl3) δ 10.08 (s, 1H), 8.20 (s, 1H), 7.88 (s, 1H), 7.30 - 7.25 (m, 2H), 6.91 - 6.88 (m, 2H), 4.78 (s, 2H), 4.24 (s, 2H), 3.81 (s, 3H), 2.36 (s, 3H). LCMS [M + H]+= 296.1.Intermediate 5: 2-(4-methoxybenzyl)-4-methyl-6-(((l-methylcyclobutyl)amino)- methyl)isoindolin-l-one
[0269] A mixture of 2-(4-methoxybenzyl)-7-methyl-3-oxoisoindoline-5-carbaldehyde (324.0 mg, 1.1 mmol), 1-methylcyclobutan-l -amine hydrochloride (400.25 mg, 3.29 mmol) and triethylamine (382.28 uL, 2.74 mmol) in methanol (1 mL) was stirred for 1 min at 100 °C at microwave, then sodium cyanoborohydride (206.82 mg, 3.29 mmol) was added, the resulting mixture was stirred for another 45 min at 80°C at microwave. The reaction was diluted with water (2 mL) and extracted with dichloromethane (3 x 20 mL). The organics were washed with brine (2 x 10 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by silica gel chromatography (mobile phase: methanol / dichloromethane, gradient 0% to 6%) to afford 2-(4-methoxybenzyl)-4-methyl-6-(((l- methylcyclobutyl)amino)methyl)isoindolin-l-one (290 mg, 73% yield) as a yellow oil.]H NMR (400 MHz, methanol-d4) δ 7.62 (s, 1H), 7.42 (s, 1H), 7.27 - 7.24 (m, 2H), 6.92 - 6.89 (m, 2H), 4.75 (s, 2H), 4.29 (s, 2H), 3.78 - 3.75 (m, 5H), 2.32 (s, 3H), 2.14 - 2.07 (m, 2H), 1.93 - 1.87 (m, 2H), 1.85 - 1.76 (m, 2H), 1.40 (s, 3H).Production of Intermediate F:
[0270] To a solution of 2-(4-methoxybenzyl)-4-methyl-6-(((l-methylcyclobutyl)amino) methyl) isoindolin-l-one (434.0 mg, 1.19 mmol) in acetonitrile (20 mL) was added Ammonium cerium nitrate (1.96 g, 3.57mmol) in water (8.5mL) at 0 °C. The mixture was stirred at 0°C for 3 h. The reaction mixture was adjusted to pH = 7 with saturated sodium bicarbonate solution, extracted with a solution of 10% methanol in dichloromethane (3 x 50 ml), the organic layers were washed with brine (2 x 10 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography on silica gel (0 - 10% methanol in dichloromethane) to afford 4-methyl-6-(((l- methylcyclobutyl)amino)methyl)isoindolin-l-one (180 mg, 62% yield) as a yellow solid.1H NMR (400 MHz, methanol-A) 6 7.63 (s, 1H), 7.47 (s, 1H), 4.41 (s, 2H), 3.85 (s, 2H), 2.40 (s, 3H), 2.22 - 2.14 (m, 2H), 1.97 - 1.91 (m, 2H), 1.89 - 1.80 (m, 2H), 1.45 (s, 3H). LCMS [M+H]+= 245.2.Example 7: Intermediate G
[0271] Intermediate G [4-methoxy-6-(((l -methylcyclobutyl)amino)methyl)isoindolin- 1 -one] can be synthesized according to the scheme in Scheme 7 (FIG. 7).Intermediate 2: 6-bromo-4-hydroxy-2-(4-methoxybenzyl)isoindolin-l-one
[0272] To a mixture of 6-bromo-4-iodo-2-(4-methoxybenzyl)isoindolin-l-one (1.0 g, 2.18 mmol) in Dimethyl sulfoxide (3 mL) and water (3 mL) was added hydroxyl potassium (367.46 mg, 6.55 mmol), copper(I) iodide (41.57 mg, 0.22 mmol) and 1,10- phenanthroline (78.68 mg, 0.44 mmol), the mixture was stirred at 100 °C for 16 h under N2. The mixture was poured into water (20 mL) and adjusted to pH = 5 with IM hydrochloride aqueous, the precipitate was filtered and dried to give 6-bromo-4-hydroxy-2-(4-methoxybenzyl)isoindolin-l-one (280 mg, 37% yield) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 7.28 (s, 1H), 7.23 - 7.20 (m, 2H), 7.11 (s, 1H), 6.92 - 6.89 (m, 2H), 4.62 (s, 2H), 4.16 (s, 2H), 3.73 (s, 3H). LCMS [M+H]+= 349.8.Intermediate 3: 6-bromo-4-methoxy-2-(4-methoxybenzyI)isoindolin-l-one
[0273] A solution of 6-bromo-4-hydroxy-2-(4-methoxybenzyl)isoindolin-l-one (1.4 g, 4.02 mmol) in N,N-Dimethylformamide (20 mL) was added potassium carbonate (1.69 g, 12.06 mmol) at 25°C, then the iodomethane (1.25 mL, 20.1 mmol) was added at 25°C, the mixture was stirred at 25 °C for 16 h. The mixture was quenched by water (5 mL), extracted with ethyl acetate (3 x 100 mL), combined the organic phase and washed with brine (2 x 50 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatographyon silica gel (0 - 30% ethyl acetate in petroleum ether) to afford 6-bromo-4-methoxy-2-(4- methoxybenzyl)isoindolin-l-one (1.1 g, 76% yield) as yellow solid.1H NMR (400 MHz, CDCl3) δ 7.62 (d, 1.2 Hz, 1H), 7.23 (d, J= 8.8 Hz, 2H), 7.10 (d, J= 0.8 Hz, 1H), 6.86 (d, J= 8.8 Hz, 2H), 4.72 (s, 2H), 4.13 (s, 2H), 3.85 (s, 3H), 3.80 (s, 3H).Intermediate 4 : 4-methoxy-2-(4-methoxybenzyl)-6-vinylisoindolin-l-one
[0274] A solution 6-bromo-4-methoxy-2-(4-methoxybenzyl)isoindolin-l-one (1 g, 2.76 mmol), sodium carbonate(l 170.45 mg, 11.04 mmol), 4,4,5,5-tetramethyl-2-vinyl-l,3,2- dioxaborolane (0.47 mL, 2.76 mmol) and Pd(dppf)Cl2 (202.0 mg, 0.28 mmol) in 1,4-dioxane (10 mL) and water (2 mL) was stirred for 16 h at 100 °C under N2. The reaction was diluted with dichloromethane (100 mL), washed with brine (2 x 30 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography on silica gel (0 - 30% ethyl acetate in petroleum ether) to afford 4-methoxy-2-(4-methoxybenzyl)-6-vinylisoindolin- 1-one (750 mg, 88% yield) as a white solid. 'll NMR (400 MHz, CDCl3) δ 7.55 (s, 1H), 7.24 (d, J= 8.8 Hz, 2H), 7.00 (s, 1H), 6.86 (d, J= 8.4 Hz, 2H), 6.78 (dd, J= 17.6, 10.8 Hz, 1H), 5.83 (d, J= 17.2 Hz, 1H), 5.33 (d, J= 10.8 Hz, 1H), 4.73 (s, 2H), 4.18 (s, 2H), 3.88 (s, 3H), 3.80 (s, 3H).Intermediate 5 : 7-methoxy-2-(4-methoxybenzyI)-3-oxoisoindoline-5-carbaldehyde
[0275] To a solution of 4-methoxy-2-(4-methoxybenzyI)-6-vinylisoindolin-l-one (500.0 mg, 1.62 mmol) in tetrahydrofuran (9 mL) and water (3 mL) was added potassium osmate (VI) dehydrate (59.55 mg, 0.16 mmol) and sodium periodate (1.4 g, 6.46 mmol), then the mixture was stirred for 16 h at 25 °C. The mixture was diluted with water (10 mL), then extracted with ethyl acetate (3 x 20 mL), combined the organic phase and washed with brine (2 x 20 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography on silica gel (0 - 30% ethyl acetate in petroleum ether) to afford 7-methoxy-2- (4-methoxybenzyl)-3-oxoisoindoline-5-carbaldehyde (340 mg, 68% yield) as a light yellow solid. NMR (400 MHz, CDCl3) δ 10.06 (s, 1H), 7.96 (s, 1H), 7.53 (s. 1H), 7.27 - 7.24 (m, 2H), 6.89 - 6.86 (m. 2H), 4.76 (s, 2H), 4.26 (s, 211), 3.93 (s, 3H), 3.80 (s, 3H).Intermediate 6: 4-methoxy-2-(4-methoxybenzyl)-6-(((l-methylcyclobutyl)amino)- methyl)isoindolin-l-one
[0276] The mixture of 7-methoxy-2-(4-methoxybenzyl)-3-oxoisomdoline-5-carbaldehyde (340.0 mg, 1.09 mmol), 1-methylcyclobutan-l -amine hydrochloride (398.43 mg, 3.28 mmol) and triethylamine (380.54 uL, 2.73 mmol) in methanol (1 mL) was stirred for 1 min at 100 °C at microwave, then sodium cyanoborohydride (205.88 mg, 3.28 mmol) was added, the resulting mixture was stirred for another 45 min at 80 °C at microwave. The reaction wasquenched with water (2 mL) and diluted with dichloromethane (20 mL), washed with brine (2 x 10 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography on silica gel (0 - 70% ethyl acetate in petroleum ether) to afford 4-methoxy-2- (4-methoxybenzyl)-6-(((l-methylcyclobutyl)amino)methyl)isoindolin-l-one (250 mg, 60% yield) as a colorless oil. LCMS [M+H]+= 381.3.Production of Intermediate G
[0277] To a solution of 4-methoxy-2-(4-methoxybenzyl)-6-(((l-methylcyclobutyl)- amino)methyl)isoindolin-l-one (250.0 mg, 0.66 mmol) in acetonitrile (9 mL) and water (3 mL) added diammonium cerium(IV) nitrate (1.8 g, 3.29 mmol), the reaction mixture was stirred at 25 °C for 16 h then adjusted to pH = 8 with saturated sodium bicarbonate solution, extracted with dichloromethane (3 x 50 mL). Combined the organic phase and washed with brine (2 x 20 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography on silica gel (0 - 5% methanol in dichloromethane) to afford (80 mg, 47% yield) as a light yellow solid. LCMS [M+H]+= 261.1.Example 8: Intermediate H
[0278] Intermediate H [6-(l -((cyclobutylmethyl)amino)ethyl)-4-(trifluoromethyl)isoindolin- 1-one] can be synthesized according to the scheme in Scheme 8 (FIG. 8).Intermediate 2: 6-acetyl-4-(trifluoromethyI)isoindolin-l-one
[0279] Under nitrogen atmosphere, to a solution of 6-bromo-4-(trifluoromethyl)isoindolin-l- one (5.0 g, 17.85 mmol) and Pd(PPh3)2Cl2(1.25 g, 1.79 mmol, CAS No: 10199-34-5) in 1,4- dioxane (50 mL) was added tributyl(l -ethoxy vinyl)stannane (8.62 mL, 25.5 mmol). The mixture was stirred at 90 °C for 16 hours. Then IM HC1 (30 mL) was added and the resulting reaction mixture was stirred at 25°C for 30 minutes. The mixture was quenched with potassium fluoride solution (50 mL), diluted with dichloromethane (150 mL), washed with brine (2 x 50 mL), dried over anhydrous sodium sulfate. Filtered and concentrated, the residue was purified by chromatography on silica gel (0 - 10% methanol in dichloromethane) to afford 6-acetyl-4-(trifhioromethyl)isoindolin-l-one (2.3 g, 58% yield) as a yellow solid.1H NMR (400 MHz, methanol-A) δ 8.56 (s, 1H), 8.43 (s, 1H), 4.69 (s, 2H), 2.72 (s, 3H). LCMS [M+H]+= 244.1.Production of Intermediate H
[0280] To a solution of 6-acetyl-4-(trifhioromethyl)isoindolin-l-one (300.0 mg, 1.23 mmol) and Ti(OiPr)4 (1.83 mL, 6.17 mmol) in methanol (4 mL) was added cyclobutylmethanamine hydrochloride (112.52 mg, 0.93 mmol) and trimethylamine (0.17 mL, 1.23 mmol). Themixture was stirred at 100 °C for 1 hour then cooled down to room temperature. Sodium cyanoborohydride (464.15 mg, 7.39 mmol) was added and stirred at 80 °C for another 45 minutes. The reaction mixture was diluted with dichloromethane (60 mL), washed with brine (3 x 20 mL), dried over anhydrous sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel (0 - 10% methanol in dichloromethane) to afford 6-(l-((cyclobutylmethyl)amino)ethyl)-4-(trifluoromethyl)isoindolin-l-one (320 mg, 83% yield) as a white solid1.H NMR (400 MHz, methanol-A) δ 8.04 (s, 1H), 7.98 (s, 1H), 4.64 (s, 2H), 4.15 (q, J= 6.8 Hz, 1H), 2.73 - 2.64 (m, 1H), 2.53 - 2.46 (m, 2H), 2.13 - 2.04 (m, 2H), 1.98 - 1.87 (m, 1H), 1.86 - 1.76 (m, 1H), 1.72 - 1.61 (m, 2H), 1.50 (d, J = 6.8 Hz, 3H). LCMS [M+H]+= 313.1.Example 9: Intermediate I
[0281] Intermediate I [6-((( 1 -methy lcyclobutyl)amino)methyl)- 1 -oxoisoindoline-4- carbonitrile] can be synthesized according to the scheme in Scheme 9 (FIG. 9).Intermediate 2 : 6-bromo-2-(4-methoxybenzyI)-l-oxoisoindoIine-4-carbonitrile
[0282] To a solution of 6-bromo-4-iodo-2-(4-methoxybenzyl)isoindolin-l-one (2.0 g, 4.4 mmol) in N'N-dimethy Iformamide (20 mL), was added dicyanozinc (307.6 mg, 2.62 mmol) and Pd(PPh3)4 (504.5 mg, 0.44 mmol), the mixture was stirred at 80 °C for 2 h then diluted with ethyl acetate (50 mL), washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated to dryness, purified by chromatography on silica gel (0 - 50% ethyl acetate in petroleum ether) to afford 6-bromo-2-(4-methoxybenzyl)-l -oxoiso indoline-4- carbonitrile (0.75 g, 48% yield) as a white solid. LCMS [M+H]+= 357.1 and 359.1.Intermediate 3 : 2-(4-methoxybenzyI)-l-oxo-6-vinylisoindoline-4-carbonitrile
[0283] To a solution of 6-bromo-2-(4-methoxybenzyl)-l-oxoisoindoline-4-carbonitrile (750.0 mg, 2.1 mmol) in 1,4-dioxane (15 mL) and water (1.5 mL) was added potassium trifhioro(vinyl)borate (562.5 mg, 4.2 mmol), Pd(dppf)Cl2 (153.6 mg, 0.2 mmol) and cesium carbonate (2.1 g, 6.3 mmol), the mixture was stirred at 100 °C for 16h under N2 then concentrated to dryness, the residue was purified by chromatography on silica gel (0 - 50% ethyl acetate in petroleum ether) to afford 2-(4-methoxybenzyl)-l-oxo-6-vinylisoindoline-4- carbonitrile (500 mg, 78% yield) as yellow solid. LCMS [M+H]+= 305.1.Intermediate 4: 6-formyI-2-(4-methoxybenzyI)-l-oxoisoindoIine-4-carbonitriIe
[0284] To a solution of 2-(4-methoxybenzyl)-l-oxo-6-vinylisoindoline-4-carbonitrile (500.0 mg, 1.64 mmol) in tetrahydro furan (10 mL) and water (1 mL) was added potassium osmate (60.5 mg, 0.16 mmol) and sodium periodate (1.8 g, 8.21 mmol) at 0 °C, the mixture was stirredat 25 °C for 2h. The mixture was diluted with water (30 mL), extracted with ethyl acetate (3 x 30 mL), washed with brine (60 mL), dried over anhydrous sodium sulfate and concentrated, purified by chromatography on silica gel (0 - 50% ethyl acetate in petroleum ether) to afford 6- formyl-2-(4-methoxybenzyl)-l-oxoisoindoline-4-carbonitrile (350 mg, 70% yield) as a white solid. LCMS [M+H]+= 307.0.Intermediate 5: 2-(4-methoxybenzyI)-6-(((l-methylcyclobutyl)amino)methyI)-l- oxoisoindoline-4-carbonitrile
[0285] To a solution of 6-formyl-2-(4-methoxybenzyl)-l-oxoisoindoline-4-carbonitrile (350.0 mg, 1.14 mmol) and 1-methylcyclobutan-l -amine hydrochloride (555.8 mg, 4.57 mmol) in methanol (6 mL) was added triethylamine (0.48 mL, 3.43 mmol). The mixture was stirred at 100 °C for 1 minute under microwave irridation, cooled to room temperature then sodium cyanoborohydride (107.7 mg, 1.71 mmol) was added and heated to 80 °C stirred for another 45 minutes under microwave irridation. The reaction mixture was concentrated under vacuum, the residue was purified by chromatography on silica gel (0 - 10% methanol in dichloromethane) to give 2-(4-methoxybenzyl)-6-(((l-methylcyclobutyl)amino)methyl)-l- oxoisoindoline-4-carbonitrile (400.0 mg, 93% yield) as a white solid. LCMS [M+H]+= 376.1.Production of Intermediate I
[0286] To a solution of 2-(4-methoxybenzyl)-6-(((l-methylcyclobutyl)amino)methyl)-l- oxoisoindoline-4-carbonitrile (400.0 mg, 1.07 mmol) in acetonitrile (6 mL) and water (1 mL) was added diammonium cerium(IV) nitrate (1.8 g, 3.2 mmol), then the mixture was stirred at 25 °C for 16 h. The mixture was diluted with ethyl acetate (30 mL), washed with brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel (0 - 10% methanol in dichloromethane) to afford 6-(((l-methylcyclobutyl)amino)methyl)-l-oxoisoindoline-4-carbonitrile (0.21 g, 77% yield) as yellow oil.1H NMR (400 MHz, CDCl3) 6 8.09 (s, 1H), 7.95 (s, 1H), 7.07 (s, 1H), 4.60 (s, 2H), 3.84 (s, 2H), 2.02 - 1.87 (m, 4H), 1.82 - 1.74 (m, 2H), 1.33 (s, 3H). LCMS [M+H]+= 256.1.Example 10: Intermediate J
[0287] Intermediate J [6-((( 1 -methylcyclobutyl)amino)methyl)-4-(trifluoromethoxy)- isoindolin-l-one] can be synthesized according to the scheme in Scheme 10 (FIG. 10).Intermediate 2 : 6-bromo-2-(4-methoxybenzyl)-4-(trifluoromethoxy)isoindolin-l-one
[0288] To a solution of 6-bromo-4-hydroxy-2-(4-methoxybenzyl)isoindolin-l-one (1.5 g, 4.31 mmol), N-fluoro-7V-(phenylsulfonyl)benzenesulfonamide (2.7 g, 8.62 mmol), cesium fluoride (3.9 g, 25.85 mmol), l-(chloromethyl)-4-fluoro-l,4-diazabicyclo[2.2.2]octane-l,4-diium tetrafluoroborate (3.1 g, 8.62 mmol) and silver(I) trifluoromethanesulfonate (5.5 g, 21.54 mmol) in toluene (14mL) and (trifluoromethyl)benzene (7 mL) was added 2-fluoropyridine (1.85 mL, 21.54 mmol) and trimethyl(trifluoromethyl)silane (3.16 mL, 21.54 mmol). The mixture was stirred at 25 °C for 48 h. The solution was filtered and washed with water (30 ml), the filtrate was extracted with dichloromethane (3 x 30 mL), combined the organic layers and washed with brine (30 mL), dried over sodium sulfate, filtrated and concentrated under vacuum. The residue was purified by chromatography on silica gel (0 - 30% ethyl acetate in petroleum ether) to afford 6-bromo-2-(4-methoxybenzyl)-4-(trifluoromethoxy)isoindolin-l-one (300 mg, 17% yield) as a yellow solid. LCMS [M+H]+= 415.9 and 418.0.Intermediate 3: 6-bromo-4-(trifluoromethoxy)isoindolin-l-one
[0289] To a solution of 6-bromo-2-(4-methoxybenzyl)-4-(trifluoromethoxy)isoindolin-l-one (300 mg, 0.72 mmol) in acetonitrile (5mL) was added the solution of diammonium cerium(IV) nitrate (1.18 g, 2.16 mmol) in water (2.5mL) at 0 °C. The mixture was stirred at 25 °C for 2 h then adjusted to pH = 8 by saturated sodium bicarbonate solution, extracted with dichloromethane (3 x 15 mL). The organic layer was washed with brine (20 mL), dried over sodium sulfate, filtrated and concentrated under vacuum. The residue was purified by chromatography on silica gel (0 - 10% methanol in dichloromethane) to afford 6-bromo-4- (trifluoromethoxy)isoindolin-l-one (110 mg, 52% yield)as a white solid. LCMS [M+H]+= 295.8 and 297.8.Intermediate 4: 6-(hydroxymethyl)-4-(trifluoromethoxy)isoindolin-l-one
[0290] A mixture of 6-bromo-4-(trifluoromethoxy)isoindolin-l-one (130 mg, 0.44 mmol), (tributylstannyl)methanol (352.5 mg, 1.1 mmol) and Pd(PPh3)4 (50.7 mg, 0.04 mmol, CAS: 14221-01-3) in 1,4-dioxane (2 mL) was stirred at 100 °C for 4 h under nitrogen. Then the reaction was quenched by potassium fluoride aqueous (10 mL), extracted with dichloromethane (3 x 10 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by preparative TLC (solvent gradient: 10% methanol in dichloromethane) to afford (50 mg, 46% yield) as a white solid. LCMS [M+H]+= 248.1.Intermediate 5: 3-oxo-7-(trifluoromethoxy)isoindoline-5-carbaIdehyde
[0291] To a solution of 6-(hydroxymethyl)-4-(trifluoromethoxy)isoindolin-l-one (50.0 mg, 0.2 mmol) in dichloromethane (3 mL) was added Dess-Martin periodinane (111.5 mg, 0.26 mmol) at 0 °C. The mixture was stirred for 3 h at 25 °C and then filtered. The filtrate was concentrated and the residue was purified by preparative TLC (solvent gradient: 10% methanolin dichloromethane) to afford 3-oxo-7-(trifluoromethoxy)isoindoline-5-carbaldehyde (49 mg, 99% yield) as a white solid. LCMS [M+H]+= 246.1.Production of Intermediate J
[0292] To a solution of 1-methylcyclobutanamine hydrochloride (48.61 mg, 0.4 mmol) in methanol (ImL) was added triethylamine (0.04 mL, 0.3 mmol), 3-oxo-7- (trifluoromethoxy)isoindoline-5-carbaldehyde (49.0 mg, 0.2 mmol), the mixture was stirred at 100 °C for 2 mins by microwave, then sodium cyanoborohydride (25 mg, 0.4 mmol) was added, the solution was stirred for another 45 min under 80 °C by microwave. The reaction mixture was quenched by saturated sodium bicarbonate solution (5 mL) and then extracted with dichloromethane (3 x 10 mL), the organic phase was dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by preparative TLC (solvent gradient: 10% methanol in dichloromethane) to afford 6-(((l-methylcyclobutyl)amino)methyl)-4- (trifluoromethoxy)isoindolin-l-one (39 mg, 62% yield) as a white solid.1H NMR (400 MHz, methanol-fih) δ 7.92 (s, 1H), 7.77 (s, 1H), 4.57 (s, 2H), 4.27 (s, 2H), 2.49 - 2.40 (m, 2H), 2.13 - 1.95 (m, 4H), 1.65 (s, 3H). LCMS [M+H]+= 315.1.Example 11: Intermediate K
[0293] Intermediate K (6-(2-cyclopropyl- 1 -((1 -methylcyclobutyl)amino)ethyl)-4-(trifluoro- methyl)isoindolin-l-one) can be synthesized according to the scheme in Scheme 11 (FIG. 11).Intermediate 2: 3-oxo-7-(trifluoromethyl)isoindoline-5-carbaldehyde
[0294] A mixture of 6-(hydroxymethyl)-4-(trifluoromethyl)isoindolin-l-one (2.7 g, 11.68 mmol) in dichloromethane (50 mL) was added Dess-Martin periodinane (6.44 g, 15.18 mmol) at 0 °C, the mixture was stirred at 25 °C for 16 h, then quenched by water (20 mL), extracted with dichloromethane (3 x 50 mL), the organic phase was washed with brine (50 mL), dried over sodium sulfate, filtrated and concentrated under vacuum. The residue was purified by chromatography on silica gel (0 - 10% methanol in dichloromethane) to afford 3-oxo-7- (trifluoromethyl)isoindoline-5-carbaldehyde (1.3 g, 49% yield) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ 10.18 (s, 1H), 7.97 (s, 1H), 7.91 (s, 1H), 4.18 (s, 2H).Intermediate 3: 6-(l-hydroxybut-3-en-l-yl)-4-(trifluoromethyI)isoindolin-l-one
[0295] To a solution of 3-oxo-7-(trifhioromethyl)isoindoline-5-carbaldehyde (1.3 g, 5.67 mmol) in tetrahydrofuran (20 mL) was added allyl magnesium chloride (IM in tetrahydrofuran, 11.34 mL, 11.35 mmol) at 0°C, the mixture was stirred at 25°C for 3 h, then quenched by water (20 mL), extracted with dichloromethane (3 x 30 mL), the organic phase was washed with brine (30 mL), dried over sodium sulfate, filtrated and concentrated undervacuum. The crude was purified by chromatography on silica gel (0 - 10% methanol in dichloromethane) to afford 6-(l-hydroxybut-3-en-l-yl)-4-(trifluoromethyl)isoindolin-l-one (320 mg, 21% yield) as a yellow solid.1H NMR (400 MHz, methanol-A) δ 8.87 (s, 1H), 7.90 (s, 1H), 7.87 (s, 1H), 5.83 - 5.72 (m, 1H), 5.61 (d, J= 4.8 Hz, 1H), 5.05 - 4.95 (m, 2H), 4.90 - 4.82 (m, 1H), 4.53 (s, 2H), 2.44 (t, J= 6 A Hz, 2H).Intermediate 4: 6-(2-cyclopropyl-l-hydroxyethyl)-4-(trifluoromethyl)isoindolin-l-one
[0296] To a solution of 6-(l-hydroxybut-3-en-l-yl)-4-(trifluoromethyl)isoindolin-l-one (510 mg, 1.88 mmol) in dichloromethane (10 mL) was added diethylzinc (IM in hexane, 18.8 mL, 18.80 mmol) and diiodomethane at -10°C, the mixture was stirred at 25 °C for 16 h, then quenched by water (10 mL), extracted with di chloromethane (3 x 30 mL), the organic phase was washed with brine (30 mL), dried over sodium sulfate, filtrated and concentrated under vacuum. The residue was purified by chromatography on silica gel (0 - 10% methanol in dichloromethane) to afford 6-(2-cyclopropyl- 1 -hydroxy ethyl)-4-(trifluoromethyl)isoindolin- 1 - one (350 mg, 65% yield) as a yellow solid. 1H NMR (400 MHz, DMSO- ) δ 8.87 (s, 1H), 7.92 (s, 1H), 7.89 (s, 1H), 5.52 (d, J= 4.8 Hz, 1H), 4.85 - 4.76 (m, 1H), 4.53 (s, 2H), 1.74 - 1.67 (m, 1H), 1.39 - 1.33 (m, 1H), 0.79 - 0.62 (m, 1H), 0.42 - 0.25 (m, 2H), 0.00 - -0.01 (m, 2H).Intermediate 5: 6-(2-cyclopropylacetyl)-4-(trifluoromethyl)isoindolin-l-one
[0297] A mixture of 6-(2-cyclopropyl-l-hydroxyethyl)-4-(trifluoromethyl)isoindolin-l-one (330 mg, 1.15 mmol) in dichloromethane (5 mL) was added Dess-Martin periodinane (735.9 mg, 1.74 mmol) at 0 °C, the mixture was stirred at 25 °C for 16 h, then quenched by water (5 mL), extracted with dichloromethane (3 ^ 10 mL), the organic phase was washed with brine (10 mL), dried over sodium sulfate, filtrated and concentrated under vacuum to afford 6-(2- cyclopropylacetyl)-4-(trifluoromethyl)isoindolin-l-one (300 mg, 92% yield) as a yellow solid.Production of Intermediate K
[0298] To a solution of 6-(2-cyclopropylacetyl)-4-(trifluoromethyl)isoindolin-l-one (300 mg, 1.05 mmol) in methanol (1 mL) was added 1-methylcyclobutan-l -amine hydrochloride (257.6 mg, 2.11 mmol), trimethylamine (75.0 mg , 0.74 mmol) and titanium(iv) isopropoxide (391.3 mg, 1.37 mmol) at 25 °C, the mixture was stirred at 120 °C for 1 h used microwave, then sodium cyanoborohydride (199.6 mg, 3.17mmol), the mixture was stirred at 100 °C for 2 h used microwave. The mixture was concentrated under vacuum. The residue was purified by silica gel chromatography (mobile phase: methanol / dichloromethane, gradient 0% to 10%) to afford 6-(2-cyclopropyl- 1 -(( 1 -methylcyclobutyl)am ino)ethy l)-4-(trifluoromethyl)isoindolin- 1 - one (300 mg, 95% yield) as a white solid. LCMS [ + H ]+= 353.2.Example 12: Intermediate L
[0299] Intermediate L [4-(difluoromethoxy)-6-(((l -methylcyclobutyl)amino)methyl)- isoindolin-l-one] can be synthesized according to the scheme in Scheme 12 (FIG. 12).Intermediate 2: 6-bromo-4-(difluoromethoxy)-2-(4-methoxybenzyl)isoindolin-l-one
[0300] To a mixture of 6-bromo-4-hydroxy-2-(4-methoxybenzyl)isoindolin-l-one (2.0 g, 5.74 mmol) and sodium 2-chloro-2,2-difluoroacetate (2.19 g, 14.36 mmol) in N,N- Dimethylformamide (35 mL) and water (5 mL) was added cesium carbonate (3.74 g, 11.49 mmol), the mixture was stirred at 100 °C for 3 h under N2 atmosphere then poured into water (10 mL), extracted with dichloromethane (3 x 30 mL), combined the organic phase and washed with brine (2 x 50 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography on silica gel (0-30% ethyl acetate in petroleum ether) to afford 6- bromo-4-(difhioromethoxy)-2-(4-methoxybenzyl)isoindolin-l-one (0.84 g, 37% yield) as a white solid.1H NMR (400 MHz, CDCl3) δ 7.89 (s, 1H), 7.42 (s, 1H), 7.24 (d, J= 8.8 Hz, 2H), 6.89 (d, J= 8.8 Hz, 2H), 6.45 (t,J= 72.4 Hz, 1H), 4.73 (s, 2H), 4.21 (s, 2H), 3.80 (s, 3H).Intermediate 3: 6-bromo-4-(difluoromethoxy)isoindolin-l-one
[0301] To a solution of 6-bromo-4-(difluoromethoxy)-2-(4-methoxybenzyl)isoindolin-l-one (840.0 mg, 2.11 mmol) in acetonitrile (9 mL) and water (3 mL) added diammonium cerium(IV) nitrate (3.5 g, 6.33 mmol), the mixture was stirred at 25 °C for 16 h then adjusted to pH = 8 with saturated sodium bicarbonate solution, extracted with dichloromethane (3 x 30 mL), combined the organic phase and washed with brine (2 x 30 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography on silica gel (0 - 5% methanol in dichloromethane) to afford 6-bromo-4-(difluoromethoxy)isoindolin-l-one (400 mg, 68% yield) as a white solid. LCMS [M+H]+= 280.0.Intermediate 4: 4-(difluoromethoxy)-6-vinylisoindolin-l-one
[0302] A solution of 4-(difluoromethoxy)-6-(hydroxymethyl)isoindolin-l-one (200.0 mg, 0.55 mmol), soudium carbonate (234.09 mg, 2.21 mmol), 4,4,5,5-tetramethyl-2-vinyl-l,3,2- dioxaborolane (0.09 mL, 0.55 mmol) and Pd(dppf)Cl2 (40.4 mg, 0.06 mmol) was stirred for 16 h at 100 °C. The reaction was diluted with dichloromethane (30 mL), washed with brine (2 x 30 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by preparative TLC (solvent gradient: 0 - 5% methanol in dichloromethane) to afford 4- (difluoromethoxy)-6-vinylisoindolin-l-one (160 mg, 94% yield) as a white solid. LCMS [M+H]+= 226.1.Intermediate 5: 7-(difluoromethoxy)-3-oxoisoindoline-5-carbaIdehyde
[0303] To a solution of 4-(difluoromethoxy)-6-(hydroxymethyI)isoindolin-l-one (160.0 mg, 0.71 mmol) in tetrahydrofuran (9 mL) and water (3 mL) was added potassium osmate (26.18 mg, 0.07 mmol) and sodium periodate (607.88mg, 2.84 mmol), then stirred for 16 h at 25 °C. The mixture was diluted with water (10 mL), then extracted with ethyl acetate (3 x 15 mL). The organics were washed with brine (2 x 10 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography on silica gel (0-10% methanol in dichloromethane) to afford 7-(difluoromethoxy)-3-oxoisoindoline-5-carbaldehyde (100 mg, 62% yield) as a light yellow solid.NMR (400 MHz, CDCl3) δ 10.10 (s, 1H), 8.23 (s, 1H), 7.88 (s, 1H), 6.72 (t, J= 72.0 Hz, 1H), 4.57 (s, 2H).Production of Intermediate L
[0304] A solution of 1-methylcyclobutanamine hydrochloride (107.07 mg, 0.88 mmol), triethylamine (0.09 mL, 0.66 mmol) and 7-(difluoromethoxy)-3-oxoisoindoline-5- carbaldehyde (100.0 mg, 0.44 mmol) in methanol (2 mL) was stirred at 100 °C by microwave for 1 min, then cooled to room temperature, sodium cyanoborohydride (55.33 mg, 0.88 mmol) was added, the resulting mixture was stirred at 80 °C by microwave for another 1 h then concentrated. The residue was purified by chromatography on silica gel (0 - 10% methanol in dichloromethane) to afford 4-(difhroromethoxy)-6-(((l- methylcyclobutyl)amino)methyl)isoindolin-l-one (120 mg, 92% yield) as a white solid.LCMS [M+H]+=297.1.Example 13: Intermediate M
[0305] Intermediate M (4-(difluoromethyl)-6-((isobutylamino)methyl)isoindolin-l-one) can be synthesized according to the scheme in Scheme 13 (FIG. 13).Intermediate 2: 4-(difluoromethyl)-6-(hydroxymethyI)isoindolin-l-one
[0306] To a solution of 6-bromo-4-(difluoromethyl)isoindolin-l-one (10.0 g, 38.33 mmol, prepared using the procedures of Intermediate 4 as shown in Scheme 1), Pd(PPh3)4 (3.54 g, 3.07 mmol) in 1,4-dioxane (150mL) was added tributyl stannylmethanol (13.54 g, 42.16mmol), the mixture was stirred at 100 °C for 16 hours under nitrogen atmosphere then concentrated under vacuum. The residue was purified by chromatography on silica gel (0 - 100% ethyl acetate in petroleum ether) to afford 4-(difluoromethyl)-6- (hydroxymethyl)isoindolin-l-one (6.5 g, 80% yield) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ 8.73 (s, 111). 7.77 (s, 1 H), 7.73 (s, 111 ). 7.37 - 7.09 (m. 1H), 4.49 (s, 2H), 3.35 (s, 3H). LCMS [M+H]+= 214.0.Intermediate 3 : 7 -(difluoromethyl)-3-oxoisoindoline-5-carbaIdehyde
[0307] To a solution 4-(difluoromethyl)-6-(hydroxymethyl)isoindolin-l-one (5.7 g, 26.74 mmol) in dichloromethane (100 mL) was added Dess-Martin Periodinane (12.47 g, 29.41 mmol), the mixture was stirred at 25 °C for 16 h then concentrated under vacuum. The residue was purified by chromatography on silica gel (0 - 100% ethyl acetate in petroleum ether) to afford 7-(difluoromethyl)-3 -oxo-isoindoline-5 -carbaldehy de (5.0 g, 89% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 10.20 (s, 1H), 8.98 (s, 1H), 8.34 (s, 1H), 8.27 (s, 1H), 7.23 (t, J= 54.8 Hz, 1H), 4.62 (s, 2H). LCMS [M+H]+= 212.0.Production of Intermediate M
[0308] To a solution of 2-methylpropan- 1 -amine (1.88 mL, 18.94 mmol) and 7- (difluoromethyl)-3-oxoisoindoline-5-carbaldehyde (2.0 g, 9.47 mmol) in dichloromethane (30 mL) was added sodium triacetoxyhydroborate (4.01 g, 18.94 mmol) and acetic acid (284.38 mg, 4.74 mmol), the mixture was stirred at 25 °C for 12 h. The reaction mixture was diluted with water (30 mL), extracted with dichloromethane (3 x 15 mL), combined the organic phase and dried over sodium sulfate, filtered and concentrated to dryness to afford 4- (difluoromethyl)-6-[(isobutylamino)methyl]isoindolin-l-one (1.85 g, 73% yield) as yellow oil. Tl NMR (400 MHz, methanol-A) δ 7.93 (s, 1H), 7.81 (s, 1H), 7.00 (t, J= 56.0 Hz 1H), 4.60 (s, 2H), 4.01 (s, 2H), 2.51 (d, J= 8.0 Hz, 2H), 1.89 - 1.82 (m, 1H), 0.95 (d, J= 8.0 Hz, 6H). LCMS [M+H]+= 268.9.Example 14: Intermediate N[0309J Intermediate N [3-((lr,3r)-l-(3-bromophenyl)-3-(difluoromethoxy)cyclobutyl)-4- methyl-4H -l ,2,4-triazole] can be synthesized according to the scheme in Scheme 14 (FIG, 14).Intermediate 2: methyl (lr,3r)-l-(3-bromophenyl)-3-(difluoromethoxy)cyclobutane-l- carboxylate
[0310] A solution of methyl (lr,3r)-l-(3-bromophenyl)-3-hydroxycyclobutane-l-carboxylate (10 g, 17.54 mmol) in acetonitrile (150 mL) was added to copper(I) iodide (670 mg, 3.51 mmol) at 0 °C, the mixture was stirred for 1 h at 0 °C. Then the 2,2-difluoro-2- (fluorosulfonyl)acetic acid (4.7 g, 26.30 mmol) was added at 0 °C over 15 min, the mixture was stirred at 50 °C for 1 h. The reaction was diluted with water (35 mL) and extracted with ethyl acetate (3 x 35 mL). The organics were washed with brine (2 x 35 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography on silica gel (0 - 50% ethyl acetate in petroleum ether) to afford (lr,3r)-l-(3-bromophenyl)-3- (difluoromethoxy)cyclobutane- 1 -carbohydrazide (3.8 g, 64% yield) as colorless oil.1H NMR(400 MHz, CDCl3) δ 7.41 - 7.40 (m, 1 H) 7.37 - 7.34 (m, 1 H), 7.21 (t, J= 7.6 Hz, 1 H) 7.16 - 7.12 (m, 1 H), 6.16 (t, J= 74.4 Hz, 1 H), 4.86 - 4.78 (m, 1 H) 3.69 (s, 3 H), 3.28 - 3.24 (m, 2 H), 2.63 - 2.657 (m, 2 H).Intermediate 3: (lr,3r)-l-(3-bromophenyl)-3-(difluoromethoxy)cyclobutane-l-carboxylate
[0311] To a mixture of methyl (lr,3r)-l-(3-bromophenyl)-3-(difluoromethoxy)cyclobutane- 1-carboxylate (3.8 g, 11.34 mmol) in methyl alcohol (15 mL) was added hydrazine hydrate (80%, 6.6 mL, 108.35 mmol), the mixture was stirred at 80 °C for 16 h. The organic layer was concentrated under vacuum to give methyl (lr,3r)-l-(3-bromophenyl)-3- (difluoromethoxy)cyclobutane-l -carboxylate (3.7 g, 97% yield) as a white solid which was used directly without further purification. LCMS [M+H]+= 335.0 and 337.0.Intermediate 4: 2-((lr,3r)-l-(3-bromophenyl)-3-(difluoromethoxy)cyclobutane-l- carbonyl)-2V-methylhydrazine-l-carbothioamide
[0312] To a mixture of methyl (lr,3r)-l-(3-bromophenyl)-3-(difluoromethoxy)cyclobutane- 1 -carboxylate (3.7 g, 11.04 mmol) in tetrahydrofuran (25 mL) was added isothiocyanatomethane (4.1 g, 55.20 mmol) at 25 °C and stirred for 1 h. The mixture was concentrated to afford 2-((lr,3r)-l-(3-bromophenyl)-3-(difluoromethoxy)cyclobutane-l- carbonyl)-A-methylhydrazine-l -carbothioamide (4.6 g, 99% yield) as crude product. LCMS [M+H]+= 408.0.Intermediate 5: 5-((lr,3r)-l-(3-bromophenyl)-3-(difluoromethoxy)cyclobutyl)-4- methyl-4fH-l,2,4-triazole-3-thiol
[0313] A mixture of 2-((lr,3r)-l-(3-bromophenyl)-3-(difhioromethoxy)cyclobutane-l- carbonyl)-A-methylhydrazine-l -carbothioamide (4.6 g, 11.27 mmol) in IM sodium hydroxide (46 mL, 46 mmol), the mixture was stirred at 25 °C for 1 h. The pH of reaction mixture was adjust to 5 with hydrogen chloride (1 M). Then the light yellow solid was filtered and washed with water (20 mL), then dried to give 5-((lr,3r)-l-(3-bromophenyl)-3-(difluoromethoxy)- cyclobutyl)-4-methyl-4H -l,2,4-triazole-3-thiol (4.3 g, 97% yield) as light yellow solid..LCMS [M+H]+= 390.0 and 392.0.Production of Intermediate N
[0314] To a solution of 5-((lr,3r)-l-(3-bromophenyl)-3-(difluoromethoxy)cyclobutyl)-4- methyl-4H -l,2,4-triazole-3-thiol (4.3 g, 11.02 mmol) in water (20 mL) and acetonitrile (20 mL) was added 1 M nitric acid (55 mL, 55.09 mmol) and sodium nitrite (3.8 g, 55.09 mmol), the reaction was stirred at 20 °C for 1 h. The reaction was diluted with water (35 mL) and extracted with dichloromethane (3 x 45 mL), combined the organic phase and washed with brine (2 x 45 mL), dried over sodium sulfate, filtered and concentrated. The residue waspurified by purified by chromatography on silica gel (0-10% methanol in dichloromethane) to afford 3-((lr,3r)-l-(3-bromophenyl)-3-(difluoromethoxy)cyclobutyl)-4-methyl-4F / -l,2,4- triazole (3.7 g, 93% yield) as colorless oil.1H NMR (400 MHz, methanol-rfi) δ 8.39 (s, 1 H), 7.46 (d, J= 8.0 Hz, 1 H), 7.37 (s, 1 H), 7.32 (t, J= 8.0 Hz, 1 H), 7.22 (d, J= 8.0 Hz, 1 H), 6.37 (t, J= 74.8 Hz, 1 H), 4.71 - 4.63 (m, 1 H), 3.43 - 3.38 (m, 2 H), 3.28 (s, 3 H), 2.84 - 2.78 (m, 2 H). LCMS [M+H]+= 358.0 and 360.0.Example 15: Intermediate O
[0315] Intermediate O [3-(l -(3-bromophenyl)-3-(2,2-difluoroethyl)cyclobutyl)-4-methyl-4H- 1,2,4-triazole] can be synthesized according to the scheme in Scheme 15 (FIG. 15).Intermediate 2: ethyl 2-(3-(3-bromophenyl)-3-(4-methyl-4H -l,2,4-triazol-3- yl)cyclobutylidene)acetate
[0316] To a solution of NaH (60%, 470.34 mg, 11.76 mmol) in tetrahydrofuran (50 mL) was added ethyl 2-(diethoxyphosphoryl)acetate (2.33 mL, 11.76 mmol) dropwise at 0 °C, then the mixture was stirred at 0 °C for 30 min. 3-(3-bromophenyl)-3-(4-methyl-4H-l,2,4-triazol-3- yl)cyclobutan-l-one (3.0 g, 9.8 mmol) was added then the reaction mixture was allowed to warm up to RT and stirred for another 16 h. The mixture was quenched with water (50 ml), extracted with ethyl acetate (3 x 50 ml), combined the organic layers, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by chromatography on silica gel (0 - 4% methanol in dichloromethane) to afford ethyl 2-(3-(3-bromophenyl)-3-(4- methyl-4H-l,2,4-triazol-3-yl)cyclobutylidene)acetate (3.50 g, 94% yield) as yellow oil.1H NMR (400 MHz, DMSO-d6) 6 8.42 (s, 1H), 7.50 (d, J= 7.6 Hz, 1H), 7.38 (s, 1H), 7.34 (t, J= 8.0 Hz, 1H), 7.23 (d, J= 7.6 Hz, 1H), 5.81 - 5.77 (m, 1H), 4.10 - 4.06 (m, 2H), 3.87 - 3.80 (m, 1H), 3.74 - 3.67 (m, 1H), 3.60 - 3.54 (m, 1H), 3.24 (s, 3H), 3.18 - 3.15 (m, 1H), 1.20 (t, J= 6.8 Hz, 3H). LCMS [M+H]+= 376.0 and 378.0.Intermediate 3: ethyl 2-(3-(3-bromophenyl)-3-(4-methyl-42Z-l,2,4-triazol-3- yl)cyclobutyl)acetate
[0317] To a solution of ethyl 2-(3-(3-bromophenyl)-3-(4-methyl-4H -l,2,4-triazol-3- yl)cyclobutylidene)acetate (1.80 g, 4.78 mmol) in tetrahydrofuran (10 mL) and methanol (30 mL) was added NiCl2 (1.14 g, 4.78 mmol) and NaBH4 (0.67 g, 17.71 mmol) at 0 °C, the resulting mixture was stirred at 0 °C for 2 h. The mixture was poured into water (50 mL) and extracted with ethyl acetate (3 x 30 ml), combined the organic layers, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by chromatography on silica gel (0 - 4% methanol in dichloromethane) to afford ethyl 2-(3-(3-bromophenyl)-3-(4-methyl-4H -l,2,4-triazol-3-yl)cyclobutyl)acetate (1.2 g, 66% yield) as yellow oil. LCMS [M+H]+= 378.1 and 380.1.Intermediate 4 : 2-(3-(3-b romopheny l)-3-(4-methy 1-4 / / - 1 ,2 ,4-triazoI-3- yl)cyclobutyl)acetaldehyde
[0318] To a solution of ethyl 2-(3-(3-bromophenyl)-3-(4-methyl-4H -l,2,4-triazol-3- yl)cyclobutyl)acetate (1.0 g, 2.64 mmol) in dichloromethane (25 mL) was added DIBAL-H (IM in tetrahydro furan, 5.82 mL, 5.82 mmol) at -70 °C under nitrogen, the resulting mixture was stirred at -70 °C for 2 h under nitrogen. The reaction was quenched by addition of water (0.4 ml), NaOH (0.4 ml), water (1 ml) separately at 0 °C, which was allowed to warm up to RT and stirred for 15 min, dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by chromatography on silica gel (0 - 6% methanol in dichloromethane) to afford 2-(3-(3-bromophenyl)-3-(4-methyl-4H - 1 ,2,4-triazol-3-yl)cyclobutyl)acetaldehyde (660 mg, 74% yield, mixture of cis and trans isomers) as yellow oil.Production of Intermediate O
[0319] To a solution of 2-(3-(3-bromophenyl)-3-(4-methyl-4H -l,2,4-triazol-3- yl)cyclobutyl)acetaldehyde (40.0 mg, 0.12 mmol) in dichloromethane (1 mL) was added DAST dropwise (0.02 mL, 0.24 mmol) at 0 °C, the resulting mixture was stirred for 2 h. The reaction was quenched by saturated sodium bicarbonate solution and extracted with dichloromethane (3 x 5 ml), combined the organic layers, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by preparative TLC (10% methanol in dichloromethane) to afford 3-(l-(3-bromophenyl)-3-(2,2-difluoroethyl)cyclobutyl)-4-methyl- 4 / / -1 ,2,4-triazole (20 mg, 47% yield, mixture of cis and trans isomers) as yellow oil. LCMS [M+H] ' = 356.0 and 358.0.Example 16: Intermediate P
[0320] Intermediate P [3-(l-(3-bromophenyl)-3-ethynylcyclobutyl)-4-methyl-42 / -l,2,4- triazole] can be synthesized according to the scheme in Scheme 16 (FIG. 16).Intermediate 2: methyl l-(3-bromophenyI)-3-(methoxymethylene)cyclobutane-l- carboxylate
[0321] Under nitrogen, to a solution of bromo(methoxymethyl)triphenyl-15-phosphane(43.77 g, 113.03 mmol) in tetrahydrofuran (100 mL) was added toT-butoxypotassium (IM in tetrahydrofuran, 105.96 mL, 105.96 mmol) at 0 °c, then stirred at 40 °C for 1 h. methyl l-(3- bromophenyl)-3-oxocyclobutane-l -carboxylate (10.0 g, 35.32 mmol) was added and the resulting mixture was stirred at 40 °C for another 16 h. The reaction was diluted with water(50 mL), extracted with ethyl acetate (3 x 100 mL). The organics were washed with brine (2 x 100 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography on silica gel (0 - 15% ethyl acetate in petroleum ether) to afford methyl l-(3- bromophenyl)-3-(methoxymethylene)cyclobutane-l -carboxylate (6.8 g, 69% yield) as yellow oil.1H NMR (400 MHz, methanol-d4) δ 7.46 (s, 1H), 7.41-7.40 (m, 1H), 7.33 - 7.29 (m, 1H), 7.28 - 7.23 (m, 1H), 5.90 (s, 1H), 3.65 (s, 3H), 3.53 (s, 3H), 3.52 - 3.40 (m, 2H), 3.15 - 3.05 (m, 2H).Intermediate 3: methyl l-(3-bromophenyl)-3-formylcyclobutane-l-carboxylate
[0322] To a solution of methyl l-(3-bromophenyl)-3-(methoxymethylene)cyclobutane-l- carboxylate (9.7 g, 31.17 mmol) was added 6M hydrochloric acid (124.69 mL, 748.1 4mmol) in acetone (120 mL) at 25 °C, the mixture was stirred for 2 h then concentrated to remove most acetone, the residue was extracted with ethyl acetate (3 x 100 mL), combined the organic layers and concentrated. The residue was purified by chromatography on silica gel (0 - 20% ethyl acetate in petroleum ether) to afford methyl l-(3-bromophenyl)-3-formylcyclobutane-l- carboxylate (3.9 g, 42% yield).Intermediate 4: methyl l-(3-bromophenyl)-3-ethynylcyclobutane-l-carboxylate
[0323] To a solution of methyl l-(3-bromophenyl)-3-formylcyclobutane-l -carboxylate (1.86 g, 6.26 mmol) in methanol (20 mL) was added dimethyl (l-diazo-2-oxopropyl)phosphonate (1.8 g, 9.39 mmol) and potassium carbonate (1.73 g, 12.52 mmol). The mixture was stirred at 25 °C for 2 h and extracted with ethyl acetate (2 x 20 mL). The combined organic layers were washed with water (30 mL), brine (30 mL), dried over sodium sulfate and concentrated. The residue was purified by chromatography on silica gel (0 - 2% ethyl acetate in petroleum ether) to afford methyl 1 -(3 -bromophenyl)-3 -ethylcyclobutane- 1 -carboxylate (1.28 g, 70% yield, mixture of cis and trans isomers) as a yellow oil.1H NMR (400 MHz, CDCl3) δ 7.46 - 7.09 (m, 4H), 3.72 - 3.65 (m, 3H), 3.21 - 3.15 (m, 2H), 2.99 - 2.81 (m, 2H), 2.67 - 2.55 (m, 1H), 2.24 - 2.15 (m, 1H).Intermediate 5: l-(3-bromophenyl)-3-ethylcyclobutane-l-carbohydrazide
[0324] To a solution of methyl 1 -(3 -bromophenyl)-3-ethynylcyclobutane-l -carboxylate (1.28 g, 4.52 mmol) in tetrahydro furan (8 mL) and water (4 mL) was added hydroxylithium (541.40 mg, 22.61 mmol). The mixture was stirred at 25 °C for 2 h, diluted with dichloromethane (50 mL), washed with brine (2 x 50 mL), dried over sodium sulfate, filtered and concentrated to afford l-(3-bromophenyl)-3-ethylcyclobutane-l-carbohydrazide (1.15 g, 95% yield) as a yellow oil.1H NMR (400 MHz, methanol-A) δ 7.44 - 7.20 (m, 4H), 3.66 - 3.63 (m, 1H), 3.20 - 3.08 (m, 2H), 2.86 (s, 1H), 2.54 - 2.44 (m, 2H).Intermediate 6: 2-(l-(3-bromophenyl)-3-ethynyIcyclobutane-l-carbonyI)- V- methylhydrazine-l-carbothioamide
[0325] To a solution of l-(3-bromophenyl)-3-ethylcyclobutane-l-carbohydrazide (1.15 g, 4.12 mmol) and A-methylhydrazinecarbothioamide (476.58 mg, 4.53 mmol) in A,A- dimethylformamide (10 mL) was added A, A-diisopropylethylamine (2.15mL, 12.36 mmol) and HATU (2.35 g, 6.18 mmol). The solution was stirred at 25 °C for 16 h then diluted with ethyl acetate (40 mL), washed with water (30 mL), brine (30 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography on silica gel (0 - 80% ethyl acetate in petroleum ether) to afford 2-(l-(3-bromophenyl)-3-ethynylcyclobutane-l-carbonyl)- A-methy Ihydrazine- 1 -carbothioamide (1.0 g, 66% yield) as a yellow solid.Intermediate 7 : 5-(l -(3-bromophenyI)-3-ethy nylcyclobiityl)-4-methyl-4 / / -l ,2,4- triazole-3-thiol
[0326] A mixture of 2-(l-(3-bromophenyl)-3-ethynylcyclobutane-l-carbonyl)-A- methylhydrazine-1 -carbothioamide (1.0 g, 2.92 mmol) in aqueous sodium hydroxide (1.0 M, 14.61 mL, 14.61 mmol) was stirred at 25 °C for 2 h then adjusted to pH = 5 with aqueous hydrochloric acid (1.0 M). The precipitate was filtered, the cake was washed with water (20 mL) and dried under vacuum to give 5-(l-(3-bromophenyl)-3-ethylcyclobutyl)-4-methyl-4A- l,2,4-triazole-3-thiol (1 g, 99% yield) as a light yellow solid. LCMS [M+H]+= 350.0.Production of Intermediate P:
[0327] To a solution of 5-(l-(3-bromophenyl)-3-ethynylcyclobutyl)-4-methyl-4A-l,2,4- triazole-3 -thiol (1.0 g, 2.87 mmol) in water (5 mL) and acetonitrile (5 mL) was added sodium nitrite (1.98 g, 28.71 mmol) and nitric acid (1 M aqueous, 34.46 mL, 34.46 mmol) at 0 °C. The reaction mixture was stirred for 2 h at 20 °C, then diluted with dichloromethane (40 mL), washed with saturated sodium bicarbonate (30 mL), brine (30 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography on silica gel (0 - 10% methanol in dichloromethane) to afford 3-(l-(3-bromophenyl)-3-ethynylcyclobutyl)-4-methyl- 4H -1,2,4-triazole (480 mg, 53% yield) as a white solid. LCMS [M+H]+= 317.9.Example 17: Intermediate Q
[0328] Intermediate Q [3-(2-(3-bromophenyl)-6,6-difluorospiro[3.3]heptan-2-yl)-4-methyl- 4 A- 1 ,2,4-triazole] can be synthesized according to Scheme 17 (FIG. 17).Intermediate 2: (3,3-dimethoxycyclobutane-l,l-diyl)dimethanol
[0329] To a solution of diisopropyl 3, 3 -dimethoxy cyclobutane- 1,1 -dicarboxylate (10.0 g, 34.7 mmol) in tetrahydrofuran (150 mL) was added lithium aluminum hydride (2.5 M intetrahydrofuran, 20.81 mL, 52.0 mmol) at 0 °C, the mixture was stirred at 0 °C for 0.5h, then warmed to 25 °C and stirred for another 16 h then quenched with ice-water (10 mL), 15% sodium hydroxide solution (10 mL) and water (30 mL), dried over sodium sulfate, filtered and concentrated to afford the crude (3,3-dimethoxycyclobutane-l,l-diyl)dimethanol (5.7 g, 93% yield) as a yellow oil which used directly for the next step.1H NMR (400 MHz, CDCl3) δ 3.74 (s, 2H), 3.64 (s, 4H), 3.09 (s, 6H), 1.90 (s, 4H).Intermediate 3: l,l-bis(bromomethyl)-3,3-dimethoxycyclobutane
[0330] To a solution of triphenylphosphane (8.93 g, 34.1 mmol) in dichloromethane (50 mL) was added bromine (1.87 mL, 34.1 mmol), triethylamine (4.75 mL, 34.1 mmol) at 0 °C, the mixture was stirred at 0 °C for 15 min, then a solution of (3,3-dimethoxycyclobutane-l,l-diyl) dimethanol (2.0 g, 11.4 mmol) in dichloromethane (5 ml) was added, the resulting mixture was warmed to 25 °C and stirred for another 16 h. The mixture was quenched by sodium thiosulfate solution (50 mL), extracted with dichloromethane (3 x 50 mL). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel (0 - 2% ethyl acetate in petroleum ether) to afford l,l-bis(bromomethyl)-3,3-dimethoxycyclobutane (1.75 g, 51% yield) as a colorless oil.1H NMR (400 MHz, CDCl3) δ 3.70 (s, 4H), 3.15 (s, 6H), 2.12 (s, 4H).Intermediate 4: 3,3-bis(bromomethyl)cyclobutan-l-one
[0331] To a solution of l,l-bis(bromomethyl)-3,3-dimethoxycyclobutane (800.0 mg, 2.65 mmol) in acetone (10 mL) was added hydrogen chloride (4M in water, 12 mL, 48 mmol), the mixture was stirred at 25 °C for 16 h then adjusted to pH 7 by sodium bicarbonate solution, extracted with dichloromethane (3 x 50 mL). The organic layers were combined and washed with brine (50 mL), dried over sodium sulfate, filtered and concentrated to afford the crude 3,3-bis(bromomethyl)cyclobutan-l-one (677 mg, 100% yield) as white solid.1H NMR (400 MHz, CDCl3) δ 3.81 (s, 4H), 3.08 (s, 4H).Intermediate 5: l,l-bis(bromomethyl)-3,3-difluorocyclobutane
[0332] Under nitrogen atmosphere, to a solution of 3,3-bis(bromomethyl)cyclobutan-l-one (470 mg, 1.84 mmol) in dichloromethane (1.5 mL) was added MOST (0.54mL, 4.41 mmol) at 0 °C, the mixture was warmed to 25°C and stirred for 16 h. The reaction was quenched by sodium bicarbonate solution (50 mL), extracted with dichloromethane (3 x 50 mL). The organic layer was washed with brine (50 mL), dried over sodium sulfate, filtered and concentrated to afford the crude 1 ,l-bis(bromomethyl)-3, 3 -difluorocyclobutane (510 mg ,100% yield) as a yellow oil which was used directly for next step.1H NMR (400 MHz, CDCl3) δ 3.71 (s, 4H), 2.58 (t, J= 12.4 Hz, 4H).Production of Intermediate Q
[0333] To a solution of 3-(3-bromobenzyl)-4-methyl-4H -l,2,4-triazole (350.0 mg, 1.4 mmol) in A,M-dimethylformamide (5 mL) was added sodium hydride (60%, 166.6 mg, 4.2 mmol) at 0 °C, the mixture was stirred at for 30 min, then a solution of l,l-bis(bromomethyl)-3,3- difluorocyclobutane in N,N-dimethylformamide (2 mL) was added, the resulting mixture was warmed to 25 °Cand stirred for 5 min , then heated to 60 °C and stirred for 16 h. The mixture was quenched by water (50 mL), extracted with ethyl acetate (3 x 50 mL), combined the organic phase and washed with brine (50 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel (0 - 2% methanol in dichloromethane) to afford 3-(2-(3-bromophenyl)-6,6-difluorospiro[3.3]heptan-2- yl)-4-methyl-4H -l,2,4-triazole (0.25 g, 49% yield) as yellow oil.1H NMR (400 MHz, CDCh) δ 8.03 (s, 1H), 7.41 - 7.38 (m, 2H), 7.25 - 7.20 (m, 1H), 7.16 - 7.13 (m, 1H), 3.26 - 3.23 (m, 2H), 3.22 (s, 3H), 2.88 (d, J= 12.8 Hz, 2H), 2.61 (t, J= 12.4 Hz, 4H). LCMS [M+H]+= 368.1 and 370.1.Example 18: Compound 1 and Compound 2
[0334] Compound 1 and Compound 2 [6-((R)- 1 -hydroxy -2-((l- methylcyclobutyl)amino)ethyl)-2-(3-((1r,3R)-3-methoxy-l-(4-methyl-4H -l,2,4-triazol-3- yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin- 1 -one and 6-((S)- 1 -hydroxy-2-(( 1 - methylcyclobutyl)amino)ethyl)-2-(3-((lr,35)-3-methoxy-l-(4-methyl-4H -l,2,4-triazol-3- yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-l-one] can be synthesized as follows, as shown in Scheme 18, FIG. 18.
[0335] A mixture of 3-(( 1 r,3r)- 1 -(3 -bromophenyl)-3 -methoxy cyclobuty l)-4-methy 1-4H - 1,2,4-triazole (50.0 mg, 0.16 mmol), 6-(l-hydroxy-2-((l-methylcyclobutyl)amino)ethyl)-4- (trifhioromethyl)isoindolin-l-one (51.0 mg, 0.16 mmol, prepared according to Example W of International patent application publication No. WO2020264398), copper(I) iodide (11.8 mg, 0.06 mmol), potassium carbonate (42.9 mg, 0.31 mmol), (1S,2S)N1,N2-dimethylcyclohexane- 1,2-diamine (8.83 mg, 0.06 mmol) in tert-amyl alcohol (2 mL) was stirred at 100 °C under nitrogen for 2h. After cooled, the reaction mixture was diluted with ethyl acetate (25 mL), washed with NH3H2O (5 mL), brine (5 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by RP-HPLC (water(NH3H2O+NH4HCO3)- ACN 40% to 70%) to afford 6-(l-hydroxy-2-((l-methylcyclobutyl)amino)ethyl)-2-(3-((lr,3r)-3-methoxy- 1 -(4-methyl-4H - 1 ,2,4-triazol-3-yl)cyclobutyl)phenyl)-4- (trifluoromethyl)isoindolin-l-one (40 mg, 45% yield) as a white solid. LCMS [M+H]+= 570.3.
[0336] The above product was further purified by chiral SFC (Column = DAICEL CHIRALPAK A; Column dimensions = 250 mm x 30 mm x 10 μm; Detection wavelength = 220 nM; Flow rate = 80 mL / min; Mobile phase: A: CO2 B: IPA (35% B) with 0.1% ammonium hydroxide) to afford tentatively assigned: Compound 1: 6-((R )-l-hydroxy-2-((l- methylcyclobutyl)amino)ethyl)-2-(3-((lr,3R) -3-methoxy-l-(4-methyl-4H -l,2,4-triazol-3- yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-l-one (Peak 1, retention time = 4.760 min) (13.5 mg, 33% yield) as a white solid.1H NMR and LCMS [M+H]+ in Table 2. Compound 2: 6-((S)-l-hydroxy-2-((l-methylcyclobutyl)amino)ethyl)-2-(3-((lr,3S)-3-methoxy-l-(4-methyl- 4H -l,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-l-one (Peak 2, retention time = 5.148 min) (12.8 mg, 32% yield) as a white solid.1H NMR and LCMS [M+H]+ in Table 2.Example 19: Compound 3
[0337] Compound 3 [2-(3-((lr,3r)-3-methoxy-l-(4-methyl-4H -l,2,4-triazol-3-yl)cyclo- butyl)phenyl)-6-(2-((l-methylcyclobutyl)amino)ethyl)-4-(trifluoromethyl)isoindolin-l-one], Scheme 19, FIG. 19.Intermediate 2: ((E)-6-(2-ethoxyvinyl)-4-(trifluoromethyl)isoindolin-l-one)
[0338] Under nitrogen, to a mixture of 6-bromo-4-(trifluoromethyl)isoindolin-l-one (500 mg, 1.79 mmol, prepared using the procedures of Intermediate 4 as shown in Scheme 1), (E)-2- (2-ethoxyvinyl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (424 mg, 2.14 mmol) in 1,4-dioxane (10 mL) and water (1 mL) was added Pd(dppf)Cl2 (196 mg, 0.27 mmol, CAS No.: 72287-26-4) and sodium carbonate (568 mg, 5.36 mmol), the mixture was stirred at 80 °C for 5 h then concentrated under vacuum. The residue was purified by chromatography on silica gel (0-50% ethyl acetate in petroleum ether) to afford (E)-6-(2-ethoxyvinyl)-4-(trifluoromethyl)isoindolin- 1-one (402 mg, 83%) as a yellow solid.1H NMR (400 MHz, methanol-A) δ 7.86 (s, 1H), 7.74 (s, 1H), 7.34 (d, J= 13.2 Hz, 1H), 6.01 (d, J= 13.2 Hz, 1H), 4.56 (s, 2H), 3.97 (q, J= 7.2 Hz, 2H), 1.34 (t, J= 7.2 Hz, 3H)..Intermediate 3: 6-((E)-2-ethoxyvinyl)-2-(3-((lr,3r)-3-methoxy-l-(4-methyl-4H -l,2,4- triazol-3-yl)cyclobutyl)phenyI)-4-(trifluoromethyl)isoindolin-l-one
[0339] A mixture of 3-((lr,3r)-l-(3-bromophenyl)-3-methoxycyclobutyl)-4-methyl-4H- 1,2,4-triazole (434 mg, 1.35 mmol), (E)-6-(2-ethoxyvinyl)-4-(trifluoromethyl)isoindolin-l-one(402 mg, 1.48 mmol), copper(I) iodide (103 mg, 0.54 mmol), potassium carbonate (559 mg, 4.04 mmol), (lA25j-A\7V2-dimethylcyclohexane-l ,2-diamine (77 mg, 0.54 mmol) in tert-amyl alcohol (10 mL) was stirred at 100 °C for 2 hours under nitrogen protection. The resulting reaction was diluted with dichloromethane (50 mL), washed with NH3TI2O (5 mL), brine (15 mL), dried over anhydrous sodium sulfate, filtrated and concentrated under vacuum. The residue was purified by chromatography on silica gel (0 - 4% methanol in dichloromethane) to afford 6-((£)-2-ethoxyvinyl)-2-(3-(( 1 r,3r)-3-methoxy- 1 -(4-methyl-4H - 1 ,2,4-triazol-3- yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-l-one (610 mg, 88%) as white solid. LCMS [M+H]+513.3.Intermediate 4: 2-(2-(3-((lr,3r)-3-methoxy-l-(4--methyl -4 / / -l,2,4-triazol-3- yl)cyclobutyl)phenyl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)acetaldehyde
[0340] A solution of 6-((£)-2-ethoxyvinyl)-2-(3-((lr,3r)-3-methoxy-l-(4-methyl-4H -l,2,4- triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-l-one (300 mg, 0.59 mmol) in formic acid (10 mL) was stirred at 25 °C for 2 hours. The reaction mixture was adjusted to pH 8 with saturated sodium bicarbonate aqueous solution. The resulting solution was extracted with dichloromethane (3 x 50 mL), combined the organic phase and washed with water (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated to afford 2-(2-(3-((lr,3r)- 3-methoxy-l-(4-methyl-4H -l,2,4-triazol-3-yl)cyclobutyl)phenyl)-3-oxo-7- (trifluoromethyl)isoindolin-5-yl)acetaldehyde (280 mg, 79%) as a yellow solid.1NHMR (400 MHz, CDCI3) 3 9.89 (s, 1H), 8.13 (s, 1H), 7.98 (s, 1H), 7.89 (s, 1H), 7.71 (s, 1H), 7.60 (d, J= 8.4 Hz, 1H), 7.43 (t, J= 8.0 Hz, 1H), 7.07 (d, J= 7.6 Hz, 1H), 5.02 (s, 2H), 4.12 - 4.04 (m, 1H), 3.98 (s, 2H), 3.42 (d, J= 6.0 Hz, 2H), 3.33 (s, 3H), 3.32 - 3.30 (m, 4H), 2.70 - 2.65 (m, 2H).Production of Compound 3
[0341] A solution of 2-(2-(3-((lr,3r)-3-methoxy-l-(4-methyl-4 / / -l,2,4-triazol-3- yl)cyclobutyl)phenyl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)acetaldehyde (280 mg, 0.58 mmol), 1-methylcyclobutanamine hydrochloride (77 mg, 0.64 mmol) and triethylamine (0.1 mL, 0.64 mmol) in methanol (5 mL) was stirred at 100 °C for 3 min at microwave. The mixture was cooled to 25 °C, sodium cyanotrihydroborate (109 mg, 1.73 mmol) was added and stirred at 80 °C for 40 min. The reaction was concentrated under vacuum. The residue was purified by RP-HPLC (water(NH3H2O+NH4HCO3)- ACN 40% to 70%) to afford 2-(3-((lr,3r)- 3-methoxy-l-(4-methyl-4 / / -l,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(2-((l- methylcyclobutyl)amino)ethyl)-4-(trifluoromethyl)isoindolin-l-one (54.7 mg, 17%) as a white solid.1H NMR (400 MHz, methanol-d4) δ 8.39 (s, 1H), 7.96 (s, 1H), 7.91 (s, 1H), 7.86 (s, 1H),7.69 (d, J = 8.4 Hz, 1H), 7.47 (t, J = 8.0 Hz, 1H), 7.09 (d, J = 7.8 Hz, 1H), 5.14 (s, 2H), 4.02 - 3.93 (m, 1H), 3.41 - 3.36 (m, 2H), 3.35 (s, 3H), 3.30 ( s, 3H), 3.03 - 2.94 (m, 2H), 2.85 - 2.77 (m, 2H), 2.69 - 2.61 (m, 2H), 2.06 - 1.96 (m, 2H), 1.89 - 1.81 (m, 2H), 1.80 - 1.69 (m, 2H), 1.29 (s, 3H). LCMS [M+H]+ = 554.3.Example 20: Compound 4 and Compound 5
[0342] Compound 4 and Compound 5 [2-(3-((lr,37?)-3-methoxy-l-(4-methyl-4H -l,2,4- triazol-3-yl)cyclobutyl)phenyl)-6-((R )-l-((l-methyIcyclobutyl)amino)propan-2-yl)-4- (trifluoromethyl)isoindolin- 1 -one and 2-(3-(( 1 r,3S)-3-methoxy- 1 -(4-methy 1-4H - 1 ,2,4-triazol-3- yl)cyclobutyl)phenyl)-6-((S)- 1 -(( 1 -methy lcyclobutyl)amino)propan-2-yl)-4- (trifluoromethyl)isoindolin-l-one], can be synthesized according to Scheme 20 (FIG. 20).
[0343] To a solution of potassium carbonate (67.7 mg, 0.49 mmol) and 3-((lr,3r)-l-(3- bromophenyl)-3 -methoxy cyclobutyl)-4-methy 1-4H -1, 2, 4-triazole (86.9 mg, 0.27 mmol) in tert - amyl alcohol (1 mL) was added copper(I) iodide (0.01 mL, 0.25 mmol) and 6-(l-((l- methylcyclobutyl)amino)propan-2-yl)-4-(trifluoromethyl)isoindolin- 1 -one (Intermediate C, 80.0 mg, 0.25 mmol) and (lS,2S)-A\AMimethylcyclohexane-l,2-diamine (17.4 mg, 0.12 mmol). The mixture was stirred at 100 °C for 5 hours under nitrogen atmosphere, the mixture was diluted with ethyl acetate with (30 mL), washed with NHrlHbO (5 mL), brine (5 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by RP- HPLC (water(NH3H2O+NH4HCO3)- ACN 50% to 80%) to afford 2-(3-((lr,3r)-3-methoxy-l- (4-methyl-4H - 1 ,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(l-((l -methylcyclobutyl)amino)propan- 2-yl)-4-(trifhioromethyl)isoindolin-l-one (60 mg, 43% yield) as a white solid. LCMS [M+H]+= 568.3.The above product was further purified by chiral SFC (Column = DAICEL CHIRALPAK A; Column dimensions = 250 mm x 30 mmx10 μm; Detection wavelength = 220 nM; Flow rate = 80 mL / min; Mobile phase: A: CO2 B: IPA (40% B) with 0.1% ammonium hydroxide) to afford tentatively assigned: 2-(3-((lr,37?)-3-methoxy-l-(4-methyl-4H -l,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-((R )-l-((l- methylcyclobutyl)amino)propan-2-yl)-4-(trifluoromethyl)isoindolin-l-one (Peak 1, retention time = 4.985 min)(17.6 mg, 29% yield).1H NMR (400 MHz, methanol-A) 5 8.39 (s, 1H), 7.98 (s, 1H), 7.91 (s, 1H), 7.85 (s, 1H), 7.69 (d, J= 8.0 Hz, 1H), 7.47 (t, J= 8.0 Hz, 1H), 7.08 (d, J = 7.6 Hz, 1H), 5.14 (s, 2H), 3.99 (m, 1H), 3.41 - 3.36 (m, 2H), 3.35 (s, 3H), 3.30 - 3.28 (m, 3H), 3.09 (m, 1H), 2.81 - 2.73 (m, 2H), 2.70 - 2.60 (m, 2H), 1.95 - 1.69 (m, 6H), 1.37 (d, J= 6.8 Hz, 3H), 1.25 (s, 3H). LCMS [M+H]+ = 568.4.2-(3-(( 1 r,3iS)-3-methoxy- 1 -(4-methyl-4H - 1 ,2,4-triazol-3-yl)cyclobutyl)pheny l)-6-((8)- 1 - (( 1 - methylcyclobutyl)amino)propan-2-yl)-4-(trifluoromethyl)isoindolin-l-one (Peak 2, retention time = 5.310 min) (15.6 mg, 26% yield) as a white solid.rH NMR (400 MHz, methanol-A) δ 8.39 (s, 1H), 7.98 (s, 1H), 7.91 (s, 1H), 7.85 (s, 1H), 7.69 (d, J= 8.0 Hz, 1H), 7.47 (t, J= 8.0 Hz, 1H), 7.08 (d, J= 8.0 Hz, 1H), 5.14 (s, 2H), 3.99 (m, 1H), 3.41 - 3.36 (m, 2H), 3.35 (s, 3H), 3.29 (s, 3H), 3.14 - 3.04 (m, 1H), 2.80 - 2.74 (m, 2H), 2.70 - 2.60 (m, 2H), 1.95 - 1.68 (m, 6H), 1.37 (d, J= 6.8 Hz, 3H), 1.25 (s, 3H). LCMS [M+H]+= 568.4.Example 21: Compound 6
[0344] Compound 6 [2-(3-((lr,3r)-3-(difluoromethoxy)-l-(4-methyl-4H-l,2,4-triazol-3- yl)cyclobutyl)phenyl)-4-(difluoromethyl)-6-((isobutylamino)methyl)isoindolin-l-one] can be synthesized according to Scheme 21 (FIG. 21).
[0345] In glove box, to a vial was added 4-(difluoromethyl)-6-((isobutylamino)- methyl)isoindolin-l-one (Intermediate M, 200 mg, 0.75 mmol), 3-((lr,3r)-l-(3- bromophenyl)-3-(difluoromethoxy)cyclobutyl)-4-methyl-4H -l ,2,4-triazole (Intermediate N, 293 mg, 0.82 mmol), copper(I) iodide (56 mg, 0.30mmol), ( 18,28) -Nl,N2- dimethylcyclohexane-l,2-diamine (42 mg, 0.30 mmol) and potassium carbonate (309 mg, 2.24 mmol) and tert-amyl alcohol (2 ml). The vial was sealed and stirred at 100 °C for 2 h then concentrated to dryness. The residue was purified by chromatography on silica gel (0 - 10% methanol in dichloromethane) to afford a crude product which was purified by RP-HPLC (water(NH3H2O+NH4HCO3)- ACN 55% to 85%) to afford 2-(3-((lr,3r)-3-(difluoromethoxy)- 1 -(4-methyl-4H - 1 ,2,4-triazol-3 -yl)cyclobutyl)phenyl)-4-(difluoromethyl)-6-((isobutyl- amino)methyl)isoindolin-l-one (34.6 mg, 8% yield).1H NMR (400 MHz, methanol-df) δ 8.40 (s, 1H), 7.96 (s, 1H), 7.94 (s, 1H), 7.83 (s, 1H), 7.70 (d, J= 8.4 Hz, 1H), 7.49 (t, J= 8.0 Hz, 1H), 7.21 - 6.90 (m, 1H), 6.63 - 6.15 (m, 1H), 5.13 (s, 2H), 4.71 (m, 1H), 3.93 (s, 2H), 3.48 - 3.42 (m, 2H), 3.34 (s, 3H), 2.93 - 2.85 (m, 2H), 2.42 (d, J= 12 Hz, 2H), 1.81 (m, 1H), 0.94 (d, J= 6.4 Hz, 6H). LCMS [M+H]+= 546.2.Example 22: Compound 7 and Compound 8
[0346] Compound 7 and Compound 8 [(R )-2-(3-(I -(4-methyl-4H -l,2,4-triazol-3-yl)-3- (trifluoromethoxy)propyl)phenyl)-6-(((l-methylcyclobutyl)amino)methyl)-4- (trifluoromethyl)isoindolin-l-one and (5)-2-(3-(l-(4-methyl-4H -l,2,4-triazol-3-yl)-3- (trifluoromethoxy)propyl)phenyl)-6-(((l-methylcyclobutyl)amino)methyl)-4- (trifluoromethyl)isoindolin-l-one], can be synthesized according to Scheme 22 (FIG. 22).Intermediate 2 (3-(l-(3-bromophenyl)-3-(trifluoromethoxy)propyl)-4-methyI-4.H-1.2.4-triazole)
[0347] Under nitrogen atmosphere, to a solution of 3-(3-bromobenzyl)-4-methyl-4 / / -l,2,4- triazole (200 mg, 0.79 mmol) in tetrahydrofuran (4 mL) was added sodium bis(trimethylsilyl)amide (1 M in tetrahydrofuran, 1.03 mL, 1.03 mmol) at 0 °C. The mixture was at 0 °C for 30 mins, then l-bromo-2-(trifluoromethoxy)ethane (229.61 mg, 1.19 mmol) was added at 0 °C. The resulting mixture was stirred at 25 °C for 1.5 hours then quenched by water (10 mL), extracted with dichloromethane (3 * 20 mL), combined the organic layers, dried over sodium sulfate, filtered and concentrated under vacuum. The residue purified by chromatography on silica gel (0 - 10% methanol in dichloromethane) to afford 3-(l-(3- bromophenyl)-3-(trifluoromethoxy)propyl)-4-methyl-4 / f-l,2,4-triazole (100 mg, 35% yield) as a yellow solid. LCMS [M+H]+= 365.8. .Production of Compounds 7 and 8:
[0348] To a solution of 3-(l-(3-bromophenyl)-3-(trifluoromethoxy)propyl)-4-methyl-4H -1.2.4-triazole (100 mg, 0.27 mmol), 6-((( 1 -methylcyclobutyl)amino)methyl)-4- (trifluoromethyl)isoindolin-l-one (90 mg, 0.30 mmol) in tert-amyl alcohol (2 mL) was added copper(I) iodide (21 mg, 0.11 mmol), potassium carbonate (76 mg, 0.55 mmol) and (15,25)- A''\A''2-dimethylcyclohexane- L2-diaiTiine (12 mg, 0.08 mmol). The mixture was stirred at 100 °C for 2 hours under nitrogen atmosphere. The mixture was diluted with dichloromethane (20 mL), washed with NH3H2O (5 mL), brine (5 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel (0 - 10% methanol in dichloromethane) to afford 2-(3-(l-(4-methyl-4TT-l,2,4-triazol-3-yl)-3- (trifluoromethoxy)propyl)phenyl)-6-(((l-methylcyclobutyl)amino)methyl)-4- (trifluoromethyl)isoindolin-l-one (80 mg, 50% yield) as a white solid. LCMS [M+H]+= 582.3.The above mixture was further purified by chiral SFC (Column = Daicel Chiralpak IG; Column dimensions = 250 mm ' 30 mm x 10 μm: Detection wavelength = 220 nM; Flow rate = 70 mL / min; Mobile phase: A: CO2 B: ethanol (0.05% DEA); Isocratic: 30% B) with 0.1% ammonium hydroxide) to afford tentatively assigned: (R )-2-(3-(l-(4-methyl-4H -l,2,4-triazol-3-yl)-3-(trifluoromethoxy)propyl)phenyl)-6-(((l- methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-l-one (Peak 1, retention time = 6.825 min) (21.7 mg, 26% yield) as white solid.1H NMR (400 MHz, methanol-d4) δ 8.40 (s, 111). 8.09 (s. I H ). 8.01 (s. 1H), 7.88 (s, I I I). 7.84 - 7.81 (m, I H ). 7.47 (t, J= 8.0 Hz. 1H), 7.12 (d. J= 8.0 Hz, I I I). 5.15 (d, J= 3.2 Hz, 2H), 4.48 (I. J= 8.0 Hz, IH), 4.17 - 4.02 (m. 211). 3.86(s, 2H), 3.52 (s, 3H), 2.81 - 2.73 (m, 1H), 2.56 - 2.47 (m, 1H), 2.12 - 2.06 (m, 2H), 1.92 - 1.84 (m, 2H), 1.82 - 1.79 (m, 2H), 1.38 (s, 3H). LCMS [M+H]+= 582.3. (S)-2-(3-(l-(4-methyl-4 / / -l,2,4-triazol-3-yl)-3-(trifluoromethoxy)propyl)phenyl)-6-(((l- methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-l-one (Peak 2, retention time = 6.813 min) (19.2 mg, 23% yield) as white solid.1H NMR (400 MHz, methanol-d4 ) δ 8.40 (s, 1H), 8.08 (s, 1H), 8.01 (s, 1H), 7.87 (t, 2.0 Hz, 1H), 7.84 - 7.81 (m, 1H), 7.47 (t, J= 8.0Hz, 1H), 7.12 (d, J= 7.6 Hz, 1H), 5.14 (d, J= 3.2 Hz, 2H), 4.48 (t, J= 7.6 Hz, 1H), 4.17 - 4.10 (m, 1H), 4.08 - 4.02 (m, 1H), 3.86 (s, 2H), 3.52 (s, 3H), 2.81 - 2.71 (m, 1H), 2.57 - 2.47 (m, 1H), 2.14 - 2.06 (m, 2H), 1.93 - 1.86 (m, 2H), 1.83 - 1.75 (m, 2H), 1.38 (s, 3H). LCMS [M+H]+= 582.3. .Example 23: Compound 9 and Compound 10
[0349] Compound 9 and Compound 10 [2-(3-((Ls',3.s')-3-(2,2-difluoroethyl)-l -(4-methyl-4H -1.2.4-triazol-3 -yl)cyclobutyl)phenyl)-6-((( 1 -methylcyclobutyl)amino)methyl)-4- (trifluoromethyl)isoindolin-l-one) and 2-(3-((lr,3r)-3-(2,2-difluoroethyl)-l-(4-methyl-4H -1.2.4-triazol-3-yl)cyclobutyl)phenyl)-6-(((l-methylcyclobutyl)amino)methyl)-4- (trifluoromethyl)isoindolin-l-one], can be synthesized according to Scheme 23, FIG. 23.
[0350] To a mixture of 3-(l-(3-bromophenyl)-3-(2,2-difluoroethyl)cyclobutyl)-4-methyl-4H -1.2.4-triazole (Intermediate O, 30.0 mg, 0.08 mmol), 6-(((l-methylcyclobutyl)amino)methyl)- 4-(trifluoromethyl)isoindolin-l-one (27.64 mg, 0.09 mmol) in tert-amyl alcohol (1 mL) was added Copper(I) iodide (6.42 mg, 0.03 mmol), potassium carbonate (34.92 mg, 0.25 mmol) and (l1S',28)-N1A2-dimethylcyclohexane-l ,2-diamine (4.79 mg, 0.03 mmol). The mixture was stirred at 100 °C for 2 h under nitrogen atmosphere then concentrated to dryness and the residue was purified by preparative TLC (solvent gradient: 10% methanol in dichloromethane) to afford 2-(3-(3-(2,2-difhioroethyl)-l-(4-methyl-4H -l,2,4-triazol-3-yl)cyclobutyl)phenyl)-6- (((l-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindoIin-l-one (30 mg, 62% yield) as yellow oil.The above product was further purified by chiral SFC (Column = DAICEL CHIRALPAK AD; Column dimensions = 250 mm x 30 mm x 10 μm; Detection wavelength = 220 nM; Flow rate = 70 mL / min; Mobile phase: A: CO2 B: ethanol (0.05% DEA); Isocratic: 30% B with 0.1% ammonium hydroxide) to afford tentatively assigned: 2-(3-((ls,3s)-3-(2,2-difhioroethyl)-l-(4-methyl-4ZLl,2,4-triazol-3-yl)cyclobutyl)phenyl)-6- (((l-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-l-one (Peak 1, retention time = 4.929 min) (4.6 mg, 15% yield) as a white solid.1H NMR (400 MHz, methanol-d4 ) δ8.31 (s, 1H), 8.11 - 8.08 (m, 2H), 8.01 (s, 1H), 7.70 (dd, J= 8.4, 1.6 Hz, 1H), 7.51 (t, J= 8.0 Hz, 1H), 7.28 (d, J= 7.6 Hz, 1H), 6.05 - 5.73 (m, 1H), 5.16 (s, 2H), 3.88 (s, 2H), 3.34 (s, 3H), 3.05 - 2.98 (m, 2H), 2.82 - 2.74 (m, 3H), 2.15 - 1.98 (m, 4H), 1.92 - 1.76 (m, 4H), 1.39 (s, 3H). LCMS [M+H]+= 574.3.2-(3-((lr,3r)-3-(2,2-difluoroethyl)-l-(4-methyl-4 / / -l,2,4-triazol-3-yl)cyclobutyl)phenyl)-6- (((l-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-l-one (Peak 2, retention time = 5.165 min) (5.4 mg, 17% yield) as a white solid.LH NMR (400 MHz, methanol-tL) 5 8.39 (s, 1H), 8.09 (s, 1H), 8.01 (s, 1H), 7.92 (s, 1H), 7.66 (dd, J= 8.0, 1.2 Hz, 1H), 7.47 (t, J= 8.0 Hz, 1H), 7.08 (d, J= 7.6 Hz, 1H), 6.05 - 5.72 (m, 1H), 5.15 (s, 2H), 3.88 (s, 2H), 3.35 (s, 3H), 3.22 - 3.12 (m, 2H), 2.67 - 2.59 (m, 1H), 2.59 - 2.52 (m, 2H), 2.16 - 1.99 (m, 4H), 1.93 - 1.77 (m, 4H), 1.39 (s, 3H). LCMS [M+H]+= 574.3.Example 24: Compound 11
[0351] Compound 11 [4-cyclopropyl-2-(3-((15,3x)-3-methoxy-l-(4-methyl-4ZZ-l,2,4-triazol- 3-yl)cyclobutyl)phenyl)-6-(((l-methylcyclobutyl)amino)methyl)isoindolin-l-one] can be synthesized according to Scheme 24, FIG. 24.
[0352] To a vial was added 3-((15,3s)-l-(3-bromophenyl)-3-methoxycyclobutyl)-4-methyl- 4H -1,2,4-triazole (47.67 mg, 0.15 mmol), 4-cyclopropyl-6-(((l- methylcyclobutyl)amino)methyl)isoindolin-l-one (intermediate D, 40.0 mg, 0.15 mmol), copper(I) iodide (5.64 mg, 0.03 mmol), (lS,2S)-.M,Af2-dimethylcyclohexane-l,2-diamine (4.21 mg, 0.03 mmol), potassium carbonate (30.67 mg, 0.22 mmol) and tert-amyl alcohol (3 mL). The vial was protected with nitrogen and sealed, then stirred at 100 °C for 2 h. The mixture was diluted with dichloromethane (30 mL), washed with NH3H2O (5 mL), brine (5 mL), dried over sodium sulfate, filtered and concentrated to dryness. The resulting residue was purified by RP-HPLC(water(NH3H2O+NH4HCO3)-ACN, acetonitrile 45 - 75%) to afford 4- cyclopropyl-2-(3-((ls,3s)-3-methoxy-l-(4-methyl-4H -l,2,4-triazol-3-yl)cyclobutyl)phenyl)-6- (((l-methylcyclobutyl)amino)methyl)isoindolin-l-one (28 mg, 37% yield) as white solid.1H NMR (400 MHz, methanol-d4) δ 8.32 (s, 1H), 8.09 (s, 1H), 7.73 (dd, J= 8.0, 1.6 Hz, 1H), 7.62 (s, 1H), 7.48 (t, J= 8.0 Hz, 1H), 7.24 (s, 1H), 7.18 (d, J= 6.8 Hz, 1H), 5.05 (s, 2H), 4.23 - 4.16 (m, 1H), 3.74 (s, 2H), 3.37 (s, 3H), 3.29 (s, 3H), 3.20 - 3.19 (m, 2H), 2.92 - 2.84 (m, 2H), 2.12 - 2.01 (m, 3H), 1.90 - 1.75 (m, 4H), 1.38 (s, 3H), 1.12 - 1.06 (m, 2H), 0.91 - 0.85 (m, 2H). LCMS [M+H]+= 512.3.Example 25: Compound 12
[0353] Compound 12 [4-cyclopropyl-2-(3-((lr,3r)-3-methoxy-l-(4-methyl-4 / f-l,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((l-methylcyclobutyl)amino)methyl)isoindolin-l-one] can be synthesized according to Scheme 25, FIG. 25.
[0354] A mixture of 3-((lr,3r)-l-(3-bromophenyl)-3-methoxycyclobutyl)-4-methyl-47t- 1,2,4-triazole (47.67 mg, 0.15 mmol), 4-cyclopropyl-6-(((l-methylcyclobutyl)amino)methyI)- isoindolin-l-one (intermediate D, 40.0 mg, 0.15 mmol), copper(I) iodide (11.27 mg, 0.06 mmol), (15,25)-A1,A2-dimethylcyclohexane-l,2-diamine (8.42 mg, 0.06 mmol) and potassium carbonate (61.34 mg, 0.44 mmol) in tert-amyl alcohol (3 mL) was stirred at 100 °C for 2 h. The mixture was diluted with dichloromethane (30 mL), washed with NHsTLO (5 mL), brine (5 mL), dried over sodium sulfate, filtered and concentrated to dryness. The resulting residue was purified by RP-HPLC(water(NH3H2O+NH4HCO3)-ACN, acetonitrile 45 - 75%) to afford4-cyclopropyl-2-(3-((lr,3r)-3-methoxy-l-(4-methyI-4H -l,2,4-triazol-3-yl)cyclobutyl)phenyl)- 6-(((l-methylcyclobutyl)amino)methyl)isoindolin-l-one (27 mg, 36% yield) as white solid.1H NMR (400 MHz, methanol-d4) δ 8.39 (s, 1H), 7.95 - 7.92 (m, 1H), 7.72 (d, J= 8.0 Hz, 1H), 7.61 (s, 1H), 7.46 (t, J= 8.0 Hz, 1H), 7.24 (s, 1H), 7.05 (d, J= 6.8 Hz, 1H), 5.05 (s, 2H), 3.99 (q, J= 7.2 Hz, 1H), 3.74 (d, J= 4.4 Hz, 2H), 3.40 - 3.36 (m, 2H), 3.35 (s, 3H), 3.30 (s, 3H), 2.70 - 2.62 (m, 2H), 2.13 - 2.03 (m, 3H), 1.92 - 1.77 (m, 4H), 1.38 (s, 3H), 1.13 - 1.06 (m, 2H), 0.91 - 0.86 (m, 2H). LCMS [M+H]+= 512.3..Example 26: Compound 13
[0355] Compound 13 [6-(((cyclopropylmethyl)amino)methyl)-2-(3-((lr,3r)-3- (difluoromethoxy)-l-(4-methyI-4H -l,2,4-triazol-3-yl)cyclobutyl)phenyl)-4- (trifluoromethyl)isoindolin-l-one] can be synthesized according to Scheme 26, FIG. 26.
[0356] To a solution of 6-(((cyclopropyhnethyl)amino)methyl)-4-(trifluoromethyl)isoindolin-l-one (Intermediate E, 100.0 mg, 0.35 mmol), 3-((lr,3r)-l-(3- bromophenyl)-3-(difluoromethoxy)cyclobutyl)-4-methyl-4H -l,2,4-triazole (142 mg, 0.39 mmol) in tert-amyl alcohol (5 mL) was added copper(I) iodide (75 mg, 0.39 mmol), (15,25)- TV'jA^-dimethylcyclohexane-l^-diamine (39 mg, 0.27 mmol) and potassium carbonate (166 mg, 1.2 mmol). The sealed vial was stirred at 100 °C for 2 h and concentrated to dryness. The residue was purified by chromatography on silica gel (0 - 10% methanol in dichloromethane) to afford a crude product which was further purified by RP-HPLC (water (NH3H2O + NH4HCO3)- ACN 55% to 85%) to afford 6-(((cyclopropylmethyl)amino)methyl)-2-(3-(( lr,3r)- 3 -(difluoromethoxy)- 1 -(4-methyl-4 / / - 1 ,2,4-triazol-3-y 1 )cyclobuty l)phenyl)-4-(trifluoromethyl)isoindolin-l-one(31.9 mg, 16% yield) as a white solid1.H NMR (400 MHz, DMSO-Je) δ 8.42 (s, 1H), 8.02 (s, 1H), 7.98 (s, 1H), 7.89 (s, 1H), 7.74 (d, J= 7.6 Hz, 1H), 7.45 (t, J= 8.0 Hz, 1H), 6.98 (d, J= 8.4 Hz, 1H), 6.71 (t, J= 75.6 Hz, 1H), 5.20 (s, 2H), 4.64 - 4.56 (m, 1H), 3.91 (s, 2H), 3.41 - 3.39 (m, 2H), 3.24 (s, 3H), 2.67 -2.60 (m, 2H), 2.39 - 2.34 (m, 2H), 0.93 - 0.85 (m, 1H), 0.42 - 0.36 (m, 2H), 0.10 - 0.05 (m, 2H). LCMS [M+H]+= 562.2.Example 27: Compound 14
[0357] Compound 14 [4-chloro-2-(3-((lr,3r)-3-chloro-l-(4-methyl-4F / -l,2,4-triazol-3- yl)cyclobuty l)phenyl)-6-(((cyclobutylmethyl)amino)methyl)isoindolin- 1 -one] can be synthesized according to Scheme 27, FIG. 27.
[0358] To a solution of 4-chloro-6-(((cyclobutylmethyl)amino)methyl)isoindolin-l-one (Intermediate B, 70 mg, 0.26 mmol) in tert-amyl alcohol (3 mL) was added 3-((lr,3r)-l-(3- bromophenyl)-3-chlorocyclobutyl)-4-methyl-4H-l,2,4-triazole (86 mg, 0.26 mmol), Copper(I) iodide (20 mg, 0.11 mmol), (l>S',2S)-JV'1^V2-dimethylcyclohexane-l,2-diamine (15 mg, 0.11 mmol) and potassium carbonate (109 mg, 0.79 mmol), the solution was purged with N2 and stirred at 100 °C for 4 hours, the reaction mixture was diluted with ethyl acetate (25 mL), washed with NH3H2O (5 mL), brine (5 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by RP-HPLC (water(NH3H2O+NH4HCO3)- ACN 50% to 80%) to afford the desired product of 4-chloro-2-(3-((lr,3r)-3-chloro-l-(4- methyl-4H - 1 ,2,4-triazol-3-yl)cyclobutyl)phenyl)-6- (((cyclobutylmethyl)amino)methyl)isoindolin-l-one (12.5 mg, 9%) as white solid.:H NMR (400 MHz, DMSO-tfc) δ 8.42 (s, 1H), 7.86 (t, J= 1.6 Hz, 1H), 7.78 (d, J= 8.4, 1.6 Hz, 1H), 7.71 (s, 2H), 7.44 (t, J= 8.0 Hz, 1H), 6.98 (d, J= 7.6 Hz, 1H), 5.03 (s, 2H), 4.56 - 4.48 (m, 1H), 3.79 (s, 2H), 3.69 - 3.64 (m, 2H), 3.24 (s, 3H), 2.96 - 2.90 (m, 2H), 2.43 - 2.36 (m, 3H), 2.02 - 1.94 (m ,2H), 1.86 - 1.74 (m, 2H), 1.67 - 1.60 (m, 2H). LCMS [M+H]+= 532.1.Example 28: Compound 15
[0359] Compound 15 [4-chloro-6-(((cyclobutyhnethyl)amino)methyl)-2-(3-((ls,3s)-3-fluoro- l-(4-methyl-4H -l,2,4-triazol-3-yl)cyclobutyl)phenyl)isoindolin-l-one] can be synthesized according to Scheme 28, FIG. 28.
[0360] To a solution of 4-chloro-6-(((cyclobutylmethyl)amino)methyl)isoindolin-l-one (Intermediate B, 100 mg, 0.38 mmol) in tert-amyl alcohol (3 mL) was added 3-((ls,3s)-l-(3- bromophenyl)-3-fluorocyclobutyl)-4-methyl-4H-l,2,4-triazole (129 mg, 0.42 mmol), Copper(I)iodide (29 mg, 0.15 mmol), ClN25)-A\A2-dimethylcycIohexane-1 ,2-diarmne (21 mg, 0.15 mmol) and potassiuim carbonate (157 mg, 1.13 mmol), the solution was purged with N2 and stirred at 100 °C for 4 hours. The solution was diluted with dichloromethane (10 mL), washed with water (10 mL) and NH3H2O (10 mL), the organic layer was dried with anhydrous Na2SO4, filtered and concentrated. The residue was purified by RP-HPLC (water(NH3H2O+NH4HCO3)- ACN 50% to 80%) to afford the desired product of 4-chloro-6- (((cyclobutyhnethyl)amino)methyl)-2-(3-((ls,3s)-3-fluoro-l-(4-methyl-4H -l,2,4-triazol-3- yl)cyclobutyl)phenyl)isoindolin-l-one (40 mg, 21%) as white solid.1H NMR (400 MHz, DMSO-Je) δ 8.35 (s, 1H), 7.89 - 7.88 (m, 1H), 7.82 - 7.80 (m, 1H), 7.71 (s, 2H), 7.44 (t, J= 8.0 Hz, 1H), 7.07 (d, J= 7.6 Hz, 1H), 5.42 - 5.21 (m, 1H), 5.04 (s, 2H), 3.79 (s, 2H), 3.25 (s, 3H), 3.21 - 3.09 (m, 4H), 2.41 - 2.36 (m, 3H), 2.02 - 1.94 (m, 2H), 1.84 - 1.74 (m, 2H), 1.67 - 1.60 (m, 2H). LCMS [M+H]+= 494.2.Example 29: Compound 16
[0361] Compound 16 (4-chloro-6-(((cyclobutylmethyl)amino)methyl)-2-(3-((lr,3r)-3-fluoro- l-(4-methyl-4 / / -l,2,4-triazol-3-yl)cyclobutyl)phenyl)isoindolin-l -one) can be synthesized according to Scheme 29 (FIG. 29).
[0362] To a solution of 4-chloro-6-(((cyclobutylmethyl)amino)methyl)isoindolin-l-one (intermediate B, 100 mg, 0.38 mmol) in terLamyl alcohol (3 mL) was added 3-((lr,3r)-l-(3- bromophenyl)-3-fluorocyclobutyl)-4-methyl-4H -l,2,4-triazole (129 mg, 0.42 mmol), Copper(I) iodide (29 mg, 0.15 mmol), (l>S',2S)-A1rA2-dimethylcyclohexane-l,2-diamine (21 mg, 0.15 mmol) and potassium carbonate (157 mg, 1.13 mmol), the solution was purged with N2 and stirred at 100 °C for 4 hours. The solution was diluted with dichloromethane (10 mL), washed with water (10 mL) and NH3H2O (10 mL), the organic layer was dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by RP-HPLC (water(NH3H2O+NH4HCO3)-ACN 50% to 80%) to afford the desired product of 4-chloro-6- (((cyclobutylmethyl)amino)methyl)-2-(3-((lr,3r)-3-fluoro-l-(4-methyl-4H -l,2,4-triazol-3- yl)cyclobutyl)phenyl)isoindolin-l-one (40 mg, 21%) as white solid.1H NMR (400 MHz, DMSO-Je) δ 8.40 (s, 1H), 7.86 (d, J= 2.0 Hz, 1H), 7.79 - 7.77 (m, 1H), 7.70 (s, 2H), 7.44 (t, J = 8.0 Hz, 1H), 8.98 (d, J= 8.0 Hz, 1H), 5.16 - 4.97 (m, 1H), 5.00 (s, 2H), 3.78 (s, 2H), 3.49 - 3.44 (m, 2H), 3.24 (s, 3H), 2.86 - 2.81 (m, 2H), 2.41 - 2.35 (m, 3H), 2.02 - 1.94 (m, 2H), 1.88 - 1.73 (m, 2H), 1.66 - 1.59 (m, 2H). LCMS [M+H]+= 494.2. .Example 30: Compound 17
[0363] Compound 17 [2-(3-((lr,3r)-3-methoxy-l-(4-methyl-4J / -l,2,4-triazol-3- yl)cyclobutyl)phenyl)-4-methyl-6-((( 1 -methy lcyclobutyl)amino)methyl)isoindolin- 1 -one] can be synthesized according to Scheme 30, FIG. 30.
[0364] To a solution of 4-methyl-6-(((l-methylcyclobutyl)amino)methyl)isoindolin-l-one (Intermediate F, 145.71 mg, 0.45 mmol) and 3-((lr,3r)-l-(3-bromophenyl)-3- methoxycyclobutyl)-4-methyl-4H -l,2,4-triazole (85.0 mg, 0.35 mmol) in te / 7-amyl alcohol (10 mL) was added (lS,2S)-A\A2-dimethylcyclohexane-l,2-diamine (24.74 mg, 0.17 mmol), potassium carbonate (96.16 mg, 0.70 mmol) and Copper(I) iodide (66.25 mg, 0.35 mmol). The mixture was stirred at 100 °C for 3 hours under nitrogen atmosphere. The mixture was diluted with ethyl acetate (30 mL), washed with NH3H2O (5 mL), brine (10 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel (0 - 6% methanol in dichloromethane) to afford crude product as a brown solid. The residue was purified by RP-HPLC (water(NH3H2O+NH4HCO3)- ACN 48% to 78%) to afford 2-(3-((lr,3r)-3-methoxy-l-(4-methyl-4 / / -l,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-methyl-6- (((l-methylcyclobutyl)amino)methyl)isoindolin-l-one (44 mg, 26% yield).1H NMR (400 MHz, methanol-A) δ 8.39 (s, 1H), 7.92 (s, 1H), 7.73 - 7.69 (m, 1H), 7.65 (s, 1H), 7.49 (s, 1H), 7.48 (t, J= 7.6 Hz, 1H), 7.05 (d, J= 7.6 Hz, 1H), 4.88 (s, 2H), 4.03 - 3.95 (m, 1H), 3.75 (s, 2H), 3.40 - 3.36 (m, 2H), 3.35 (s, 3H), 3.30 (s, 3H), 2.68 - 2.62 (m, 2H), 2.45 (s, 3H), 2.14 - 2.04 (m, 2H), 1.92 - 1.86 (m, 2H), 1.84 - 1.75 (m, 2H), 1.39 (s, 3H). LCMS [M+H]+= 486.4.Example 31: Compound 18
[0365] Compound 18 (2-(3-((15,35)-3-methoxy-l-(4-methyl-4 / / -l,2,4-triazol-3- yl)cyclobutyl)phenyl)-4-methyl-6-(((l-methylcyclobutyl)amino)methyl)isoindolin-l-one) can be synthesized according to Scheme 31 (FIG. 31).
[0366] To a solution of 4-methyl-6-(((l-methylcyclobutyl)amino)methyl)isoindolin-l-one (intermediate F, 145.71 mg, 0.45 mmol) and 3-((Ls,3s)-l-(3-bromophenyl)-3- methoxycyclobutyl)-4-methyl-4H - 1 ,2,4-triazole (85.0 mg, 0.35 mmol) in tert-amyl alcohol (10 ml.) was added ( I.S'.2.S)-\ ..V-dimethx lcyclohexane-l,2-diamine (24.74 mg, 0.17 mmol), potassium carbonate (96.16 mg, 0.70 mmol) and Copper(l) iodide (66.25 mg, 0.35 mmol). The mixture was stirred at 100 °C for 3 hours under nitrogen atmosphere. The mixture was diluted with ethyl acetate (30 mL), washed with NH3H2O (5 mL), brine (10 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel (0 - 6% methanol in dichloromethane) to afford crude product as a brown solid whichwas further purified by RP-HPLC (water(NH3H2O+NH4HCO3)- ACN 48% to 78%) to afford 2-(3-((ls,35)-3-methoxy-l-(4-rnethyl-4H -l,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-methyl-6- (((l-methylcyclobutyl)amino)methyl)isoindolin-l-one (44 mg, 26% yield).1H NMR (400 MHz, methanol-d4) δ 8.33 (s, 1H), 8.05 (s, 1H), 7.74 - 7.70 (m, 2H), 7.56 (s, 1H), 7.49 (t, J= 8.0 Hz, 1H), 7.19 - 7.15 (m, 1H), 4.96 (s, 2H), 4.24 - 4.15 (m, 1H), 4.02 (s, 2H), 3.37 (s, 3H), 3.29 (s, 3H), 3.23 - 3.17 (m, 2H), 2.92 - 2.85 (m, 2H), 2.49 (s, 3H), 2.40 - 2.25 (m, 2H), 1.92 - 1.86 (m, 2H), 1.82 - 1.75 (m, 2H), 1.38 (s, 3H). LCMS [M+H]+= 486.3.Example 32: Compound 19
[0367] Compound 19 [4-chloro-2-(3-((lr,3r)-3-(difluoromethoxy)-l-(4-methyl-4H -l,2,4- triazol-3-yl)cyclobutyl)phenyl)-6-((isobutylamino)methyl)isoindolin-l-one] can be synthesized according to Scheme 32, FIG. 32.
[0368] To a solution of 4-chloro-6-((isobutylamino)methyl)isoindolin-l-one (intermediate A, 60.0 mg, 0.24 mmol) in tert-amyl alcohol (5 mL) was added 3-((lr,3r)-l-(3-bromophenyl)- 3-(difluorornethoxy)cyclobutyl)-4-methyl-4H -l,2,4-triazole (85.03 mg, 0.24 mmol), copper(I) iodide (20 mg, 0.11 mmol), (llS',2S)-7V1,A2-dimethylcyclohexane-l,2-diamine (15 mg, 0.11 mmol) and potassium carbonate (65.62 mg, 0.47 mmol). The reaction was stirred at 100 °C for 2 h then concentrated to dryness. The residue was purified by purified by chromatography on silica gel (0 - 10% methanol in dichloromethane) to afford a crude product which was further purified by RP-HPLC (water(NH3H2O+NH4HCO3)- ACN 55% to 85%) to afford 4-chloro-2- (3-((lr,3r)-3-(difluoromethoxy)-l-(4-methyl-4H -l,2,4-triazol-3-yl)cyclobutyl)phenyl)-6- ((isobutylamino)methyl)isoindolin-l-one (24.4 mg, 19%yield) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 8.42 (s, 1H), 7.86 (s, 1H), 7.80 - 7.76 (m, 1H), 7.72 (s, 2H), 7.43 (t, J= 8.0 Hz, 1H), 6.96 (d, J= 8.0 Hz, 1H), 6.71 (t, J= 72.0 Hz, 1H), 5.04 (s, 2H), 4.65 - 4.57 (m, 1H), 3.80 (s, 2H), 3.45 - 3.42 (m, 2H), 3.24 (s, 3H), 2.75 - 2.71 (m, 2H), 2.26 (d, J = 6.4 Hz, 2H), 1.71 - 1.63 (m, 1H), 0.87 (d, J= 6.8 Hz, 6H). LCMS [M+H]+= 530.2.Example 33: Compounds 20 and 21
[0369] Compounds 20 and Compound 21 [(R )-2-(3-(l ,2-difluoro-l -(4-methy 1-4H - 1,2,4- triazol-3-yl)ethyl)phenyl)-6-(((l-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin- 1 -one and (<S)-2-(3-(l ,2-difluoro-l -(4-methyl-4H - 1 ,2,4-triazol-3- yl)ethyl)phenyl)-6-((( 1 -methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin- 1 -one] can be synthesized according to Scheme 33 (FIG. 33).Intermediate 2: (3-(l-(3-bromophenyl)vinyl)-4-methyl-4fir-l,2,4-triazole)
[0370] To a solution of 3-(3-bromobenzyl)-4-methyl-4 / / -l,2,4-triazole (4 g, 15.87 mmol) in tetrahydrofuran (100 mL) was added M / V, / V-trimethy 1-1 -phenylmethanaminium hydroxide (19.9 g, 47.6 mmol) and formaldehyde (2.1 g, 71.4 mmol), the mixture was stirred at 65 °C for Ih then concentrated, the residue was diluted with water (50 mL), extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered and concentrated to dryness. The crude was purified by chromatography on silica gel (0 - 2% methanol in dichloromethane) to afford a crude product which was further purified by RP-HPLC (water(NH3H2O+NH4HCO3)-ACN 20% to 50%) to afford 3-(l-(3-bromophenyl)vinyl)-4-methyl-4H -l ,2,4-triazole (2.02 g, 48% yield) as a white solid.1H NMR (400 MHz, methanol-d4) δ 8.53 (s, IH), 7.56 (d, J= 8.0 Hz, IH), 7.53 (d, J= 1.6 Hz, IH), 7.33 (t, J= 7.6 Hz, IH), 7.28 (d, J= 8.0 Hz, IH), 6.20 (s, IH), 5.82 (s, IH), 3.49 (s, 3H).Intermediate 3: (3-(l-(3-bromophenyl)-l,2-difluoroethyI)-4-methyl-4H -l,2,4-triazole)
[0371] The reaction was performed in an IKA ElectraSym 2.0 using an IKA Ni electrode as a cathode and Pt as a anode. A 10 mL IKA ElectraSym 2.0 vial was equipped with a stir bar and charged with 3-(l-(3-bromophenyl)vinyl)-4-methyl-4H -l,2,4-triazole (300 mg, 1.14 mmol) and triethylamine trihydrofluoride (5 mL, 30.1 mmol). The electrolysis was initiated with a constant current of 5 mA and a 800 rpm stirring speed. After 5F / mol of charge had been passed, the reaction mixture was diluted with dichloromethane (20 mL), washed with saturated sodium bicarbonate solution (3 x 15 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel (0 - 10% methanol in dichloromethane) to afford 3-(l-(3-bromophenyl)-l,2-difluoroethyl)-4-methyl-4H -l,2,4- triazole (227 mg, 66% yield) as a yellow solid.1H NMR (400 MHz, methanol-<ii) δ 8.58 (s, IH), 7.68 - 7.62 (m, IH), 7.56 (t, J= 1.6 Hz, IH), 7.41 (t, J= 8.0 Hz, IH), 7.28 (d, J= 8.0 Hz, IH), 5.38 - 4.98 (m, 2H), 3.57 - 3.51 (m, 3H). LCMS [M+H]+= 302.0 and 304.0.Compounds 20 and 21
[0372] A mixture of 6-(((l-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-l- one (173.77 mg, 0.58 mmol), 3-(l-(3-bromophenyl)-l,2-difluoroethyl)-4-methyl-4H -l,2,4- triazole (160.0 mg, 0.53 mmol), (15,2s)-N1,N2-dimethylcyclohexane- l ,2-diamine (30 mg, 0.21 mmol), potassium carbonate (220 mg, 1.59 mmol) and copper(I) iodide (40 mg, 0.21 mmol) in tert-amyl alcohol (3 mL) was stirred at 100 °C for 2 h under nitrogen. The mixture was diluted with dichloromethane (20 mL), washed with NH3H2O (10 mL), brine (10 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by RP-HPLC(water(NH3H2O+NH4HCO3)-ACN 40% to 70%) to afford 2-(3-( l ,2-difluoro-1 -(4-methyl-4 / f- l,2,4-triazol-3-yl)ethyl)phenyl)-6-(((l-methylcyclobutyl)amino)methyl)-4- (trifluoromethyl)isoindolin-l-one (100 mg, 36% yield) as a white solidThe above mixture was further purified by chiral SFC (Column = Daicel Chiralpak AS; Column dimensions = 250 mm x 30 mm x 10 jim; Detection wavelength = 220 nM; Flow rate = 100 mL / min; Mobile phase: A: CO2 B: ethanol (0.05% DEA); Isocratic: 15% B) with 0.1% ammonium hydroxide) to afford tentatively assigned:(R)-2-(3-(l,2-difluoro-l-(4-methyl-47:7-l,2,4-triazol-3-yl)ethyl)phenyl)-6-(((l- methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-l-one (Peak 1, retention time = 2.449 min) (38.3 mg, 38% yield) as a white solid.1H NMR (400 MHz, methanol-d4) δ 8.54 (s, 1H), 8.08 (s, 1H), 8.06 (t, J= 2.0 Hz, 1H), 8.03 - 7.98 (m, 1H), 7.87 (dd, J= 8.4, 1.6 Hz, 1H), 7.57 (t, J= 8.0 Hz, 1H), 7.17 (d, J= 8.0 Hz, 1H), 5.33 - 5.02 (m, 4H), 3.84 (s, 2H), 3.55 (s, 3H), 2.14 - 2.06 (m, 2H), 1.90 - 1.76 (m, 4H), 1.38 (s, 3H). LCMS [M+H]+= 520.3.(S)-2-(3-(l,2-difluoro-l-(4-methyl-4H -l,2,4-triazol-3-yl)ethyl)phenyl)-6-(((l- methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-l-one (Peak 1, retention time = 2.747 min) (34.9 mg, 35% yield) as a white solid.1H NMR (400 MHz, methanol-d4) δ 8.54 (s, 1H), 8.11 - 8.04 (m, 2H), 8.01 (s, 1H), 7.87 (dd, J= 8.0, 1.6 Hz, 1H), 7.57 (t, J= 8.0 Hz, 1H), 7.17 (d, J= 8.0 Hz, 1H), 5.59 - 5.01 (m, 4H), 3.85 (s, 2H), 3.55 (s, 3H), 2.14 - 2.05 (m, 2H), 1.92 - 1.75 (m, 4H), 1.38 (s, 3H). LCMS [M+H]+= 520.3.Example 34: Compound 22
[0373] Compound 22 [4-chloro-2-(3-((lr,3r)-3-chloro-l-(4-methyl-4H -l,2,4-triazol-3- yl)cyclobutyl)phenyl)-6-((isobutylamino)methyl)isoindolin-l-one] can be synthesized according to Scheme 34 (FIG. 34).
[0374] To a solution of 4-chloro-6-((isobutylamino)methyl)isoindolin-l-one (intermediate A, 60.0 mg, 0.24 mmol), 3-((lr,3r)-l-(3-bromophenyl)-3-chlorocyclobutyl)-4-methyl-4H - 1,2,4-triazole (77.54 mg, 0.24 mmol) in tert-amyl alcohol (2 mL) was added copper(I) iodide (20 mg, 0.11 mmol), (16)2S)-A^A2-dimethylcyclohexane-l ,2-diamine (15 mg, 0.11 mmol) and potassium carbonate (65.62 mg, 0.47 mmol). The reaction was stirred at 100 °C for 2 h then concentrated to dryness. The residue was purified by chromatography on silica gel (0 - 10% methanol in dichloromethane) to afford a crude product which was further purified by RP- HPLC (water(NH3H2O+NH4HCO3)- ACN 55% to 85%) to afford 4-chloro-2-(3-((lr,3r)-3- chloro- 1 -(4-methyl-4H - 1 ,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-((isobutylamino)methyl)- isoindolin-l-one (16.32 mg, 14% yield) as a white solid.1H NMR (400 MHz, DMSO-de) δ8.41 (s, 1H), 7.86 (s, 1H), 7.77 (d, J= 7.2 Hz, 1H), 7.72 (s, 2H), 7.44 (t, J= 8.0 Hz, 1H), 6.98 (d, J= 8.4 Hz, 1H), 5.03 (s, 2H), 4.54 - 4.49 (m, 1H), 3.79 (s, 2H), 3.69 - 3.63 (m, 2H), 3.24 (s, 3H), 2.95 - 2.89 (m, 2H), 2.26 (d, J= 6.4 Hz, 2H), 1.70 - 1.60 (m, 1H), 0.86 (d, J= 6.8 Hz, 6H). LCMS [M+H]+= 498.1.Example 35: Compound 23
[0375] Compound 23 [4-chloro-2-(3-((15,35)-3-chloro-l-(4-methyl-4H -l,2,4-triazol-3- yl)cyclobutyl)phenyl)-6-((isobutylamino)methyl)isoindolin-l-one] can be synthesized according to Scheme 35 (FIG. 35).
[0376] To a solution of 4-chloro-6-((isobutylamino)methyl)isoindolin-l-one (60.0 mg, 0.24 mmol), 3-((15,35)-l-(3-bromophenyl)-3-chlorocyclobutyl)-4-methyl-47 / -l,2,4-triazole (77.54 mg, 0.24 mmol) in tert-amyl alcohol (2 mL) was added copper(I) iodide (20 mg, 0.11 mmol), (lS,2S)-A\A2-dimethylcyclohexane-l,2-diamine (15 mg, 0.11 mmol) and potassium carbonate (65.62 mg, 0.47 mmol). The reaction mixture was stirred at 100 °C for 2 h then concentrated to dryness. The residue was purified by chromatography on silica gel (0 - 10% methanol in dichloromethane) to afford a crude product which was further purified by RP-HPLC (water(NH3H2O+NH4HCO3)- ACN 55% to 85%) to afford 4-chloro-2-(3-((ls,3s)-3-chloro-l- (4-methyl-4H - 1 ,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-((isobutylamino)methyl)isoindolin- 1 - one(31.53 mg, 27% yield). T1 NMR (400 MHz, DMSO-rA) δ 8.35 (s, 1H), 7.90 (s, 1H), 7.85 (d, J= 8.4 Hz, 1H), 7.72 (s, 2H), 7.45 (t, J= 8.0 Hz, 1H), 7.09 (d, J= 8.0 Hz, 1H), 5.06 (s, 2H), 4.82 - 4.76 (m, 1H), 3.80 (s, 2H), 3.46 - 3.38 (m, 2H), 3.30 - 3.23 (m, 2H), 3.22 (s, 3H), 2.27 (d, J= 6.8 Hz, 2H), 1.70 - 1.63 (m, 1H), 0.87 (d, J= 6.8 Hz, 6H). LCMS [M+H]+= 498.1.Example 36: Compound 24
[0377] Compound 24 [4-chloro-2-(3-((lr,3r)-3-chloro-l-(4-methyl-4H -l,2,4-triazol-3- yl)cyclobutyl)phenyl)-6-((propylamino)methyl)isoindolin-l-one], can be synthesized according to Scheme 36 (FIG. 36).Intermediate 2: (4-chloro-2-(3-((lr,3r)-3-chloro-l-(4-methyl-4jfir-l,2,4-triazol-3- yl)cyclobutyl)phenyl)-6-(hydroxymethyl)isoindolin-l-one)
[0378] A mixture of 3-((lr,3r)-l-(3-bromophenyl)-3-chlorocyclobutyl)-4-methyl-42 / -l,2,4- triazole (1.25 g, 2.68 mmol), 4-chloro-6-(hydroxymethyl)isoindolin-l-one (529.4 mg, 2.68 mmol), (lS',25)-A1^V2-dimethylcyclohexane-l,2-diamine (152.4 mg, 1.07 mmol), potassium carbonate (740.5 mg, 5.36 mmol) and copper(I) iodide (204.1 mg, 1.07 mmol) in tert-amylalcohol (10 mL) was stirred at 100 °C for 2 h under nitrogen then concentrated. The residue was dissolved with dichloromethane (50 mL), washed with ammonia aqueous (30 mL), brine (30 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel (0 - 10% methanol in dichloromethane) to afford 4- chloro-2-(3-((lr,3r)-3-chloro-l-(4-methyl-4H -l,2,4-triazol-3-yl)cyclobutyl)phenyl)-6- (hydroxymethyl)isoindolin-l-one (950 mg, 80% yield) as a white solid.1H NMR (400 MHz, methanol- d4) δ 8.43 (s, 1H), 7.92 (s, 1H), 7.77 (s, 1H), 7.72 (dd, J= 8.4, 1.6 Hz, 1H), 7.68 (s, 1H), 7.52 - 7.48 (m, 1H), 7.10 (d, J= 8.0 Hz, 1H), 4.99 (s, 2H), 4.72 (s, 2H), 4.61 (s, 1H), 4.55 - 4.47 (m, 1H), 3.69 - 3.61 (m, 2H), 3.34 (s, 3H), 3.07 - 2.99 (m, 2H). LCMS [M+H]+= 541.3.Intermediate 3: (7-chloro-2-(3-((lr,3r)-3-chloro-l-(4-methyl-4.Hr-l,2,4-triazol-3- yl)cyclobutyl)phenyl)-3-oxoisoindoline-5-carbaldehyde)
[0379] To a solution of 4-chloro-2-(3-((lr,3r)-3-chloro-l-(4-methyl-4H -l,2,4-triazol-3- yl)cyclobutyl)phenyl)-6-(hydroxymethyl)isoindolin-l-one (800 mg, 1.8 mmol) in dichloromethane (10 mL) was added Dess-Martin periodinane (918 mg, 2.17 mmol) at 0 °C and stirred for 1 h. The reaction was quenched with saturated sodium bicarbonate (25 mL), extracted with dichloromethane (3 x 25 mL), combined the organic phases, washed with water (2 x 25 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel (0 - 4% methanol in dichloromethane) to afford 7- chloro-2-(3-((lr,3r)-3-chloro-l-(4-methyl-4H -l,2,4-triazol-3-yl)cyclobutyl)phenyl)-3- oxoisoindoline-5-carbaldehyde (790 mg, 99% yield) as a white solid. LCMS [M+H]+= 443.1.Compound 24
[0380] A mixture of 7-chloro-2-(3-((lr,3r)-3-chloro-l-(4-methyl-4H - l ,2,4-triazol-3- yl)cyclobutyl)phenyl)-3-oxoisoindoline-5-carbaldehyde (70 mg, 0.16 mmol) and propan-1- amine (10.3 mg, 0.17 mmol) in methanol (3 mL) was stirred at 100 °C at microwave for 1 minute. Then NaBHsCN (29.9 mg, 0.48 mmol) was added to the reaction mixture and the resulting mixture was stirred at 85 °C at microwave for another 45 minute. The reaction solution was directly purified by RP-HPLC (water(NH3H2O+NH4HCO3)- ACN 55% to 75%) to afford 4-chloro-2-(3-((lr,3r)-3-chloro-l-(4-methyl-4H -l,2,4-triazol-3- yl)cyclobutyl)phenyl)-6-((propylamino)methyl)isoindolin-l-one (32.7 mg, 42% yield) as a white solid.1H NMR (400 MHz, methanol-A) 88.42 (s, 1H), 7.94 (d, J= 2.0 Hz, 1H), 7.78 (s, 1H), 7.76 - 7.71 (m, 2H), 7.52 (t, J= 8.0 Hz, 1H), 7.12 (d, J= 8.0 Hz, 1H), 5.01 (s, 2H), 4.58 - 4.49 (m, 1H), 3.90 (s, 2H), 3.70 - 3.63 (m, 2H), 3.36 (s, 3H), 3.08 - 3.01 (m, 2H), 2.61 - 2.56 (m, 2H), 1.62 - 1.55 (m, 2H), 0.96 (t, J= 7.2 Hz, 3H). LCMS [M+H]+= 484.1.Example 37: Compounds 25 and 26
[0381] Compound 25 and Compound 26 [(S)-3-(4-methyl-47f-l,2,4-triazol-3-yl)-3-(3-(6-((( 1 -methylcyclobutyl)amino)methyl)- 1 -oxo-4-(trifluoromethyl)isoindolin-2- yl)phenyl)propanenitrile and (R )-3-(4-methyl-4H -l,2,4-triazol-3-yl)-3-(3-(6-(((l- methylcyclobutyl)amino)methyl)-l-oxo-4-(trifluoromethyl)isoindolin-2- yl)phenyl)propanenitrile], can be synthesized according to Scheme 37 (FIG. 37).Intermediate 2: (3-(3-bromophenyl)-3-(4-methyl-41?-l,2,4-triazol-3-yl)propanenitrile)
[0382] To a solution of 3-(3-bromobenzyl)-4-methyl-4H -l,2,4-triazole (1 g, 3.97 mmol) in tetrahydrofuran (20 mL) was added LDA (2M in tetrahydrofuran, 2.38 mL, 4.76 mmol) slowly at -78 °C for 0.5 h. Then 2-iodoacetonitrile (430.57 uL, 5.95 mmol) in tetrahydrofuran (5mL) was added and the reaction mixture was stirred for another 16 h. The reaction mixture was quenched by addition of saturated ammonium chloride aqueous, extracted with ethyl acetate (50 mL), washed with brine (10 mL x 2), dried over sodium sulfate, filtered and concentrated to dryness. The crude product was purified by chromatography on silica gel (0 - 10% methanol in dichloromethane) to afford 3-(3-bromophenyl)-3-(4-methyl-4H -l,2,4-triazol-3- yl)propanenitrile (462 mg, 40% yield) as a brown solid. LCMS [M+H]+= 292.9.Compounds 34 and 35
[0383] To a solution of 3-(3-bromophenyl)-3-(4-methyl-4H -l,2,4-triazol-3-yl)propanenitrile (200.0 mg, 0.69 mmol) and 6-(((l-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl) isoindolin-l-one (143.27 mg, 0.48 mmol) in terLamyl alcohol (10 mL) was added (15,25)- A*,.V2-dimethylcyclohexane-l,2-diamine (29.28 mg, 0.21 mmol), potassium carbonate (189.65 mg, 1.37 mmol) and Copper(I) iodide (39.2 mg, 0.21 mmol). The mixture was stirred at 100°C for 16 hours under nitrogen atmosphere then concentrated, the reaction mixture was diluted with ethyl acetate (30 mL), washed with NHyfhO (10 mL), brine (10 mL), dried over sodium sulfate, filtered and concentrated to dryness. The mixture was purified by chromatography on silica gel (0 - 6% methanol in dichloromethane) to afford crude product as a brown solid which was purified by RP-HPLC (water(NH3H2O+NH4HCO3)- ACN 50% to 80%) to afford 3-(4- methyl-4H - 1 ,2,4-triazol-3-yl)-3-(3-(6-(((l -methylcyclobutyl)amino)methyl)- 1 -oxo-4- (trifluoromethyl)isoindolin-2-yl)phenyl)propanenitrile (110 mg, 32% yield) as a white solid. LCMS [M+H]+= 509.3.
[0384] The above product was further purified by chiral SFC (Column =DAICEL CHIRALCEL OD; Column dimensions = 250 mm x 50 mm x 10 μm; Detection wavelength = 254 nM; Flow rate = 80 mL / min; Mobile phase: A: CO2 B: ethanol; Isocratic: 40% B with 0.1% ammonium hydroxide) to afford tentatively assigned:(S)-3-(4-methyl-47 / - 1 ,2,4-triazol-3 -yl)-3-(3 -(6-((( 1 -methylcyclobutyl)amino)methyl)- 1 -oxo-4- (trifluoromethyl)isoindolin-2-yl)phenyl)propanenitrile (18.4 mg, 16% yield) (Peak 1, retention time = 2.188 min) as a white solid.1H NMR (400 MHz, methanol-d)) δ 8.45 (s, 1H), 8.09 (s, 1H), 8.01 (s, 1H), 7.92 (s, 1H), 7.88 (dd, J= 8.4, 1.6 Hz, 1H), 7.50 (t, J= 8.0 Hz, 1H), 7.14 (d, J= 8.0 Hz, 1H), 5.16 (s, 2H), 4.80 (t, J= 7.6 Hz, 1H), 3.86 (s, 2H), 3.51 (s, 3H), 3.48 - 3.40 (m, 1H), 3.36-3.28 (m, 1H), 2.15 - 2.04 (m, 2H), 1.92 - 1.85 (m, 2H), 1.84 - 1.74 (m, 2H), 1.38 (s, 3H). LCMS [M+H]+= 509.3. (R )-3-(4-methy 1-4H - 1 ,2,4-triazol-3 -yl)-3 -(3 -(6-((( 1 -methylcyclobutyl)amino)methyl)- 1 -oxo-4- (trifluoromethyl)isoindolin-2-yl)phenyl)propanenitrile (8.05 mg, 7% yield) (Peak 2, retention time = 3.127 min) as a white solid.1H NMR (400 MHz, methanol-d4) δ 8.45 (s, 1H), 8.09 (s, 1H), 8.01 (s, 1H), 7.92 (s, 1H), 7.88 (dd, J= 8.4, 1.6 Hz, 1H), 7.50 (t, J = 8.0 Hz, 1H), 7.14 (d, J= 8.0 Hz, 1H), 5.16 (s, 2H), 4.80 (t, J= 7.6 Hz, 1H), 3.87 (s, 2H), 3.51 (s, 3H), 3.47 - 3.40 (m, 1H), 3.36 - 3.29 (m, 1H), 2.15 - 2.07 (m, 2H), 1.92 - 1.86 (m, 2H), 1.84 - 1.74 (m, 2H), 1.39 (s, 3H). LCMS [M+H]+= 509.3.Example 38: Compounds 27 and 28
[0385] Compound 27 and Compound 28 [(>S)-2-(3-(2 -methoxy- l-(4-methyl-4H- 1,2, 4-triazol- 3-yl)ethyl)phenyl)-6-(((l-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-l- one) and (R )-2-(3-(2-methoxy-l-(4-methyl-4H -l,2,4-triazol-3-yl)ethyl)phenyl)-6-(((l- methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-l-one], can be synthesized according to Scheme 38 (FIG. 38).Intermediate 2: (3-(1-(3-broniophenyl)-2-methoxyethyl)-4-methyl-4 / / -l,2,4-triazole)
[0386] To a solution of 3-(3-bromobenzyl)-4-methyl-4H -l ,2,4-triazole (200.0 mg, 0.79 mmol) in tetrahydrofuran (4 mL) was added lithium diisopropylamide (2 M in tetrahydrofuran, 0.4 mL, 0.79 mmol) slowly at -78 °C for 30 mins under N2. Then bromo(methoxy)methane (0.08 mL, 1.03 mmol) was added to the reaction mixture and stirred at 0 °C for 3 h. The reaction mixture was quenched by addition of ammonium chloride aqueous (10 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organics were washed with brine (30 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified RP-HPLC (water(NH3H2O+NH4HCO3)- ACN 30% to 60%) to afford 3-(l-(3-bromophenyl)-2- methoxyethyl)-4-methyl-4H -l,2,4-triazole (100 mg, 34% yield) as a yellow oil.NMR (400 MHz, methanol-d4) δ 8.39 (s, 1H), 7.48 - 7.43 (m, 2H), 7.29 - 7.25 (m, 2H), 4.53 - 4.52 (m, 1H), 4.14 - 4.10 (m, 1H), 3.90 - 3.85 (m, 1H), 3.53 (s, 3H), 3.35 (s, 3H). LCMS [M + H]+= 296.0.Compounds 27 and 28
[0387] A mixture of 3-(l-(3-bromophenyl)-2-methoxyethyl)-4-methyl-4H -l,2,4-triazole (100.0 mg, 0.34 mmol), 6-(((l-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin- 1-one (110.8 mg, 0.37 mmol), copper(I) iodide (20 mg, 0.11 mmol), (liS,,28)-A1rA2- dimethylcyclohexane-l,2-diamine (15 mg, 0.11 mmol) and potassium carbonate (140.0 mg, 1.01 mmol) in tert-amyl alcohol (2 mL) was stirred at 100 °C for 16 h under nitrogen atmosphere. The reaction mixture was diluted with ethyl acetate (25 mL), washed with NH3H2O (10 mL), brine (10 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by pre-HPLC with the following conditions: Phenomenex Cl 8 80*40mm*3um / water (NH3H2O+NH4HCO3)-ACN / 45%-75% to afford 2-(3 -(2 -methoxy - 1 -(4-methy 1 -4H - 1 ,2,4-triazol-3-yl)ethyl)phenyl)-6-((( 1 -methylcyclobutyl)amino)methyl)-4- (trifluoromethyl)isoindolin-l-one (30.0 mg, 17% yield) as a yellow solid. LCMS [M + H]+= 514.3.
[0388] The above product was further purified by chiral SFC (Column = DAICEL CHIRALPAK AD; Column dimensions = 250 mm x 30 mm x 10 μm; Detection wavelength = 220 nM; Flow rate = 80 mL / min; Mobile phase: A: CO2 B: ethanol (0.05% DEA); Isocratic: 40% B) with 0.1% ammonium hydroxide) to afford: (1S)-2-(3-(2-methoxy-l-(4-methyl-4H -l,2,4-triazol-3-yl)ethyl)phenyl)-6-(((l- methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-l-one (Peak 1, retention time = 1.925 min) (5.9 mg, 19% yield) as a yellow solid.NMR (400 MHz, DMSO-t / e) 6 8.36 (s, 1H), 8.05 (s, 1H), 8.00 (s, 1H), 7.94 (s, 1H), 7.82 (d, J= 8.4 Hz, 1H), 7.40 (t, J= 7.6 Hz, 1H), 7.12 (d, J= 6.8 Hz, 1H), 5.16 (s, 2H), 4.56 (t, J= 7.2 Hz, 1H), 4.10 - 4.06 (m, 1H), 3.93 - 3.88 (m, 1H), 3.81 (s, 2H), 3.48 (s, 3H), 3.27 (s, 3H), 2.02 - 1.94 (m, 2H), 1.75 - 1.64 (m, 4H), 1.23 (s, 3H). LCMS [M+ H]+= 514.3.(R)-2-(3-(2-methoxy-l-(4-methyl-4H -l,2,4-triazol-3-yl)ethyl)phenyl)-6-(((l- methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-l-one (Peak 2, retention time = 2.237 min) (2.4 mg, 8% yield) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ 8.37 (s, 1H), 8.05 (s, 1H), 8.00 (s, 1H), 7.94 (s, 1H), 7.84 - 7.81 (m, 1H), 7.40 (t, J= 8.0 Hz, 1H), 7.12 (d, J= 7.6 Hz, 1H), 5.16 (s, 2H), 4.56 (t, J= 7.2 Hz, 1H), 4.10 - 4.06 (m, 1H), 3.93 - 3.88 (m, 1H), 3.81 (s, 2H), 3.48 (s, 3H), 3.27 (s, 3H), 2.02 - 1.97 (m, 2H), 1.74 - 1.65 (m, 4H), 1.23 (s, 3H). LCMS [M+ H]+= 514.3.Example 39: Compound 29
[0389] Compound 29 [4-methoxy-2-(3-((15,35)-3-methoxy- 1 -(4-methyl-4H - 1 ,2,4-triazol-3- yl)cyclobutyl)phenyl)-6-(((l -methylcyclobutyl)amino)methyl)isoindolin-l -one], can be synthesized according to Scheme 38 (FIG. 38).
[0390] A mixture of 3-((15,35)-l-(3-bromophenyl)-3-methoxycyclobutyl)-4-methyl-4H - 1,2,4-triazole (50.0 mg, 0.16 mmol), 4-methoxy-6-(((l-methylcyclobutyl)- amino)methyl)isoindolin-l-one (Intermediate G, 36.36 mg, 0.14 mmol), copper(I) iodide (11.82 mg, 0.06 mmol), (l<S',2>S)-A1rA2-dimethylcyclohexane-l,2-diamine (8.83 mg, 0.06 mmol) and potassium carbonate (64.34 mg, 0.47 mmol) in tert-amyl alcohol (6mL) was stirred at 100 °C for 2 h then concentrated to dryness. The reaction mixture was diluted with dichloromethane (30 mL), washed with NH3H2O (10 mL), brine (10 mL), dried over sodium sulfate, filtered and concentrated to dryness. The resulting residue was purified by RP-HPLC (0.1% NH4OH in water / ACN 45% to 75%) to afford 4-methoxy-2-(3-(( k’,3.s')-3-methoxy- l -(4- methyl-4H -1 ,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((l - methylcyclobutyl)amino)methyl)isoindolin-l-one (5.3 mg, 6.8% yield) as a white solid.1H NMR (400 MHz, methanol-A) 3 8.33 (s, 1H), 8.03 (t, J= 2.0 Hz, 1H), 7.71 (dd, J= 8.0, 1.2 Hz, 1H), 7.46 (t, J= 8.0 Hz, 1H), 7.41 (s, 1H), 7.29 (s, 1H), 7.17 (d, J= 8.0 Hz, 1H), 4.88 (s, 2H), 4.23 - 4.15 (m, 1H), 3.99 (s, 3H), 3.78 (s, 2H), 3.36 (s, 3H), 3.29 (s, 3H), 3.19 - 3.16 (m, 2H), 2.91 - 2.84 (m, 2H), 2.16 - 2.06 (m, 2H), 1.93 - 1.78 (m, 4H), 1.39 (s, 3H). LCMS [M+H]+= 502.2.Example 40: Compound 30
[0391] Compound 30 [4-methoxy-2-(3-((lr, 3r)-3-methoxy-l -(4-methyl-4rt-l, 2, 4-triazol-3- yl) cyclobutyl) phenyl)-6-(((l -methylcyclobutyl) amino)methyl)isoindolin-l-one] can be synthesized according to Scheme 40 (FIG. 40).
[0392] A mixture of 3-((lr,3r)-l-(3-bromophenyl)-3-methoxycyclobutyl)-4-methyl-4Z / - 1,2,4-triazole (50.0 mg, 0.16 mmol), 4-methoxy-6-(((l-methylcyclobutyl)amino)methyl)- isoindolin-I-one (intermediate G, 40.4 mg, 0.16 mmol), copper(I) iodide (11.82 mg, 0.06 mmol), N],A2-dimethylcyclohexane-l ,2-diamine (8.83 mg, 0.06 mmol) and potassium carbonate (64.34 mg, 0.47 mmol) in tert-amyl alcohol (6 mL) was stirred at 100 °C for 2 h then concentrated to dryness. The reaction mixture was diluted with dichloromethane (30 mL), washed with NH3H2O (10 mL), brine (10 mL), dried over sodium sulfate, filtered and concentrated to dryness. The resulting residue was purified by RP-HPLC (0.1% NH4OH in water / ACN 46% to 76%) to afford 4-methoxy-2-(3-((lr,3r)-3-methoxy-l-(4-methyl-4H -l,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((l-methylcyclobutyl)amino)methyl)isoindolin-l-one (31.2 mg, 40% yield) as a white solid.1H NMR (400 MHz, methanol-c / 4) δ 8.39 (s, 1H), 7.88 (s, 1H), 7.69 (dd, J= 8.0, 1.2 Hz, 1H), 7.45 (t, J= 8.0 Hz, 1H), 7.39 (s, 1H), 7.28 (s, 1H), 7.04 (d, J= 7.6 Hz, 1H), 4.87 (s, 2H), 4.01 - 3.96 (m, 4H), 3.77 (s, 2H), 3.39 - 3.36 (m, 2H), 3.34 (s, 3H), 3.29 (s, 3H), 2.68 - 2.60 (m, 2H), 2.15 - 2.06 (m, 2H), 1.92 - 1.77 (m, 4H), 1.39 (s, 3H). LCMS [M+H]+= 502.2.Example 41: Compounds 31 and 32
[0393] Compound 31 and Compound 32 [6-((R)-l-((cyclobutylmethyl)amino)ethyl)-2-(3- ((lr,3R)-3-methoxy-l-(4-methyl-4H -l,2,4-triazol-3-yl)cyclobutyl)phenyl)-4- (trifluoromethyl)isoindolin-l-one and 6-((S)-l-((cyclobutylmethyl)amino)ethyl)-2-(3-((lr,3S)- 3-methoxy- 1 -(4-methy 1-417- 1 ,2,4-triazol-3-yl)cyclobuty l)phenyl)-4- (trifluoromethyl)isoindolin-l-one] can be synthesized according to Scheme 41 (FIG. 41).
[0394] To a solution of 6-(l-((cyclobutylmethyl)amino)ethyl)-4-(trifluoromethyl)isoindolin- 1-one (100.0 mg, 0.32 mmol) and 3-((lr,3r)-l-(3-bromophenyl)-3-methoxycyclobutyl)-4- methyl-4H -l,2,4-triazole (103.16 mg, 0.32 mmol) in tert-amyl alcohol (1 mL) was added copper(I) iodide (18.29 mg, 0.10 mmol), potassium carbonate (132.75 mg, 0.96 mmol) and (lS',25)-7V'17V2-dimethylcyclohexane-l,2-diamine (13.66 mg, 0.10 mmol). The mixture was stirred at 100 °C for 4 hours under nitrogen atmosphere. The reaction mixture was diluted with dichloromethane (20 mL), washed with NFLThO (10 mL), brine (10 mL), dried over sodium sulfate, filtered and concentrated to dryness. The crude product was purified by chiral SFC (Column = Daicel Chiralcel OD-H; Column dimensions = 250 mm x 30 mm x 5 μm;Detection wavelength = 220 nM; Flow rate = 80 mL / min; Mobile phase: A: CO2 B: ethanol; Isocratic: 40% B with 0.1% ammonium hydroxide) to afford tentatively assigned: 6-((R )-l-((cyclobutylmethyl)amino)ethyl)-2-(3-((lr,37?)-3-methoxy-l-(4-methyl-4H-l,2,4- triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-l-one (Peak 1, retention time = 1.541 min) (11.3 mg, 6% yield) as a white solid.1H NMR (400 MHz, methanol-cL) 6 8.39 (s, 1H), 8.06 (s, 1H), 7.99 (s, 1H), 7.92 (s, 1H), 7.70 (dd, J= 8.4, 1.6 Hz, 1H), 7.48 (t, J= 8.0 Hz, 1H), 7.08 (d, J= 8.0 Hz, 1H), 5.16 (s, 2H), 4.01 - 3.95 (m, 2H), 3.41 - 3.36 (m, 2H), 3.35 (s, 3H), 3.29 (s, 3H), 2.68 - 2.62 (m, 2H), 2.55 - 2.43 (m, 2H), 2.39 - 2.32 (m, 1H), 2.10 - 2.03 (m, 2H), 1.94 - 1.85 (m, 1H), 1.84 - 1.76 (m, 1H), 1.67 - 1.58 (m, 2H), 1.42 (d, .7= 6.4 Hz, 3H). LCMS [M+H]+= 554.3.6-((S)- 1 -((cyclobutylmethyl)amino)ethyl)-2-(3 -(( 1 r,3S)-3 -methoxy- 1 -(4-methy 1-4H - 1 ,2,4- triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-l-one (Peak 2, retention time =1.639 min) (14.5 mg, 8% yield) as a white solid.1H NMR (400 MHz, methanol-d4) δ 8.39 (s, 1H), 8.06 (s, 1H), 7.99 (s, 1H), 7.93 (s, 1H), 7.69 (dd, J= 8.4, 1.6 Hz, 1H), 7.48 (t, J= 8.0 Hz, 1H), 7.08 (dd, J = 7.6, 1.2 Hz, 1H), 5.16 (m, 2H), 4.02 - 3.94 (m, 2H), 3.42 - 3.36 (m, 2H), 3.35 (s, 3H), 3.29 (s, 3H), 2.69 - 2.61 (m, 2H), 2.56 - 2.42 (m, 2H), 2.39 - 2.32 (m, 1H), 2.12 - 2.01 (m, 2H), 1.94 - 1.85 (m, 1H), 1.85 - 1.75 (m, 1H), 1.68 - 1.57 (m, 2H), 1.42 (d, J= 6.4 Hz, 3H). LCMS [M+H]+= 554.3.Example 42: Compounds 33 and 34
[0395] Compound 33 ((S)-4-(4-methyl-4K-l,2,4-triazol-3-yl)-4-(3-(6-(((l-methylcyclo- butyl)amino)methyl)-l-oxo-4-(trifluoromethyl)isoindolin-2-yl)phenyl)butanenitrile) andCompound 34 ((R )-4-(4-methyl-4H -l,2,4-triazol-3-yl)-4-(3-(6-(((l-methylcyclo- butyl)amino)methyl)- 1 -oxo-4-(trifluoromethyl)isoindolin-2-yl)phenyl)butanenitrile), can be synthesized according to Scheme 42 (FIG. 42).Intermediate 2: (4-(3-bromophenyl)-4-(4-methyl-4 / / -l,2>4-triazoI-3-yl)butanenitrile)
[0396] To a solution of 3-(3-bromobenzyl)-4-methyl-4H -l,2,4-triazole (200 mg, 0.79 mmol) in tetrahydrofuran (2 mL) was added LiHMDS (IM in tetrahydrofuran, 1.03 mL, 1.03 mmol) at -78 °C and stirred for 30 min, then 3 -bromopropanenitrile (0.09 mL, 1.03 mmol) was added to the reaction and the mixture was stirred for 12 hours under nitrogen atmosphere. The mixture was quenched by saturated aqueous ammonia chloride (10 mL), extracted with ethyl acetate (2 x 30 mL), combined the organic phase and washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography on silica gel (0 - 10% methanol in dichloromethane) to give 4-(3-bromophenyl)-4-(4-methy 1-4H - l,2,4-triazol-3-yl)butanenitrile (240 mg, 99% yield) as a yellow oil. LCMS [M + H]+= 307.2.Compounds 33 and 34
[0397] To a solution of 4-(3-bromophenyl)-4-(4-methyl-4H -l,2,4-triazol-3-yl)butanenitrile (140 mg, 0.46 mmol) and 6-(((l-methylcyclobutyl)amino)methyl)-4- (trifluoromethyl)isoindolin-l-one (150 mg, 0.50 mmol) in tert-amyl alcohol (3 mL) was added and potassium carbonate (190 mg, 1.38 mmol) and copper(I) iodide (26.2 mg, 0.14 mmol), (18',2S)-7\71^V2-dimethylcyclohexane-l,2-diamine (19.6 mg, 0.14 mmol). The mixture was stirred at 100 °C for 4 hours under nitrogen atmosphere, the reaction mixture was diluted with ethyl acetate (25 mL), washed with NH3H2O (10 mL), brine (10 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue purified by purified by chromatography on silica gel (0 - 10% methanol in dichloromethane) to afford crude productwhich was further purified by RP-HPLC (CO2-EtOH(0.1%NH3H2O)) to give a mixture of enantiomers products.The above product was separated by chiral SFC (Column =DAICEL CHIRALCEL OD; Column dimensions = 250 mm x 50 mm x 10 μm; Detection wavelength = 254 nM; Flow rate = 80 mL / min; Mobile phase: A: CO2 B: ethanol; Isocratic: 40% B with 0.1% ammonium hydroxide) to afford tentatively assigned:(S)-4-(4-methyl-4H - 1,2, 4-triazol-3-yl)-4-(3-(6-(((l-methylcyclobutyl)amino)methyl)-l -oxo-4- (trifluoromethyl)isoindolin-2-yl)phenyl)butanenitrile (18.4 mg, 16% yield)(Peak 1, retention time = 4.039 min) as a white solid.1H NMR (400 MHz, methanol-cL) δ 8.43 (s, 1H), 8.11 (s, 1H), 8.03 (s, 1H), 7.90 (s, 1H), 7.84 (d, J= 8.0 Hz, 1H), 7.50 (t, J= 8.0 Hz, 1H), 7.14 (d, J = 7.6 Hz, 1H), 5.18 (s, 2H), 4.46 - 4.39 (m, 1H), 3.89 (s, 2H), 3.55 (s, 3H), 2.74 - 2.66 (m, 1H), 2.63 - 2.54 (m, 2H), 2.53 - 2.45 (m, 1H), 2.16 - 2.08 (m, 2H), 1.94 - 1.87 (m, 2H), 1.87 - 1.78 (m, 2H), 1.41 (s, 3H). LCMS [M+H]+= 523.1. (R )-4-(4-methyl-4H - 1,2, 4-triazol-3-yl)-4-(3-(6-(((l-methylcyclobutyl)amino)methyl)-l -oxo-4- (trifhioromethyl)isoindolin-2-yl)phenyl)butanenitrile (8.05 mg, 7% yield) (Peak 2, retention time = 4.299 min) as a white solid.1H NMR (400 MHz, methanol-c / f) δ 8.41 (s, 1H), 8.10 (s, 1H), 8.02 (s, 1H), 7.88 (s, 1H), 7.83 (d, J= 8.0 Hz, 1H), 7.48 (t, J= 8.0 Hz, 1H), 7.12 (d, J= 8.0 Hz, 1H), 5.16 (s, 2H), 4.43 - 4.38 (m, 1H), 3.88 (s, 2H), 3.53 (s, 3H), 2.72 - 2.65 (m, 1H), 2.61-2.52 (m, 2H), 2.51 - 2.45 (m, 1H), 2.15 - 2.06 (m, 1H), 1.93 - 1.86 (m, 2H), 1.85 - 1.75 (m, 2H), 1.39 (s, 3H). LCMS [M+H]+= 523.1.Example 43: Compounds 35 and 36
[0398] Compound 35 (2-(3-((15,35)-3-(difluoromethyl)-l-(4-methyl-4H-l,2,4-triazol-3- yl)cyclobutyl)phenyl)-6-(((l-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-l- one) and Compound 36 (2-(3-((lr,3r)-3-(difluoromethyl)-l -(4-methyl-47:7-l,2,4-triazol-3- yl)cyclobutyl)phenyl)-6-((( 1 -methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin- 1 - one and (trifluoromethyl)isoindolin-l-one), can be synthesized according to Scheme 43 (FIG. 43).Intermediate 2: (methyl l-(3-bromophenyl)-3-(methoxymethylene)cyclobutane-l- carboxylate)
[0399] To a solution of (methoxymethyl)triphenylphosphonium bromide (43.77 g, 113.03 mmol) in tetrahydrofuran (100 mL) was added tert-butoxy potassium (IM in tetrahydrofuran, 105.96 mL, 105.96 mmol) at 0 °C, then stirred at 40 °C for 1 h. methyl l-(3-bromophenyl)-3- oxocyclobutane-1 -carboxylate (10.0 g, 35.32 mmol) was added at 0 °C, the reaction mixturewas stirred at 40 °C for another 16 h. The reaction was quenched with water (50 mL), extracted with ethyl acetate (3 x 100 mL), combined the organic phase then washed with brine (2 x 100 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography on silica gel (0 - 15% ethyl acetate in petroleum ether) to afford methyl 1- (3 -bromophenyl)-3-(methoxymethylene)cyclobutane-l -carboxylate (6.8 g, 69% yield) as yellow oil.1H NMR (400 MHz, methanol-A) δ 7.45 (d, J= 2.0 Hz, 1H), 7.41 - 7.40 (m, 1H), 7.33 - 7.29 (m, 1H), 7.28 - 7.23 (m, 1H), 3.63 (s, 3H), 3.42 (s, 3H), 3.52 - 3.40 (m, 2H), 3.15 - 3.05 (m, 2H).Intermediate 3: (methyl l-(3-bromophenyl)-3-formylcyclobutane-l-carboxylate)
[0400] To a solution of methyl l-(3-bromophenyl)-3-(methoxymethylene)cyclobutane-l- carboxylate (9.7 g, 31.17 mmol) in acetone (120 mL)was added hydrochloride acid aqueous (6M, 124.69 mL, 748.14 mmol) and stirred at 25 °C for 16 h. The resulting solution was concentrated to remove mostly solvent, then the residue solution was extracted with ethyl acetate (3 x 100 mL), combined the organic layers and concentrated. The residue was The residue was purified by chromatography on silica gel (0 - 20% ethyl acetate in petroleum ether) to afford methyl l-(3-bromophenyl)-3-formylcyclobutane-l -carboxylate (3.9 g, 42% yield, mixture of cis and trans isomers).Intermediate 4: (methyl l-(3-bromophenyl)-3-(difluoromethyl)cycIobutane-l- carboxylate)
[0401] To a solution of methyl l-(3-bromophenyl)-3-formyl-cyclobutanecarboxylate (500.0 mg, 1.7 mmol) in dichloromethane (10 mL) was added DAST (0.7 mL, 5.1 mmol) at -78 °C then the mixture was stirred for 1.5 h. The reaction was quenched by water (10 mL), extracted with dichloromethane (3 x 10 mL), the organic phase was combined and washed with saturated sodium bicarbonate solution (20 mL) and brine (20 mL), dried over sodium sulfate, filtrated and concentrated under vacuum. The residue was purified by chromatography on silica gel (0 - 30% ethyl acetate in petroleum ether) to afford methyl l-(3-bromophenyl)-3- (difluoromethyl)cyclobutane-l -carboxylate (350 mg, 65% yield) as colorless oil.Intermediate 5: (l-(3-bromophenyl)-3-(difluoromethyl)cyclobutane-l- carbohydrazide)
[0402] To a mixture of methyl l-(3-bromophenyl)-3-(difluoromethyl)cyclobutane-l- carboxylate (350.0 mg, 1.1 mmol) in methanol (5 mL) was added hydrazine hydrate (80%, 0.7 mL, 10.9 mmol), the mixture was stirred at 80 °C for 16 h. The organic layer was concentrated under vacuum to give crude l-(3-bromophenyl)-3-(difluoromethyl)cyclobutane-l-carbohydrazide (400.0 mg, 1.25 mmol,) as a white solid which was used for next step without further purification. LCMS [M+H]+= 319.0 and 321.0.Intermediate 6: (2-(l-(3-bromophenyl)-3-(difluoromethyl)cycIobutane-l-carbonyl)-7V- methylhydrazine-l-carbothioamide)
[0403] To a mixture of l-(3-bromophenyl)-3-(difluoromethyl)cyclobutane-l-carbohydrazide (400.0 mg, 1.25 mmol) in tetrahydrofuran (5mL) was added isothiocyanatomethane (458.2 mg,6.3 mmol) at 25 C and the mixture was stirred for 2 h. The mixture was concentrated to afford 2-(l -(3-bromophenyl)-3-(difluoromethyl)cyclobutane- 1 -carbonyl)-7V-methylhydrazine- l - carbothioamide (400 mg, 1.0 mmol) as white solid which was used directly without further purification. LCMS [M+H]+= 392.0 and 394.1.Intermediate 7 : (5-( 1 -(3-bromopheny l)-3-(difluoromethy l)cyclobuty l)-4-methyl-4H -1.2.4-triazole-3-thio)
[0404] A mixture of 2-(l-(3-bromophenyl)-3-(difluoromethyl)cyclobutane-l-carbonyl)-N- methylhydrazine-1 -carbothioamide (400.0 mg, 1.0 mmol) in sodium hydroxide solution (2M,15.3 mL, 30.6 mmol) was stirred at 25 °C for 12 h. Then adjusted pH to 5 with IM hydrochloride aqueous. The precipitate was filtered and washed with water, the cake was dried to give 5-(l-(3-bromophenyl)-3-(difhioromethyl)cyclobutyl)-4-methyl-4 / / -l,2,4-triazole-3-thio as white solid (400 mg, crude used directly). LCMS [M+H]+= 374.0 and 376.0.Intermediate 8: (3-(l-(3-bromophenyl)-3-(difluoromethyl)cyclobutyl)-4-methyl-417-1.2.4-triazole)
[0405] To a solution of 5-(l-(3-bromophenyl)-3-(difluoromethyl)cyclobutyl)-4-methyl-417-1.2.4-triazole-3-thio (400.0 mg, 1.1 mmol) in water (4 mL) and acetonitrile (4 mL) was added sodium nitrite (369.7 mg, 5.4 mmol), then IM nitric acid (337.6 mg, 5.7 mmol) was added dropwise and the resulting mixture was stirred for another 16 h at 20 °C. The reaction mixture was quenched with sodium bicarbonate aqueous solution (30 mL), extracted with dichloromethane (3 x 30 mL), combined the organic phase and washed with brine (30 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography on silica gel (0 - 4% methanol in dichloromethane) to give 3-(l-(3- bromophenyl)-3-(difluoromethyl)cyclobutyl)-4-methyl-4H -l,2,4-triazole (280 mg, 77% yield) as yellow oil. LCMS [M+H]+= 342.8 and 343.8.Compounds 35 and 36
[0406] To a solution of 6-(((l-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)- isoindolin-l-one (156.9 mg, 0.5 mmol) in tert-amyl alcohol (3 mL) was added (1S,2S)-N1JV2- dimethylcyclohexane-l,2-diamine (28 mg, 0.2 mmol), copper(I) iodide (33.4 mg, 0.2mmol), 3-(l-(3-bromophenyl)-3-(difluoromethyl)cyclobutyl)-4-methyl-4H -l,2,4-triazole (150.0 mg, 0.44 mmol), potassium carbonate (151.5 mg, 1.1 mmol), the solution was stirred at 100 °C for 2 hours under Ns. The reaction mixture was diluted with ethyl acetate (25 mL), washed with NH3H2O (5 mL), brine (5 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by RP-HPLC (RP-HPLC (waterlNHaHsO+NILHCCL)- ACN 40% to 70%)) to give a mixture of diastereoisomers (110 mg, 45% yield) as white solid.
[0407] The above product was further purified by chiral SFC (Column = Daicel Chiralpak AD; Column dimensions = 250 mm x 30 mm * 10 μm; Detection wavelength = 220 nM; Flow rate = 80 mL / min; Mobile phase: A: CO2 B: ethanol (0.1% NH3H2O); Isocratic: 35% B)) to afford tentatively assigned:2-(3-((l,s',3.s)-3-(difIuoromethyl)-l-(4-methyl-4 / / -l,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((l- methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-l-one (49.5 mg, 45% yield) (peakl, retention time = 5.084 min) as white solid.1H NMR (400 MHz, methanol-<74) δ 8.41 (s, 1H), 8.08 (s, 1H), 8.01 (s, 1H), 7.93 (d, J= 2.0 Hz, 1H), 7.68 (dd, J =8.0, 1.2 Hz, 1H), 7.49 (t, J= 8.0 Hz, 1H), 7.11 (d, .7= 8.0 Hz 1H), 6.09 (td, J = 57.2, 3.2 Hz, lH), 5.15 (s, 2H), 3.86 (s, 2H), 3.36 (s, 3H), 3.14 - 3.06 (m, 2H), 2.88 - 2.80 (m, 3H), 2.15 - 2.05 (m, 2H), 1.92 - 1.84 (m, 2H), 1.84 - 1.74 (m, 2H), 1.38 (s, 3H). LCMS [M+H]+= 560.62-(3 -(( 1 r,3r)-3-(difluoromethyl)- 1 -(4-methy 1-4 H- 1 ,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-((( 1 - methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin- 1 -one and (trifhioromethyl)isoindolin-l-one (19.8 mg, 18% yield) (peak2, retention time = 5.554 min).1H NMR (400 MHz, methanol-d4) δ 8.35 (s, 1H), 8.09 (d, J= 2.4 Hz, 2H), 8.01 (s, 1H), 7.72 (d, J= 8.4 Hz, 1H), 7.52 (t, J= 8.0 Hz, 1H), 7.25 (d, J= 9.2 Hz, 1H), 5.93 (td, J= 56.4, 3.2 Hz, 1H), 5.17 (s, 2H), 3.86 (s, 2H), 3.35 (s, 3H), 3.15 - 3.03 (m, 3H), 2.95 - 2.87 (m, 2H), 2.15- 2.05 (m, 2H), 1.92 - 1.85 (m, 2H), 1.84 - 1.75 (m, 2H), 1.38 (s, 3H). LCMS [M+H]+ = 560.3Example 44: Compound 37
[0408] Compound 37 (2-(3-((15,35)-3-methoxy-l-(4-methyl-4 / / -l,2,4-triazol-3-yl)cyclo- butyl)phenyl)-6-((( 1 -methylcyclobutyl)amino)methyl)- 1 -oxoisoindoline-4-carbonitrile) can be synthesized according to Scheme 44 (FIG. 44).
[0409] A mixture of 3 -((l.s',3.s’)- 1 -(3 -bromophenyl)-3 -methoxy cyclobuty l)-4-methy 1-4H - 1,2,4-triazole (50.0 mg, 0.16 mmol), 6-(((l-methylcyclobutyl)amino)methyl)-l- oxoisoindoline-4-carbonitrile (intermediate I, 43.6 mg, 0.17 mmol), copper(7) iodide (11.8 mg, 0.06 mmol), (l1S',2S)-A1,A2-dimethylcyclohexane-l,2-diamine (8.8 mg, 0.06 mmol) and potassium carbonate (64.3 mg, 0.47 mmol) in tert-amyl alcohol (3 mL) was stirred at 100 °Cfor 5 h under N2. the reaction mixture was diluted with ethyl acetate (25 mL), washed with NH3H2O (5 mL), brine (5 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by RP-HPLC (25% to 55% ACN / (0.05%NH3H20+10mM NH4HCO3in water)) to afford 2-(3-((ls,3s)-3-methoxy-l-(4-methyl-427-l,2,4-triazol-3- yl)cyclobutyl)phenyl)-6-((( 1 -methy lcyclobutyl)amino)methyl)- 1 -oxoisoindoline-4-carbonitrile (19.5 mg, 25% yield) as a white solid.1H NMR (400 MHz, methanol-di) δ 8.32 (s, 1H), 8.12 (s, 1H), 8.05 (s, 2H), 7.73 (d, J= 8.4 Hz, 1H), 7.50 (t, J= 8.0 Hz, 1H), 7.22 (d, J= 8.0 Hz, 1H), 5.18 (s, 2H), 4.26 - 4.13 (m, 1H), 3.84 (s, 2H), 3.37 (s, 3H), 3.29 (s, 3H), 3.23 - 3.19 (m, 2H), 2.91 - 2.85 (m, 2H), 2.14 - 2.06 (m, 2H), 1.91 - 1.78 (m, 4H), 1.38 (s, 3H). LCMS [M+H]+= 497.2.Example 45: Compound 38
[0410] Compound 38 (2-(3-((lr,3r)-3-methoxy-l-(4-methyl-4H-l,2,4-triazol-3-yl)cyclo- butyl)phenyl)-6-(((l-methylcyclobutyl)amino)methyl)-l-oxoisoindoline-4-carbonitrile) can be synthesized according to Scheme 45 (FIG. 45).
[0411] A mixture of 3-((lr,3r)-l-(3-bromophenyl)-3-methoxycyclobutyl)-4-methyl-4H - 1,2,4-triazole (30.0 mg, 0.09 mmol), 6-(((l-methylcyclobutyl)amino)methyl)-l- oxoisoindoline-4-carbonitrile (26.1 mg, 0.1 mmol), copper(7) iodide (7.1 mg, 0.04 mmol), (IS^S^A’^-dimethylcyclohexane-l^-diamine (5.3 mg, 0.04 mmol) and potassium carbonate (38.6 mg, 0.28 mmol) in tert-amyl alcohol (2 mL) was stirred at 100 °C for 5 h under N2. The reaction was diluted with water (20 mL) and extracted with dichloromethane (3 x 25 mL). The combined organic phases were washed with brine (2 x 25 mL), dried over sodium sulfate and concentrated to dryness, purified by RP-HPLC (25% to 55% ACN / (0.05%NH3H20+ lOmM NH4HCO3in water)) to afford 2-(3-((lr,3r)-3-methoxy-l-(4-methyl-4H-l,2,4-triazol-3- yl)cyclobutyl)pheny l)-6-((( 1 -methylcyclobutyl)amino)methyl)- 1 -oxoisoindoline-4-carbonitrile (12.7 mg, 27% yield) as a white solid.1H NMR (400 MHz, methanol-d4) δ 8.39 (s, 1H), 8.11 (s, 1H), 8.05 (s, 1H), 7.90 (s, 1H), 7.72 (d, J= 8.8 Hz, 1H), 7.48 (t, J= 8.0 Hz, 1H), 7.08 (d, J = 8.4 Hz, 1H), 5.17 (s, 2H), 4.03 - 3.95 (m, 1H), 3.83 (s, 2H), 3.41 - 3.36 (m, 2H), 3.35 (s, 3H), 3.30 (s, 3H), 2.69 - 2.61 (m, 2H), 2.14 - 2.05 (m, 2H), 1.91 - 1.75 (m, 4H), 1.37 (s, 3H). LCMS [M+H]+= 497.2.Example 46: Compounds 39 and 40
[0412] Compound 39, ((R)-6-(((l-methylcyclobutyl)amino)methyl)-2-(3-(3,3,3-trifluoro-l-(4-methyl-4H- 1 ,2,4-triazol-3 -yl)propyl)phenyl)-4-(trifluoromethyl)isoindolin- 1 -one) andCompound 40, ((1S)-6-(((l-methylcyclobutyl)amino)methyl)-2-(3-(3,3,3-trifluoro-l-(4-methyl- 4H -l,2,4-triazol-3-yl)propyl)phenyl)-4-(trifluoromethyl)isoindolin-l-one) can be synthesized according to Scheme 46 (FIG. 46).Intermediate 2: (3-(l-(3-bromophenyl)-3,3,3-trifluoropropyl)-4-methyl-4H-l,2,4- triazolel)
[0413] To a solution of 3-(3-bromobenzyl)-4-methyl-4H -l,2,4-triazole (1 g, 3.97 mmol) in tetrahydrofuran (20 mL) was added sodium bis(trimethylsilyl)amide (1 M in tetrahydrofuran, 5.16 mL, 5.16 mmol) at 0 °C. The mixture was at 0 °cfor 30 mins, then 2,2,2-trifluoroethyl trifluoromethanesulfonate (0.83 mL, 5.95 mmol) was added at 0 °c. The resulting residue was stirred at 25 °C for 1.5 hours. The mixture was quenched by water (20 mL), extracted with dichloromethane (3 x 30 mL), combined the organic layers and dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by RP-HPLC (27% to 57% ACN / (0.05%NH3H20+10mM NH4HCO3in water)) to afford 3-(l-(3-bromophenyl)-3,3,3- trifluoropropyl)-4-methyl-4H - l ,2,4-triazolel (150 mg, 11% yield) as a yellow solid. LCMS [M+H]+= 336.0.Compounds 39 and 40
[0414] To a solution of 6-(((l-methylcyclobutyl)amino)methyl)-2-(3-(3,3,3-trifluoro-l-(4- methyl-4H -l,2,4-triazol-3-yl)propyl)phenyl)-4-(trifluoromethyl)isoindolin-l-one (150 mg, 0.45 mmol), 6-(((l -methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin- 1 -one (147.3 mg, 0.49 mmol), copper(I) iodide (34 mg, 0.18 mmol), potassium carbonate (186 mg, 1.35 mmol) and (1S,2S)-N1,N2-dimethylcyclohexane-l ,2-diamine (19 mg, 0.13 mmol) in tert- amyl alcohol (2 mL). The mixture was stirred at 100 C for 2 hours under nitrogen atmosphere. The reaction mixture was diluted with dichloromethane (25 mL), washed with NH3H2O (10 mL), brine (10 mL), dried over sodium sulfate, filtered and concentrated to dryness. The mixture was purified by RP-HPLC (58% to 88% ACN / (0.05%NH3H2O+10mM NH4HCO3in water)) to afford 6-(((l-methylcyclobutyl)amino)methyl)-2-(3-(3,3,3-trifluoro-l- (4-methy 1-4H -1,2.4-triazol-3-yl)propyl)phenyr)-4-(trifluoromethy l)isoindol in- 1 -one (100 mg, 40% yield) as a white solid. LCMS [M+H]+= 552.3.The above product was further separated by chiral SFC (Column = Daicel Chiralpak IG; Column dimensions = 250 mm x 30 mm x 10 μm; Detection wavelength = 220 nM; Flow rate = 100 mL / min; Mobile phase: A: CO2 B: ethanol (0.05% DEA); Isocratic: 20% B) with 0.1% ammonium hydroxide) to afford tentatively assigned: (R ) - 6 - ((( 1 -methylcyclobutyl)amino)methyl)-2-(3 -(3 ,3,3 -trifluoro- 1 -(4-methy 1-4H - 1 ,2,4-triazol- 3-yl)propyl)phenyl)-4-(trifhroromethyl)isoindolin-l-one (Peak 1, retention time = 2.199 min)(35.3 mg, 35% yield) as white solid.1H NMR (400 MHz, methanol-d4) δ 8.39 (s, 1H), 8.08 (s, 1H), 8.01 (s, 1H), 7.96 (s, 1H), 7.85 - 7.77 (m, 1H), 7.47 (t, J= 8.0 Hz, 1H), 7.20 (d, J= 7.2 Hz, 1H), 5.15 (s, 2H), 4.71 (t, J= 7.2 Hz, 1H), 3.85 (s, 2H), 3.57 (s, 3H), 3.45 -3.34 (m, 1H), 3.16 - 3.01 (m, 1H), 2.16 - 2.04 (m, 2H), 1.91 - 1.73 (m, 4H), 1.38 (s, 3H). LCMS [M+H]+= 552.3.(S)-6-(((l-methylcyclobutyl)amino)methyl)-2-(3-(3,3,3-trifluoro-l-(4-methyl-4H -l,2,4-triazol- 3-yl)propyl)phenyl)-4-(trifluoromethyl)isoindolin-l-one (Peak 2, retention time = 2.412 min) (47.2 mg, 47% yield) as white solid.1H NMR (400 MHz, methanol-rL) δ 8.40 (s, 1H), 8.08 (s, 1H), 8.00 (s, 1H), 7.95 (s, 1H), 7.83 - 7.78 (m, 1H), 7.47 (t, J= 8.0 Hz, 1H), 7.19 (d, J= 7.6 Hz, 1H), 5.15 (s, 2H), 4.71 (t, J= 7.2 Hz, 1H), 3.85 (s, 2H), 3.57 (s, 3H), 3.41 -3.34 (m, 1H), 3.10 - 3.04 (m, 1H), 2.11 - 2.08 (m, 2H), 1.90 - 1.77 (m, 4H), 1.38 (s, 3H). LCMS [M+H]+= 552.3.Example 47: Compound 41(0415] Compound 41 (4-(dimethylamino)-2-(3-((l,s,3.5')-3-methoxy-l -(4-methy 1-4H -1 ,2,4- triazol-3-yl)cyclobutyl)phenyl)-6-(((l-methylcyclobutyl)amino)methyl)isoindolin-l-one) can be synthesized according to Scheme 47 (FIG. 47).Intermediate 2 : (4-amino-6-bromo-2-(4-methoxybenzyl)isoindolin-l -one)
[0416] In glovebox, to a solution of 6-bromo-4-iodo-2-(4-methoxybenzyl)isoindolin-l-one (2.5 g, 5.46 mmol) in Ethanol (15 mL) was added hydroxypotassium (398 mg, 7.09 mmol), ammonia aqueous (210 mg, 6.00 mmol), 7V^V-bis(2,4,6-trimethoxyphenyl)oxamide (BPMTO, 229 mg, 0.55 mmol) and copper(I) oxide (143 mg, 0.55 mmol), The mixture was stirred at 70 °C for 1 h, diluted with dichloromethane (30 mL), washed with brine (2 x 30 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography on silica gel (0 - 60% ethyl acetate in petroleum ether) to afford 4-amino-6-bromo-2-(4- methoxybenzyl)isoindolin-l-one (1.0 g, 53% yield) as a yellow solid. LCMS [M+H]+= 347.0.Intermediate 3: (6-bromo-4-(dimethylamino)-2-(4-methoxybenzyl)isoindolin-l-one)
[0417] To a solution of 4-amino-6-bromo-2-(4-methoxybenzyl)isoindolin-l-one (1.0 g, 2.88 mmol) in MN-Dimethylformamide (10 mL) was added potassium carbonate (2.4 g, 17.29 mmol) and iodomethane (2.0 g, 14.40 mmol). The mixture was stirred at 60 °C for 1 h then diluted with water (20 mL), extracted with ethyl acetate (3 x 20 mL). The combined organic phase was washed with brine (2 x 20 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel (0 - 30% ethyl acetate inpetroleum ether) to afford 6-bromo-4-(dimethylamino)-2-(4-methoxybenzyl)isoindolin-l-one (550 mg, 1.46 mmol). LCMS [M+H]+= 375.0.Intermediate 4: (6-bromo-4-(dimethylamino)isoindolin-l-one)
[0418] To a vial was added 6-bromo-4-(dimethylamino)-2-(4-methoxybenzyl)isoindolin-l- one (500.0 mg, 1.33 mmol) and 2,2,2-trifluoroacetic acid (2 mL), the vial was sealed then stirred 10 h at 100 °C at microwave. The reaction solution was diluted with water (15 mL), extracted with ethyl acetate (3 x 15 mL), combined the organic phase and washed with brine (2 x 15 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography on silica gel (0 - 50% ethyl acetate in petroleum ether) to afford 6-bromo-4- (dimethylamino)isoindolin-l-one (330 mg, 83% yield) as a yellow solid. LCMS [M+H]+= 255.0.Intermediate 5: (4-(dimethylamino)-6-(hydroxymethyl)isoindolin-l-one)
[0419] To a solution of 6-bromo-4-(dimethylamino)isoindolin-l-one (330.0 mg, 1.33 mmol) in dioxane (5 mL) was added (tributylstannyl)methanol (988 mg, 3.10 mmol) and Pd(PPh3)4 (155.0 mg, 0.13 mmol), the reaction mixture was stirred at 100 °C for 16 h under nitrogen atmosphere. Then the mixture was diluted with water (15 mL), extracted with dichloromethane (3 x 15 mL). The combined organics were washed with brine (2 x 15 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by purified by chromatography on silica gel (0 - 4% methanol in dichloromethane) to afford 4- (dimethylamino)-6-(hydroxymethyl)isoindolin-l-one (135 mg, 51% yield) as a yellow solid. LCMS [M+H]+= 207.1.Intermediate 6: (4-(dimethylamino)-6-(hydroxymethyI)-2-(3-((ls,3s,)-3-methoxy-l-(4- methyI-4J?-l,2,4-triazol-3-yl)cyclobutyl)phenyl)isoindolin-l-one)
[0420] A mixture of (dimethylamino)-6-(hydroxymethyl)isoindolin-l-one (73.0 mg, 0.35 mmol), 3-((15,35)-l-(3-bromophenyl)-3-methoxycyclobutyl)-4-methyl-4H -l,2,4-triazole (90.0 mg, 0.28 mmol), (L ,2S)-A\A imethylcyclohexane-l,2-di a ine (16.0 mg, 0.11 mmol), potassium carbonate (116.0 mg, 0.83 mmol) and copper(I) iodide (21.3 mg, 0.11 mmol) in tertamy alcohol (1 mL) was stirred at 100 °C for 4 h under nitrogen atmosphere. Then the mixture was poured into water (5 mL) and extracted with dichloromethane (3 x 10 mL). The combined organic layers were concentrated. The residue was purified by preparative TLC (solvent gradient: 10% methanol in dichloromethane) to afford 4-(dimethylamino)-6- (hydroxymethyl)-2-(3-((15,3s)-3-methoxy- 1 -(4-methyl-4H - 1 ,2,4-triazol-3- yl)cyclobutyl)phenyl)isoindolin-l-one (75 mg, 60% yield) as a yellow oil. LCMS [M+H]+= 448.2.Intermediate 7: (7-(dirnethylaniin())-2-(3-((ls.3v)-3-rnethoxy-l-(4-methyl-4 / / -l,2,4- triazol-3-yl)cyclobutyl)phenyl)-3-oxoisoindoline-5-carbaldehyde)
[0421] To a solution of 4-(dimethylamino)-6-(hydroxymethyl)-2-(3-((ls,3s)-3-methoxy-l-(4- methyl-4LM,2,4-triazol-3-yl)cyclobutyl)phenyl)isoindolin-l-one (75.0 mg, 0.17 mmol) in dichloromethane (ImL) was added Dess-Martin periodinane (85.3 mg, 0.20 mmol) at 0 °C. Then the mixture was at 25 °C for 4 hours. The mixture was quenched with saturated sodium bicarbonate solution (10 mL), extracted with dichloromethane (3 x 10 mL), combined the organic layers, dried over sodium sulfate, filtrated and concentrated under vacuum. The residue was purified by preparative TLC (solvent gradient: 10% methanol in dichloromethane) to afford 7-(dimethylamino)-2-(3-((ls,3s)-3-methoxy-l-(4-methyl-4H -l,2,4-triazol-3- yl)cyclobutyl)phenyl)-3-oxoisoindoline-5-carbaldehyde (45 mg, 60% yield) as a white solid. LCMS [M + H]+= 446.2.Compound 41
[0422] A mixture of 7-(dimethylamino)-2-(3-((15,35)-3-methoxy-l-(4-methyl-4H -l,2,4- triazol-3-yl)cyclobutyl)phenyl)-3-oxoisoindoline-5-carbaldehyde (45.0 mg, 0.10 mmol), 1- methylcyclobutan-1 -amine hydrochloride (49.1 mg, 0.40 mmol), triethylamine (0.04 mL, 0.30 mmol) in methanol (ImL) was stirred for 1 min at 100 °cat micro wave, then sodium cyanotrihydroborate (9.5 mg, 0.15 mmol) was added, the mixture was stirred for another 45 min at 80 °C at microwave. The reaction solution was directly purified by RP-HPLC (water(NH3H2O+NH4HCO3) / ACN 45% to 75%) to afford 4-(dimethylamino)-2-(3-((U3s)-3- methoxy-l-(4-methyl-4H-l,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((l- methylcyclobutyl)amino)methyl)isoindolin-l-one (19.7 mg, 37% yield) as a white solid. ' H NMR (400 MHz, methanol-J4) δ 8.33 (s, 1H), 8.10 - 8.05 (m, 1H), 7.70 (d, J= 6.8 Hz, 1H), 7.48 (t, J = 7.6 Hz, 1H), 7.33 (s, 1H), 7.19 (d, J = 8.4 Hz, 1H), 7.13 (s, 1H), 5.07 (s, 2H), 4.20 (t, J= 7.2 Hz, 1H), 3.78 (s, 2H), 3.37 (s, 3H), 3.29 (s, 3H), 3.20 - 3.19 (m, 2H), 3.02 (s, 6H), 2.92 - 2.83 (m, 2H), 2.15 - 2.12 (m, 2H), 1.96 - 1.79 (m, 4H), 1.42 (s, 3H). LCMS [M+H]+= 515.3.Example 48: Compound 42
[0423] Compound 42 (4-(dimethylamino)-2-(3-((lr,3r)-3-methoxy-l-(4-methyl-4 / / -l,2,4- triazol-3-yl)cyclobutyl)phenyl)-6-(((l-methylcyclobutyl)amino)methyl)isoindolin-l-one) can be synthesized according to Scheme 48, FIG. 48.Intermediate 2 : (4-(d imethyIamino)-6-(hyd roxy methy l)-2-(3-((l r,3r)-3-methoxy-l -(4- methyl-4Zir-l,2,4-triazol-3-yl)cycIobutyI)phenyl)isoindolin-l-one)
[0424] A mixture of (dimethylamino)-6-(hydroxymethyl)isoindolin-l-one (68.0 mg, 0.33 mmol), 3 -((1 r,3r)- 1 -(3 -bromophenyl)-3 -methoxy cyclobutyl)-4-methyl-4H - 1 ,2,4-triazole (80.0 mg, 0.33 mmol), (IS^^-A'A^-dimethylcyclohexane-l^-diamine (18.7 mg, 0.13 mmol), potassium carbonate (136.0 mg, 0.98 mmol) and copper(I) iodide (25.0 mg, 0.13 mmol) in tert - amyl alcohol (1 mL) was stirred at 100 °C for 4 h under nitrogen atmosphere. Then the mixture was poured into water (5 mL), extracted with dichloromethane (3 x 10 mL). The combined organic layers were concentrated. The residue was purified by preparative TLC (solvent gradient: 10% methanol in dichloromethane) to afford 4-(dimethylamino)-6- (hydroxymethyl)-2-(3-((lr,3r)-3-methoxy-l-(4-methyl-4LZ-l,2,4-triazol-3- yl)cyclobutyl)phenyl)isoindolin-l-one (80 mg, 54% yield) as a yellow oil. LCMS [M + H]+= 448.2.Intermediate 3: (7-(dimethylamino)-2-(3-((lr,3r)-3-methoxy-l-(4-methyl-4fir-l,2,4- triazol-3-yl)cyclobutyl)phenyl)-3-oxoisoindoline-5-carbaldehyde)
[0425] To a solution of 4-(dimethylamino)-6-(hydroxymethyl)-2-(3-((lr,3r)-3-methoxy-l-(4- methyl-47Z-l,2,4-triazol-3-yl)cyclobutyl)phenyl)isoindolin-l-one (80.0 mg, 0.18 mmol) in dichloromethane (ImL) was added Dess-Martin periodinane (90.9 mg, 0.21mmol) at 0 °C. Then the mixture was at 25 °C for 4 hours. The mixture was quenched with saturated sodium bicarbonate solution (10 mL), extracted with dichloromethane (3 x 10 mL), combined the organic layers, dried over sodium sulfate, filtrated and concentrated under vacuum. The residue was purified by preparative TLC (solvent gradient: 10% methanol in dichloromethane) to afford 7-(dimethylamino)-2-(3-((lr,3r)-3-methoxy-l-(4-methyl-4H -l,2,4-triazol-3- yl)cyclobutyl)phenyl)-3-oxoisoindoline-5-carbaldehyde (65 mg, 81% yield) as a white solid. LCMS [M + H]+= 446.2.Compound 42
[0426] The mixture of 7-(dimethylamino)-2-(3-((lr,3r)-3-methoxy-l-(4-methyl-4Z / -l,2,4- triazol-3-yl)cyclobutyl)phenyl)-3-oxoisoindoline-5-carbaldehyde (65.0 mg, 0.15 mmol), 1- methylcyclobutan-1 -amine hydrochloride (70.9 mg, 0.58mmol), triethylamine (0.06 mL, 0.44 mmol) in methanol (1 mL) was stirred for 1 min at 100 °cat micro wave, then sodium cyanotrihydroborate (13.7 mg, 0.22 mmol) was added, the mixture was stirred for 45 min at 80°C at microwave. The residue was purified by RP-HPLC (wate^NHsHzO+NlLHCCh) / ACN 45% to 75%) to afford 4-(dimethylamino)-2-(3-((lr,3r)-3-methoxy-l-(4-methyl-4H - l,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((l-methylcyclobutyl)amino)methyl)isoindolin-l-one(39.6 mg, 51% yield) as a white solid.1H NMR (400 MHz, methanol-rA) δ 8.39 (s, 1H), 7.93 (s, 1H), 7.68 (dd, J= 8.0, 1.6 Hz, 1H), 7.45 (t, J= 8.0 Hz, 1H), 7.31 (s, 1H), 7.12 (s, 1H), 7.05 (d, J= 8.4 Hz, 1H), 5.05 (s, 2H), 4.02 - 3.94 (m, 1H), 3.74 (s, 2H), 3.40 - 3.36 (m, 2H), 3.35 (s, 3H), 3.29 (s, 3H), 3.00 (s, 6H), 2.69 - 2.60 (m, 2H), 2.16 - 2.06 (m, 2H), 1.93 - 1.75 (m, 4H), 1.39 (s, 3H). LCMS [M+H]+= 515.3.Example 49: Compounds 43 and 44
[0427] Compound 43 (2-(3-((15,35)-3-ethynyl-l-(4-methyl-4H -l,2,4-triazol-3- yl)cyclobutyl)phenyl)-6-(((l-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-l- one) and Compound 44 (2-(3-((lr,3r)-3-ethynyl-l-(4-methyl-4 / / -l,2,4-triazol-3- yl)cyclobutyl)phenyl)-6-(((l-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-l- one) can be synthesized according to Scheme 49 (FIG. 49).
[0428] A mixture of 3-(l-(3-bromophenyl)-3-ethylcyclobutyl)-4-methyl-4F / -l,2,4-triazole (50.0 mg, 0.16 mmol), 6-(((l-methylcyclobutyl)amino)methyl)-4-(trifhroromethyl)isoindolin- 1-one (intermediate P, 47.17 mg, 0.16 mmol), copper(I) iodide (6.02 mg, 0.03 mmol), (1A25)-A^ A^2-dimethylcyclohexane-l ,2-diamine (9.0 mg, 0.06 mmol) and potassium carbonate (65.56 mg, 0.47 mmol) in tert-amyl alcohol (2 mL) was stirred at 100 °C for 10 h under N2. Then the reaction was diluted with water (25 mL) and extracted with dichloromethane (3 x 25 mL). The combined organic phases were washed with brine (2 x 25 mL), dried over sodium sulfate and concentrated to dryness. The residue was purified by chromatography on silica gel (0 - 10% methanol in dichloromethane) to afford 2-(3-(3-ethynyl-l-(4-methyl-4_H-l,2,4-triazol- 3-yl)cyclobutyl)phenyl)-6-(((l-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1 -one (60 mg, 71% yield) as a white solid. LCMS [M+H]+= 534.2.
[0429] The above mixture was further purified by prep-HPLC (waterlNHsILO+NlLHCCh)- ACN 40% to 70%) to afford:2-(3-((ls,3s)-3-ethynyl-l-(4-methyl-4H -l,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((l- methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-l-one (2.9 mg, 2.8% yield) as a white solid.1H NMR (400 MHz, methanol-r / 4) δ 8.33 (s, 1H), 8.09 (s, 1H), 8.07 (t, J= 2.4 Hz, 1H), 8.01 (s, 1H), 7.73 - 7.71 (m, 1H), 7.51 (t, J= 8.0 Hz, 1H), 7.24 (d, J= 7.6 Hz, 1H), 5.17 (s, 2H), 3.87 (s, 2H), 3.34 (s, 3H), 3.29 - 3.26 (m, 1H), 3.20 - 3.06 (m, 4H), 2.55 (d, J= 2.4 Hz, 1H), 2.14 - 2.07 (m, 2H), 1.91 - 1.78 (m, 4H), 1.38 (s, 3H). LCMS [M+H]+= 534.2. 2-(3-((lr,3r)-3-ethynyl-l-(4-methyl-4H-l ,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((l- methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-l-one (4 mg, 3.8% yield) as white solid.1H NMR (400 MHz, methanol-A) 5 8.42 (s, 1H), 8.10 (s, 1H), 8.03 (s, 1H), 7.95(t, J= 2.0 Hz, 1H), 7.73 - 7.71 (m, 1H), 7.51 (t, J= 8.0 Hz, 1H), 7.12 (d, J= 7.6 Hz, 1H), 5.18 (s, 2H), 3.88 (s, 2H), 3.40 - 3.37 (m, 2H), 3.36 (s, 3H), 3.19 - 3.14 (m, 1H), 2.90 - 2.85 (m, 2H), 2.58 (d, J= 2.0 Hz, 1H), 2.16 - 2.09 (m, 2H), 1.92 - 1.80 (m, 4H), 1.40 (s, 3H). LCMS [M+H]+= 534.3.Example 50: Compound 45
[0430] Compound 45 (4-chloro-6-(((cyclobutylmethyl)amino)methyl)-2-(3-((lr,3r)-l-(4- methyl-4H - 1 ,2,4-triazol-3-yl)-3-(trifluoromethoxy)cyclobutyl)phenyl)isoindolin- 1 -one) can be synthesized according to Scheme 50 (FIG. 50).
[0431] In glovebox, a mixture of 3-((ls,35)-l-(3-bromophenyl)-3-(trifhioromethoxy)- cyclobutyl)-4-methyl-4H-l ,2,4-triazole (60 mg, 0.16 mmol), (1S,2S)-N!J^2- dimethylcyclohexane- 1,2 -diamine (9 mg, 0.06 mmol), potassium carbonate (66 mg, 0.48 mmol), 4-chloro-6-[(cyclobutylmethylamino)methyl]isoindolin-l-one (intermediate B, 43 mg, 0.16 mmol) and copper(I) iodide (12 mg, 0.06 mmol) in tert-amyl alcohol (2 mL) was stirred at 100 °C for 2 h under N2, then concentrated. The reaction mixture was diluted with ethyl acetate (25 mL), washed with NHa'HiO (5 mL), brine (5 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by RP- HPLC(water(NH3H2O+NH4HCO3)- ACN 61% to 91%) to afford ethyl 2-(4-(6-(((l- methylcyclobutyl)amino)methyl)- 1 -oxo-4-(trifluoromethyl)isoindolin-2-yl)- 177-pyrazol- 1 -yl)- 2-(oxetan-3-yl)acetate (20 mg, 27% yield) as a white solid.1H NMR (400 MHz, methanol- di) 8 8.41 (s, 1H), 7.93 (s, 1H), 7.76 (s, 1H), 7.77 - 7.73 (m, 1H), 7.70 (s, 1H), 7.50 (t, J= 8.0 Hz, 1H), 7.10 (d, J= 8.0 Hz, 1H), 4.99 (s, 2H), 4.83 - 4.79 (m, 1H), 3.86 (s, 2H), 3.55 - 3.46 (m, 2H), 3.34 (s, 3H), 3.01 - 2.98 (m, 2H), 2.63 - 2.60 (m, 2H), 2.54 -2.49 (m, 1H), 2.11 - 2.08 (m, 2H), 1.92 - 1.71 (m, 2H), 1.77 - 1.66 (m, 2H). LCMS [M+H]+= 560.3.Example 51: Compound 46
[0432] Compound 46 (4-chloro-6-(((cyclobutyhnethyl)amino)methyl)-2-(3-((ls,31s,)-l-(4- methyl-4 / / -l,2,4-triazol-3-yl)-3-(trifluoromethoxy)cyclobutyl)phenyl)isoindolin-l-one) can be synthesized according to Scheme 40 (FIG. 40).Intermediate 2: (3-((ls,3sr)-l-(3-bromophenyI)-3-(trifluoromethoxy)cyclobutyl)-4- methyl-4 / / - 1 ,2,4-triazole)
[0433] To a solution of 3-(3-bromophenyl)-3-(4-methyl-4H -l,2,4-triazol-3-yl)cyclobutan-l- ol (6.0 g, 19.47 mmol) in ethyl acetate (60 mL) was added l-(chloromethyl)-4-fluoro-l,4- diazabicyclo[2.2.2]octane-l,4-diium tetrafluoroborate (10.35 g, 29.2 mmol), AgSO3CF3(20 g,77.88 mmol), 2-fluoropyridine (6.7 mL, 77.88 mmol), trimethyl(trifluoromethyl)silane (6.92 g, 48.67 mmol) and KF (4.52 g, 77.88 mmol). The mixture was stirred at 50 °C for 24 hours then filtered. The filtrate was washed with water (50 ml), extracted with dichloromethane (3 x 50 mL), combined the organic phase and concentrated, The residue was purified by RP-HPLC (water(NH3H2O+NH4HCO3)- ACN 43% to 73%) to afford 3-((ls,3s)-l-(3-bromophenyl)-3-(trifluoromethoxy)cyclobutyl)-4-methyl-4H -l,2,4-triazole (3 g, 41% yield) as brown oil.:H NMR (400 MHz, DMSO-rfe) 6 8.36 (s, 1H), 7.51 - 7.49 (m, 2H), 7.35 - 7.34 (m, 2H), 5.06 - 4.99 (m, 1H), 3.28 - 3.25 (m, 2H), 3.20 (s, 3H), 3.18 - 3.13 (m, 2H). LCMS [M+H]+= 375.9. and3-(( 1 r,3r)- 1 -(3 -bromophenyl)-3-(trifluoromethoxy)cyclobutyl)-4-methyl-4LT- 1 ,2,4-triazole (3 g, 41% yield) as a brown oil.1H NMR (400 MHz, DMSO-rfe) δ 8.43 (s, 1H), 7.49 (dd, J= 8.0, 0.8 Hz, 1H), 3.78 (t, J= 1.6 Hz, 1H), 7.34 (t,8.0 Hz, 1H), 7.20 (d, J = 8.4 Hz, 1H), 4.77 -4.70 (m, 1H), 3.48 - 3.43 (m, 2H), 3.19 (s, 3H), 2.89 - 2.84 (m, 2H). LCMS [M+H]+= 375.9.Compound 46
[0434] To a solution of 3-((ls,3s)-l-(3-bromophenyl)-3-(trifluoromethoxy)cyclobutyl)-4- methyl-4H -l,2,4-triazole (70 mg, 0.19 mmol) in tert-amyl alcohol (3 mL) was added potassium carbonate (77 mg, 0.56 mmol), copper(I) iodide (14 mg, 0.07 mmol), 4-chloro-6- (((cyclobutylmethyl)amino)methyl)isoindolin-l-one (49 mg, 0.19 mmol), (\S,2S)-Nl,N2- dimethylcyclohexane-l,2-diamine (11 mg, 0.07 mmol). The solution was stirred at 100 °C for 4 hours under N2, the reaction mixture was diluted with dichloromethane (25 mL), washed with NH3H2O (5 mL), brine (10 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by RP-HPLC(water(NH3H2O + NH4HCO3)- ACN 50% to 80%) to afford4-chloro-6-(((cyclobutylmethyl)amino)methyl)-2-(3-((15,35')-l -(4-methyl-4H - l,2,4-triazol-3-yl)-3-(trifluoromethoxy)cyclobutyl)phenyl)isoindolin-l-one (20 mg, 27% yield) as white solid.NMR (400 MHz, methanol-d4) δ 8.35 (s, 1H), 8.06 (s, 1H), 7.77 - 7.71 (m, 3H), 7.52 (t, J= 8.4 Hz, 1H), 7.23 (d, . / = 9.2 Hz, 1H), 5.03 - 4.98 (m, 3H), 3.86 (s, 2H), 3.39 - 3.34 (m, 5H), 3.26 - 3.32 (m, 2H), 2.62 - 2.61 (m, 2H), 2.55 - 2.51 (m, 1H), 2.12 - 2.06 (m, 2H), 1.95 - 1.84 (m, 2H), 1.72 - 1 .67 (m, 2H). LCMS [M+H]+= 560.3.Example 52: Compound 47
[0435] Compound 47 (2-(3-(( l.$',3.s)- l -(4-methyl-4H- L2,4-triazol-3-yl)-3-(trifhioromethyl)cyclobutyl)phenyl)-6-(((l-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-l-one) can be synthesized according to Scheme 41 (FIG. 41).Intermediate 2: (3-(3-bromophenyl)-3-(4-methyl-4 / f-l,2,4-triazol-3-yl)-l- (trifluoromethyl)cyclobutan-l-ol)
[0436] To a solution of 3-(3-bromophenyl)-3-(4-methyl-4H -l,2,4-triazol-3-yl)cyclobutan-l- one (2.0 g, 6.5 mmol) and cesium fluoride (1.29 g, 8.49 mmol) in tetrahydrofuran (15 mL) was added trimethyl(trifluoromethyl)silane (1.11 g, 7.8 mmol), then the mixture was stirred at 25 °C for 12 hours. The reaction mixture was diluted with ethyl acetate (30 mL), washed with brine (30 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel (0 - 5% methanol in dichloromethane) to afford 3-(3-bromophenyl)-3-(4-methyl-4H -l,2,4-triazol-3-yl)-l-(trifluoromethyl)cyclobutan-l-ol (1.5 g, 61% yield) as white solid. [M+H]+= 376.1 &378.1.Intermediate 3 : (3-(3-bromophenyl)-3-(4-methyI-4ZM,2,4-triazol-3-yl)-l- (trifluoromethyl)cyclobutyl trifluoromethanesulfonate)
[0437] A solution of 3-(3-bromophenyl)-3-(4-methyl-4H -l,2,4-triazol-3-yl)-l- (trifluoromethyl)cyclobutan-l-ol (500.0 mg, 1.3 mmol), pyridine (0.2 mL, 3.3 mmol), trifluoromethanesulfonic anhydride (0.44 mL, 2.7 mmol) in dichloromethane (10 mL) at 25 °C for 12 h. The reaction mixture was diluted with dichloromethane (30 mL), washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated. The crude was purified by column chromatography (silica gel, 4% methanol in dichloromethane) to give 3-(3- bromophenyl)-3-(4-methyl-4H -l,2,4-triazol-3-yl)-l-(trifluoromethyl)cyclobutyl trifluoromethanesulfonate (400 mg, 59% yield) as a white solid. LCMS [M+H]+= 507.8 and 509.8.Intermediate 4: (3-(l-(3-bromophenyl)-3-(trifluoromethyl)cyclobut-2-en-l-yl)-4- methyl-47 / -l ,2, 4- triazole)
[0438] A solution of 3-(3-bromophenyl)-3-(4-methyl-4H-1 ,2,4-triazol-3-yl)-l - (trifluoromethyl)cyclobutyl trifluoromethanesulfonate (690.0 mg, 1.4 mmol) andtetramethylethane-l,2-diamine (0.4 mL, 2.7 mmol) in A,A-Dimethylformide (4 mL) was stirred at 80 °C for 16 hours. The reaction solution was purified by RP-HPLC (0.05% FA in water / ACN 40% to 70%) to afford 3-(l-(3-bromophenyl)-3-(trifluoromethyl)cyclobut-2-en-l- yl)-4-methyl-47Z-l,2,4-triazole (300 mg, 51% yield) as yellow oil. LCMS [M+H]+= 358.0 and 360.0.Intermediate 5: (tert-butyl ((2-(3-(l-(4-methyI-4jEI-l,2,4-triazoI-3-yl)-3- (trifluoromethyl)cyclobut-2-en-l-yl)phenyl)-3-oxo-7-(trifluoromethyI)isoindoIin-5- yl)methyl)(l-methylcyclobutyl)carbamate)
[0439] To a solution of 3-(l-(3-bromophenyl)-3-(trifluoromethyl)cyclobut-2-en-l-yl)-4- methyl-4H -L2,4-triazole (300.0 mg, 0.8 mmol) in tert-amyl alcohol (3 mL) was added (1S,25)- TVLA^-dimethylcyclohexane-LZ-diamine (45 mg, 0.34 mmol), copper(I) iodide (63.8 mg, 0.34 mmol) tert-butyl (l-methylcyclobutyl)((3-oxo-7-(trifluoromethyl)isoindolin-5- yl)methyl)carbamate (434.0 mg, 1.1 mmol) and potassium carbonate (289.5 mg, 2.1 mmol), the solution was stirred at 100 °C for 2 hours under N2. The reaction mixture was diluted with ethyl acetate (40 mL), washed with NLE'LLO (15 mL), brine (2 x 15 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel (0 - 5% methanol in dichloromethane) to give tert-butyl ((2-(3-(l-(4-methyl-4 / f- l,2,4-triazol-3-yl)-3-(trifluoromethyl)cyclobut-2-en-l-yl)phenyl)-3-oxo-7- (trifluoromethyl)isoindolin-5-yl)methyl)(l-methylcyclobutyl)carbamate (210 mg, 37% yield) as a yellow oil. LCMS [M+H]+= 676.6.Intermediate 6: (tert-butyl ((2-(3-(l-(4-niethyl-4 / / -L2,4-triazol-3-yl)-3- (trifluoromethyl)cyclobutyl)phenyl)-3-oxo-7-(trifluoromethyl)isoindoIin-5-yl)methyI)(l- methylcyclobutyl)carbamate)
[0440] To a solution of tert-butyl ((2-(3-(l-(4-methyl-47L-l,2,4-triazol-3-yl)-3- (trifhioromethyl)cyclobut-2-en-l-yl)phenyl)-3-oxo-7-(trifhioromethyl)isoindolin-5- yl)methyl)(l-methylcyclobutyl)carbamate (200.0 mg, 0.35 mmol) and Palladium on carbon (10%, 258.9 mg) in Ethyl acetate (2 mL), then the mixture was stirred at 40 °C for 4 h under H2(15 psi). The reaction solution was filtered, the filtrate was concentrated to give crude tert - butyl ((2-(3 -( 1 -(4-methyl-4L / - 1 ,2,4-triazol-3-yl)-3-(trifluoromethyl)cyclobutyl)phenyl)-3-oxo- 7-(trifhioromethyl)isoindolin-5-yl)methyl)(l-methylcyclobutyl)carbamate (180 mg, 90% yield) as yellow oil. LCMS [M+Na]+= 700.3.Compound 47
[0441] To a solution of tert-butyl ((2-(3-(l-(4-methyl-4H -l,2,4-triazol-3-yl)-3- (trifhioromethyl)cyclobutyl)phenyl)-3-oxo-7-(trifhioromethyl)isoindolin-5-yl)methyl)(l- methylcyclobutyl)carbamate (140.0 mg, 0.2 mmol) in dichloromethane (3 mL) was added 2,2,2-trifluoroacetic acid (1.0 mL, 12.98 mmol), the mixture was stirred at 25 °C for 1 hour then concentrated under vacuum. The residue was purified by RP-HPLC (water(NH3H2O+NH4HCO3)- ACN 60% to 90%) to give only 2-(3-((ls,3s)-l-(4-methyl-4H --l,2,4-triazol-3-yl)-3-(trifluoromethyl)cyclobutyl)phenyl)-6-(((l-methylcyclobutyl)amino)- methyl)-4-(trifluoromethyl)isoindolin-l-one (44.7 mg, 37% yield) as a white solid.1NHMR (400 MHz, methanol-d4) δ 8.43 (s, 1H), 8.08 (s, 1H), 8.01 (s, 1H), 7.97 (d, J= 2.0 Hz, 1H), 7.69 (dd, J= 7.6, 1.2 Hz, 1H), 7.50 (t, J= 8.0 Hz, 1H), 7.11 (dd, J= 7.6, 1.2 Hz, 1H), 5.16 (s, 2H), 3.86 (s, 2H), 3.36 (s, 3H), 3.28 - 3.22 (m, 2H), 3.21 - 3.13 (m, 1H), 2.98 - 2.90 (m, 2H), 2.15 - 2.05 (m, 2H), 1.93 - 1.85 (m, 2H), 1.84 - 1.74 (m, 2H), 1.38 (s, 3H). LCMS [M+H]+= 578.6.Example 53: Compounds 48 and 49
[0442] Compound 48 (2-(3-((l1S)-2-hydroxy-l-(4-methyl-4H -l,2,4-triazol-3-yl)propyl)- phenyl)-6-((( 1 -methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin- 1 -one) and Compound 49 (2-(3-((17?)-2-hydroxy-l-(4-methyl-4H -l,2,4-triazol-3-yl)propyl)phenyl)-6- (((l-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-l-one) can be synthesized according to Scheme 53 (FIG. 53).Intermediate 2: (l-(3-bromophenyI)-l-(4-methyl-4 / Z-l,2,4-triazol-3-yl)propan-2-ol)
[0443] To a solution of 3-(3-bromobenzyl)-4-methyl-427-l,2,4-triazole (500.0 mg, 1.98 mmol) in tetrahydrofuran (20 mL) was added LDA (2M in tetrahydrofuran, 1.19 mL, 2.38 mmol) at -70 °C. The mixture was stirred at -70 °C for 30 min then acetaldehyde (0.13 mL, 2.38 mmol) was added, the resulting mixture was stirred at 0 °C for 2 h then quenched by saturated ammonium chloride solution (10 mL). Extracted with ethyl acetate (3 x 50 ml), combined the organic layers, washed with brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by chromatography on silica gel (0 - 6% methanol in dichloromethane) to afford l-(3-bromophenyl)-l-(4-methyl-4 / / -l,2,4-triazol-3- yl)propan-2-ol (400 mg, 68% yield) as a white solid.1H NMR (400 MHz, CDCl3) δ 8.06 (s, 1H), 7.51 - 7.41 (m, 1H), 7.37 - 7.31 (m, 1H), 7.21 (t, J= 7.6 Hz, 1H), 7.17 - 7.09 (m, 1H), 4.64 - 4.54 (m, 1H), 3.82 (d, J= 8.4 Hz, 1H), 3.34 (s, 3H), 1.20 (d, J= 6.4 Hz, 3H). LCMS [M+H]+= 295.9&297.9.Compounds 48 and 49
[0444] Compounds 48 and 49 are prepared as a mixture of diastereomers, meaning that each compound is a mixture of stereoisomers at the hydroxyl-carbon.]0445] A mixture of l -(3-bromophenyl)-l -(4-methyl-4H -l,2,4-triazol-3-yl)propan-2-ol (460.0 mg, 1.55 mmol), Copper(I) iodide (118.32 mg, 0.62 mmol), 6-(((l-methylcyclobutyl)- amino)methyl)-4-(trifluoromethyl)isoindolin-l-one (463.32 mg, 1.55 mmol), ( 1S, 2S)-N1,N2- dimethylcyclohexane-l,2-diamine (88.37 mg, 0.62 mmol), potassium carbonate (429.34 mg, 3.11 mmol) in tert-amyl alcohol (15 mL) was stirred at 100 °C for 4 h under nitrogen atmosphere. The mixture was then concentrated to dryness and the residue was purified by preparative TLC (solvent gradient: 10% methanol in dichloromethane) to afford 2-(3-(2- hydroxy-1 -(4-methyl-4H -l, 2, 4-triazol-3-yl)propyl)phenyl)-6-(((l -methylcyclobutyl)- amino)methyl)-4-(trifluoromethyl)isoindolin-l-one (150 mg, 19% yield) as a yellow solid.
[0446] The above product was further purified by chiral SFC (Column = DAICEL CHIRALCEL OD; Column dimensions = 250 mm x 30 mm x 10 μm; Detection wavelength = 220 nM; Flow rate = 150 mL / min; Mobile phase: A: CO2 B: ethanol (0.05% DEA); Isocratic: 30% B) to afford tentatively assigned:2-(3-(2 -hydroxy- 1 -(4-methyl-4H - 1 ,2,4-triazol-3 -yl)propyl)phenyl)-6-((( 1 - methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-l-one (Peak 1, retention time = 3.416 min) (50 mg, 33% yield) as a white solid.1H NMR (400 MHz, methanol-d4) δ 8.37 (s, 1H), 8.09 (s, 1H), 8.01 (s, 1H), 7.91 (s, 1H), 7.84 (dd, J= 8.0, 1.2 Hz, 1H), 7.45 (t, J= 8.0 Hz, 1H), 7.24 (d, J= 7.6 Hz, 1H), 5.16 (s, 2H), 4.72 - 4.63 (m, 1H), 4.16 (d, J= 8.8 Hz, 1H), 3.86 (s, 2H), 3.62 (s, 3H), 2.15 - 2.05 (m, 2H), 1.92 - 1.75 (m, 4H), 1.38 (s, 3H), 1.17 (d, J= 6.4 Hz, 3H). LCMS [M+H]+= 514.3.2-(3-(2-hydroxy-l-(4-methyl-4H -l,2,4-triazol-3-yl)propyl)phenyl)-6-(((l- methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-l-one (Peak 2, retention time = 4.538 min) (50 mg, 33% yield) as a white solid. 'll NMR (400 MHz, methanol-c / 4) 5 8.37 (s, 1H), 8.09 (s, 1H), 8.01 (s, 1H), 7.91 (s, 1H), 7.84 (dd, J= 8.4, 1.6 Hz , 1H), 7.45 (t, J= 8.0 Hz, 1H), 7.24 (d, J= 7.6 Hz, 1H), 5.16 (s, 2H), 4.71 - 4.63 (m, 1H), 4.16 (d, J= 8.8 Hz, 1H), 3.85 (s, 2H), 3.62 (s, 3H), 2.15 - 2.04 (m, 2H), 1.92 - 1.74 (m, 4H), 1.38 (s, 3H), 1.17 (d, J = 6.4 Hz, 3H). LCMS [M+H]+= 514.3.Example 54: Compounds 50 and 51
[0447] Compound 50 (2-(3-((1s,3s)-l-(4-methyl-4H -l,2,4-triazol-3-yl)-3- vinylcyclobutyl)phenyl)-6-(((l-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one), and Compound 51 (2-(3-((lr,3r)-l-(4-methyl-4H -l,2,4-triazol-3-yl)-3- vinylcyclobutyl)phenyl)-6-(((l-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin- 1-one), can be synthesized according to Scheme 43 (FIG. 43).Intermediate 2 : (3-(l-(3-bromopheny l)-3-vinylcyclobutyl)-4-inethy 1-417-1, 2, 4-triazole)
[0448] To a solution of 3-(l-(3-bromophenyl)-3-ethynylcyclobutyl)-4-methyl-4H-l,2,4- triazole (0.23g, 0.73 mmol) in hexane (3mL) was added Lindlar catalyst (120.46 mg, 0.01 mmol). The reaction solution was stirred at 20 °C for 2 h under H2(15 psi) then filtered. The filtrate was concentrated and the residue was purified by chromatography on silica gel (0 - 4% methanol in dichloromethane) to give 3-(l-(3-bromophenyl)-3-vinylcyclobutyl)-4-methyl-4H - 1,2,4-triazole (0.23 g, 99% yield) as a yellow solid. LCMS [M+H]+= 320.0.Compounds 50 and 51
[0449] A mixture of 3-((3-bromophenyl)(cyclopropyl)methyl)-4-methyl-4H-l,2,4-triazole (200.0 mg, 0.63 mmol), 6-(((l-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one (187.49 mg, 0.63 mmol), copper(I) iodide (23.94 mg, 0.13 mmol), (1S,2S)-N1,7V2- dimethylcyclohexane-l,2-diamine (35.76 mg, 0.25 mmol) and potassium carbonate (260.6 mg, 1.89 mmol) in tert-amyl alcohol (2 mL) was stirred at 100 °C for 10 h under N2. The reaction mixture was diluted with ethyl acetate (25 mL), washed with NHsTbO (5 mL), brine (5 mL), dried over sodium sulfate, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (solvent gradient: 10% methanol in dichloromethane) to afford 2-(3- ( 1 -(4-methyl-4H - 1 ,2,4-triazol-3-yl)-3-vinylcyclobutyl)phenyl)-6-((( 1 - methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-l-one (230 mg, 68% yield) as a white solid. LCMS [M+H]+= 536.2.
[0450] The above mixture was further purified by prep-HPLC (water(NH3H2O+NH4HCO3)- ACN 43% to 73%) to afford:2-(3 -(( 1 s,3s)~ 1 -(4-methyl-4H - 1 ,2,4-triazol-3 -y l)-3 -vinylcyclobutyl)phenyl)-6-((( 1 - methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-l-one (80 mg, 33% yield) as a white solid.1H NMR (400 MHz, methanol-d4) δ 8.31 (s, 1H), 8.11 (s, 2H), 8.04 (s, 1H), 7.72 - 7.70 (m, 1H), 7.52 (t, J= 8.0 Hz, 1H), 7.30 (d, J= 8.8 Hz, 1H), 6.02 - 5.94 (m, 1H), 5.18 (s, 2H), 5.06 (d, J= 17.2 Hz, 1H), 4.99 (d, J= 10.4 Hz, 1H), 3.95 (s, 2H), 3.35 (s, 3H), 3.26 - 3.20 (m, 1H), 3.04 - 2.99 (m, 2H), 2.89 - 2.84 (m, 2H), 2.20 - 2.13 (m, 2H), 1.95 - 1.90 (m, 2H), 1.88 - 1.80 (m, 2H), 1.43 (s, 3H). LCMS [M+H]+= 536.2.2-(3-((lr,3r)-l-(4-methyl-4H -l,2,4-triazol-3-yl)-3-...
Claims
CLAIMS1. A compound of formula (I),Q is a 5-membered heteroaryl group, optionally substituted by one or more alkyl, cycloalkyl, or haloalkyl groups;Y1and Y2 are independently CH, CF, or N; R1is dialkylamino, cyano, halo, haloalkyl, alkoxy, haloalkoxy, sulfonyl, alkyl, or cycloalkyl,J is C(R3)(R4), wherein: R3, R4are independently selected from: H, halogen, CN, OH, amino, and LoaR2a, wherein Loa is O, NRo, CHRo, C(=O), or a bond, wherein Ro is H or alkyl, and R2a is selected from alkyl, alkenyl, alkynyl, alkylcarboxy, cyanoalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, and a 3 - 14 membered ring moiety, wherein at least one of R3and R4is not H; or R3and R4together with the carbon atom to which they are both bonded form a 3 - 14 membered ring moiety, wherein: if either of R3or R4is alkyl, haloalkyl, or hydroxyalkyl, R3or R4is optionally substituted by a 3 - 14 membered ring moiety; and wherein, if either of Rj or R4is a 3 - 14 membered ring moiety, or R3and R4together are a 3 - 14 membered ring moiety, the ring moiety is selected from: a monocyclic ring, a fused bicyclic ring system, a bridged bicyclic ring system, and a spirocyclic ring system, and wherein the ring moiety: is saturated; is carbocyclic, heterocyclic, or heteroaryl; and is optionally substituted by one or more groups independently selected from halogen, CN, amino, oxo, alkenyl, carbenyl, alkynyl, OH, or L0bR2b, wherein L0bis CH2, C(=O), NH, O, S, S(=O), S(=O)2, or a bond, and R2bis alkyl, cycloalkyl, heterocycly 1. alkenyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, cyanoalkyl, and aminoalkyl;R5is selected from: H, halo, or L1-R10, wherein L1is -N(R11)-, -C(=O)N(R11)-, O, S, carbonyl, or a bond, and wherein R10and R11are independently H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, and when either of R10and R11are not H, R10or Ru is optionally substituted by one or more groups selected from: halo, CN, amino, oxo, OH, alkoxy, alkyl, perhaloalkyl, haloalkyl, heterocyclyl, aryl, and heteroaryl, or R10and R11together form a cycloalkyl or heterocyclyl ring, a spirocyclic ring, a fused bicyclic ring, or a bridged bicyclic ring, wherein the ring formed by R10and R11together is optionally substituted by one or more groups selected from halo, CN, amino, oxo, carbenyl, OH, alkoxy, alkyl, perhaloalkyl, or haloalkyl;Z is — L2NR7R8wherein:L2is -C(H)R6a- or -C(H)R6aC(H)R6b-;R6aand R6bare each independently selected from H, alkyl, hydroxyl, halo, cycloalkyl, heterocyclyl, haloalkyl, alkoxy, and hydroxyalkyl, wherein if either of R6aor R6bis alkyl it is optionally substituted by cycloalkyl, and if either of R6aor R6bis cycloalkyl it is optionally substituted by halo, cyano, sulfonyl, hydroxyl, alkoxy, aminocarbonyl, hetercyclyl, heteroaryl, alkyl or cycloalkyl; and R7andR8are independentlLy3R9, wherein: L3= -(C(H) R10)n-, or a bond, wherein n = 1 or 2; R10is selected from H and alkyl; R9is selected from H, alkyl, haloalkyl, perhaloalkyl, hydroxyalkyl, aminoalkyl, cycloalkyl, hydroxyalkyl, alkoxyalkyl, alkyl alkanoate, heterocyclyl, spirocyclyl ring system, fused ring system, bicyclyl ring system, a 5 or 6 member heteroaromatic ring, or a 3 - 10 member fused heteroaromatic ring system, and a bridged bicyclyl ring; and wherein, if any of R7orR8is cycloalkyl, heterocyclyl, spirocyclyl, a fused bicyclyl, a bridged bicyclic ring, a 5 or 6 member heteroaromatic ring, or a 3 - 10 member fused heteroaromatic ring system, said ring or ring system is optionally substituted with one or more groups selected from: sulfonyl, halo, hydroxyl, alkoxy, alkyl, cycloalkyl, alkoxyalkyl, carbenyl, alkenyl, hydroxyalkyl, cyano, carboxyalkyl, or haloalkyl.
2. The compound of claim 1, wherein Q is 4-methyl-4H-l,2,4-triazol-3-yl.
3. The compound of claims 1 and 2, wherein Y1= Y2 = CH.
4. The compound of claims 1 - 3, wherein R1= H, CHF2, CF3, cyclopropyl, F, Cl, CH3, OCH3, OCF3, OCHF2, -CN, or-N(CH3)2.
5. The compound of claims 1 - 3, wherein R1is CF3.
6. The compound of claims 1 - 5, wherein R3is H or F, and R4is selected from 3-oxetanyl, cyciobutyl, alkyl, and alkoxyalkyl, and wherein R4is optionally substituted by one or more groups selected from: halo, cyano, hydroxyl, and cyanoalkyl.
7. The compound of any one of claims 1 - 6, wherein R3is H, and R4is selected from 3- oxetanyl, 3-fluoro-cyclobytyl, and 3 -cyanomethylcyclobutyl.
8. The compound of any one of claims 1 - 6, wherein R3is H, and R4is selected from: methyl, ethyl, isopropyl, methoxy methyl, and cyanoethyl, and wherein R4is optionally substituted by halo, or hydroxyl.
9. The compound of any one of claims 1 - 5, wherein R3and R4together with the carbon atom to which they are both bonded form a 3 - 8 membered ring moiety selected from: cyclobutyl, oxetanyl, and spiro[3.3]hept-2-yl, wherein the ring moiety is optionally substituted by one or more groups independently selected from: halo, alkenyl, cyano, haloalkyl, alkoxy, and haloalkoxy.
10. The compound of any one of claims 1 - 5 and 9, wherein R3and R4together with the carbon atom to which they are both bonded form a cyclobutyl ring, and the cyclobutyl ring is substituted by a group selected from: fluoro, chloro, cyano, vinyl, methoxy, difluoromethoxy, trifluoromethoxy, difluoromethyl, trifluoromethyl, and 1,1, -difluoroethyl.
11. The compound of claims 1 - 10 wherein R5is H.
12. The compound of claims 1 - 11, wherein L2is -C(H)R6aC(H)R6b-, and R6ais hydroxyl, methyl, or H, and R6bis H.
13. The compound of claims 1 - 12, wherein: R7is cyclobutyl, optionally substituted by one or two instances of fluoro, or methyl; and R8is H.
14. The compound of claims 1 - 12, wherein R7is 1 -methylcyclobutyl, andR8is H.
15. The compound of claims 1 - 11, wherein Z is -C(H)R6aNR7R8, and wherein:R6ais H, methyl, or cyclopropyl-methyl;R7is cyclobutyl, which is optionally substituted with one or more methyl or fluoro groups; andR8is H.
16. The compound of claims 1 - 11, wherein Z is -C(H)R6aNR7R8, and wherein:R6ais H, or methyl; R7isL3R9, whereinL3is CH2, and R9is cyclobutyl or cyclopropyl, and wherein R9is optionally substituted with methyl or fluoro; and R8is H.
17. The compound of claims 1 - 11, wherein Z is -C(H)R6aNR7R8, and wherein:R6ais H, or methyl; R7isL3R9, whereinL3is a bond, and R9is alkyl; and R8is H.
18. The compound of claims 1 - 11, wherein Z is -CfTTjR6NRzR8, and wherein:R6 is H or methyl; R7is cyclobutyl, optionally substituted with methyl or fluoro; and R8is H.
19. The compound of claims 1 - 11, wherein Z is -C(H)R6aNR7R8, and wherein:R6ais H, or methyl; R7isL3R9, whereinL3is a bond, and R9is Ci-ealkyl; and R8is H.
20. The compound of claims 1 - 11, wherein Z is -C(H)R6aNR7R8, and wherein:R6ais H, or methyl; R7isL3R9, whereinL3is CH(CH3), and R9is cyclobutyl; and R8is H.
21. The compound of claim 1, selected from the group consisting of the Compound Nos. 1 - 345 in Table 1, or a pharmaceutically acceptable salt thereof.
22. A compound selected from the group consisting of:6-(((cyclobutylmethyl)amino)methyl)-2-(3-((lr,3r)-3-(difluoromethoxy)-l-(4-methyl-4H- l,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-l-one;4-chloro-6-((R)-l-((cyclobutylmethyl)amino)ethyl)-2-(3-((lr,3R)-3-(fluoromethyl)-l-(4- methyl-4H-l,2,4-triazol-3-yl)cyclobutyl)phenyl)isoindolin-l-one;4-chloro-6-((R)-l -((cyclobuty lmethyl)amino)ethyl)-2-(3-((R)-(3-fluorooxetan-3-yl)(4- methyl-4H-l,2,4-triazol-3-yl)methyl)phenyl)isoindolin-l-one;4-chloro-2-(3 -(( 1 r,3R)-3 -chloro- 1 -(4-methy 1-4H- 1 ,2,4-triazol-3 -yl)cyclobutyl)phenyl)-6- ((R)- 1 -((cyclobuty Imethy l)amino)ethyl)isoindolin- 1 -one ;4-chloro-6-((R)-l -((cyclobuty lmethyl)amino)ethyl)-2-(3-((R)-((ls,3S)-3- fluorocyclobutyl)(4-methyl-4H-l,2,4-triazol-3-yl)methyl)phenyl)isoindolin-l-one;4-chloro-6-((R)-l-((cyclobutylmethyl)amino)ethyl)-2-(3-((lr,3R)-3-fluoro-l-(4-methyl-4H-l,2,4-triazol-3-yl)cyclobutyl)phenyl)isoindolin-l-one;4-chloro-6-((R)-l -((cyclobuty lmethyl)amino)ethyl)-2-(3-((lr,3R)-l-(4-methyl-4H- 1,2, 4- triazol-3-yl)-3-vinylcyclobutyl)phenyl)isoindolin-l-one;(lR,3r)-3-(3-(4-chloro-6-((R)-l-((cyclobutylmethyl)amino)ethyl)-l-oxoisoindolin-2- yl)phenyl)-3 -(4-methyl-4H-l, 2, 4-triazol-3-yl)cyclobutane-l -carbonitrile;3-((6-(6-((R)-l -((cyclobuty lmethyl)amino)ethyl)-l-oxo-4-(trifluoromethyl)isoindolin-2-yl)-4-((S)-(4-methyl-4H-l,2,4-triazol-3-yl)(oxetan-3-yl)methyl)pyridin-2-yl)amino)propanenitrile;2-(3-((lr,3r)-3-(difluoromethoxy)-l-(4-methyl-4H-l,2,4-triazol-3-yl)cyclobutyl)phenyl)-6- ((isobutylamino)methy l)-4-(trifluoromethyl)isoindolin- 1 -one;2-(3-((lr,3R)-3-(difluoromethoxy)-l-(4-methyl-4H-l,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-((R)- 1 -(( 1 -methylcyclobutyl)amino)ethyl)-4-(trifluoromethyl)isoindolin- 1 -one;4-chloro-2-(3-((lr,3S)-3-chloro-l-(4-methyl-4H-l,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-((((S) - 1 -cyclobutylethyl)amino)methyl)isoindolin- 1 -one;4-chloro-6-((((S)-l-cyclobutylethyl)amino)methyl)-2-(6-cyclopropyl-4-((R)-((ls,3S)-3- fluorocyclobuty l)(4-methyl-4H- 1 ,2,4-triazol-3 -y l)methyl)pyridin-2-yl)isoindolin- 1 -one;2-(3-((lr,3R)-3-chloro-l-(4-methyl-4H-l,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-((R)-l- ((cyclobutylmethyl)amino)ethyl)-4-(difluoromethyl)isoindolin-l-one;2-(3-((lr,3r)-3-(difluoromethoxy)-l-(4-methyl-4H-l,2,4-triazol-3-yl)cyclobutyl)phenyl)-4- (difluoromethyl)-6-((isobutylamino)methyl)isoindolin- 1 -one;6-(((cyclopropylmethyl)amino)methyl)-2-(3-((lr,3r)-3-(difluoromethoxy)-l-(4-methyl-4H- 1 ,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin- 1 -one;4-chloro-2-(3-((lr,3r)-3-(difluoromethoxy)-l-(4-methyl-4H-l,2,4-triazol-3- yl)cyclobutyl)phenyl)-6-((isobutylamino)methyl)isoindolin-l-one;2-((lR, 3r)-3-((R)-(3-(4-chloro-6-(((cyclobutylmethyl)amino)methyl)-l -oxoiso indolin-2- yl)phenyl)(4-methyl-4H-l,2,4-triazol-3-yl)methyl)cyclobutyl)acetonitrile;(S)-4-chloro-6-(((cyclopropylmethyl)amino)methyl)-2-(3-((3-fluorooxetan-3-yl)(4-methyl-4H- 1 ,2,4-triazol-3 -yl)methyl)phenyl)isoindolin- 1 -one; and6-(((cyclobutylmethyl)amino)methyl)-2-(3-((lr,3r)-3-(difluoromethoxy)-l-(4-methyl-4H-1 ,2,4-triazoI-3 -yl)cyclobutyl)phenyl)-4-fluoroisoindolin- 1 -one, or a pharmaceutically acceptable salt thereof.
23. A method of treating a cancer, comprising administering to a subject in need thereof, a compound according to any one of claims 1 - 22.
24. A compound of formula (II):or an enantiomer, diastereomer or a pharmaceutically acceptable salt or solvate thereof, wherein:J is C(R3)(R4), wherein: R3, R4are independently selected from: H, halogen, CN, OH, amino, and LoaRza, wherein Loa is O, NRo, CHRo, C(=O), or a bond, wherein Ro is H or alkyl, and Rza is selected from alkyl, alkenyl, alkynyl, alkylcarboxy, cyanoalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, and a 3 - 14 membered ring moiety, wherein at least one of R3and R4is not H; or R3and R4together with the carbon atom to which they are both bonded form a 3 - 14 membered ring moiety, wherein: if either of R3or R4is alkyl, haloalkyl, or hydroxyalkyl, R3or R4is optionally substituted by a 3 - 14 membered ring moiety; and wherein, if either of R3or R4is a 3 - 14 membered ring moiety, or R3and R4together are a 3 - 14 membered ring moiety, the ring moiety is selected from: a monocyclic ring, a fused bicyclic ring system, a bridged bicyclic ring system, and a spirocyclic ring system, and wherein the ring moiety: is saturated; is carbocyclic, heterocyclic, or heteroaryl; and is optionally substituted by one or more groups independently selected from halogen, CN, amino, oxo, alkenyl, carbenyl, OH, or L0bR2b, wherein L0bis CH2, C(=O), NH, O,S, S(=O), S(=O)2, or a bond, and R2bis alkyl, cycloalkyl, heterocyclyl, alkenyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, cyanoalkyl, and aminoalkyl.Q is a 5-membered heteroaryl, optionally substituted by one or more alkyl, cycloalkyl, or haloalkyl groups;Y1is CH, CF, or N; R5is selected from: H, halo, or L1-R10, wherein L1is -N(R11)-, -C(=O)N(R11)-, O, S, carbonyl, or a bond, and wherein R10and R11are independently H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, and when either of R10and R11 are not H, R10or R11 is optionally substituted by one or more groups selected from: halo, CN, amino, oxo, OH, alkoxy, alkyl, perhaloalkyl, haloalkyl, heterocyclyl, aryl, and heteroaryl, or R10and R11together form a cycloalkyl or heterocyclyl ring, a spirocyclic ring, a fused bicyclic ring, or a bridged bicyclic ring, wherein the ring formed by R10and R11together is optionally substituted by one or more groups selected from halo, CN, amino, oxo, carbenyl, OH, alkoxy, alkyl, perhaloalkyl, or haloalkyl;Xi and X2 are independently H, halo, haloalkyl, dialkylamino, cyano, alkoxy, haloalkoxy, alkyl, or cycloalkyl, wherein at least one of Xi and X2is not H;One of Zi and Z2 is H and the other is -L2aNR7R8,L2ais -C(H)R6a- or -C(H)R6aC(H)R6b-;R6aand R6bare each independently selected from H, alkyl, hydroxyl, halo, cycloalkyl, haloalkyl, alkoxy, and hydroxyalkyl, wherein if either of R6aor R6bis alkyl it is optionally substituted by cycloalkyl, and if either of R6aor R6bis cycloalkyl it is optionally substituted by halo, alkyl or cycloalkyl; and R7andR8are independentlyL3R9, wherein:L3= _(C(H) R10)n-, or a bond, wherein n = 1 or 2; R10is selected from H and alkyl; R9is selected from H, alkyl, haloalkyl, perhaloalkyl, hydroxyalkyl, aminoalkyl, cycloalkyl, hydroxyalkyl, alkoxyalkyl, alkyl alkanoate, heterocyclyl, spirocyclyl ring system, fused ring system, bicyclyl ring system, a 5 or 6 member heteroaromatic ring, or a 3 10 member fused heteroaromatic ring system, and a bridged bicyclyl ring; and wherein, if any of R7orR8is cycloalkyl, heterocyclyl, spirocyclyl, a fused bicyclyl, a bridged bicyclic ring, a 5 or 6 member heteroaromatic ring, or a 3 - 10 member fused heteroaromatic ring system, said ring or ring system is optionally substituted with oneor more groups selected from: sulfonyl, halo, hydroxyl, alkoxy, alkyl, cycloalkyl, alkoxyalkyl, carbenyl, alkenyl, hydroxyalkyl, cyano, carboxyalkyl, or haloalkyl.
25. The compound of claim 24, selected from the group consisting of the Compound Nos.Al - A14 in Table Al, or a pharmaceutically acceptable salt thereo.
26. A method of treating a cancer, comprising administering to a subject in need thereof, a compound according to any one of claims 24 and 25.
Citation Information
Patent Citations
Polylactide-drug mixtures
US3773919A
Substituted benzyl-triazole compounds for CBL-b inhibition, and further uses thereof
WO2020264398A1
Lactams as CBL-b inhibitors selective over c-cbl
WO2023081853A1
